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BACKGROUND AND SIGNIFICANCE 
 
The number and functional capacity of an organism’s pancreatic β-cells, in 
combination with peripheral insulin sensitivity, determine the ability of that organism to 
maintain glucose homeostasis.  Because β cells are the only cell type in the body to 
secrete insulin in response to glucose, the size of this cell population, or β cell mass, is an 
important determinant of an organism’s ability to regulate its blood glucose levels.  
Diabetes mellitus is characterized by either an absolute (Type I) or relative (Type II and 
gestational) insufficiency of insulin production by β cells.  Existing treatments for 
diabetes primarily focus on replacing insulin and improving β cell function.  However, 
increasing a patient’s β cell mass could potentially improve or cure their condition.  To 
this end, islet transplantation has been used to treat some patients with Type I diabetes, 
but limited supply and low yield of islets from donor pancreata, as well as graft failure, 
prevent widespread use of this therapy.  Currently, efforts are being made to differentiate 
β cells from precursor populations and to expand β cells in vitro to generate an unlimited 
supply of β cells for transplantation.  Theoretically, the same could be done in vivo to 
expand a patient’s existing or transplanted β cell population.  Thus, it is important to 






 The pancreas originates from the foregut endoderm as ventral and dorsal buds 
beginning at embryonic day (e) 9.5 in the mouse, and the two buds later fuse at 
approximately e12.5 (Kim and MacDonald, 2002).  The endodermal epithelium 
proliferates in response to various fibroblast growth factors (FGFs) produced by the 
adjacent mesenchyme (Bhushan et al., 2001), undergoes branching morphogenesis, and 
differentiates into ductal, exocrine, and endocrine cells.  Evagination and development of 
the ventral pancreatic bud is slightly delayed compared to that of the dorsal bud, and the 
ventral bud gives rise to fewer endocrine cells than does the dorsal bud (Spooner et al., 
1970).  The ventral and dorsal buds also differ with regard to the signals they require for 
development.  For example, the homeobox 9 (Hb9) transcription factor is required for 
formation of the dorsal, but not ventral, bud (Harrison et al., 1999; Li et al., 1999).  
Additionally, the LIM homeodomain protein islet 1 (Isl1) is specifically expressed in the 
mesenchyme surrounding the dorsal, but not ventral, bud at e9.0, as well as later in 
differentiated endocrine cells throughout the pancreas.  Isl1-/- mice reveal that Isl1 is 
required specifically in the dorsal mesenchyme for formation of the dorsal pancreatic 
bud, and is required in the endoderm for differentiation of all endocrine cells (Ahlgren et 
al., 1997). 
 Pancreatic progenitors within the foregut epithelium are marked by expression of 
pancreatic-duodenal homeobox 1 (Pdx1), which is induced at e8.5 in the posterior foregut 
endoderm and is expressed throughout the pancreatic epithelium at e9.5 (Guz et al., 
1995).  Forkhead box A2 (FoxA2), previously called hepatic nuclear factor 3β (Hnf3β), 
can activate transcription of Pdx1, although there are many other upstream regulators of 
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Pdx1 (Melloul et al., 2002; Gerrish et al., 2004).  Pdx1 is required for growth, rather than 
formation, of the pancreatic buds, as evidenced by Pdx1-/- mice in which both pancreatic 
buds initially form but then arrest at a very early stage of development, resulting in an 
apancreatic phenotype at birth (Jonsson et al., 1994; Offield et al., 1996).  The same 
phenotype has been observed in a human infant with a homozygous inactivating point 
mutation of PDX1 (Stoffers et al., 1997b).  Pdx1 expression is down-regulated in acinar 
and ductal cells beginning at approximately e13.0 but is maintained in differentiated 
endocrine cells and up-regulated specifically in β cells (Guz et al., 1995).  This 
expression pattern is maintained throughout life. 
 Pancreas transcription factor 1a (Ptf1a) is also expressed throughout the 
developing pancreas beginning at e9.5 and is required for growth of the pancreatic buds 
(Krapp et al., 1998; Kawaguchi et al., 2002).  Ptf1a is later down-regulated in ductal and 
endocrine cells but is maintained in acinar cells throughout life, where it induces 
expression of Amylase and Elastase.  Ptf1a-/- mice form a rudimentary dorsal pancreas 
that fails to grow or produce differentiated acinar tissue (Krapp et al., 1998).  
Differentiated endocrine cells are present in these mice, although these cells are reduced 
in number and found scattered throughout the adjacent spleen.  Furthermore, the cells that 
would otherwise have expressed Ptf1a and contributed to the pancreas become 
incorporated into the duodenum (Kawaguchi et al., 2002). 
 
β Cell Differentiation 
 No “master regulator” of β cell differentiation has been identified.  Instead, the 
process of β cell differentiation is a complex pathway requiring the specification of 
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pancreas versus other endodermal organs, endocrine cells versus ductal or exocrine cells, 
and β cells versus non-β endocrine cells (Figure 1).  Proper differentiation of β cells 
requires dynamic changes in transcription factor expression levels in appropriate 
sequences and within an appropriate timeline.  Much of what is currently known 
regarding β cell differentiation has been discovered by studying endocrine cell 
differentiation in vivo, with the hope that these findings will aid attempts to differentiate 
β cells in vitro. 
 
In Vivo β Cell Differentiation 
 The murine pancreas undergoes two waves of endocrine cell differentiation, the 
first of which gives rise to glucagon+, insulin+, and double-positive cells between e9.5 
and e13.5.  These cells appear to be a transient population, however, and lineage tracing 
studies show that they do not contribute to mature islets (Herrera, 2000).  The second 
wave of endocrine differentiation begins at approximately e13.5 and yields endocrine 
cells that contribute to mature islets (Prasadan et al., 2002).  Second wave endocrine 
differentiation, unlike the first wave, relies on the transcription factors Pdx1 and Hnf6 
(Offield et al., 1996; Jacquemin et al., 2000). 
 Differentiation of endocrine versus exocrine cells is regulated by the Notch 
signaling pathway (Apelqvist et al., 1999; Jensen et al., 2000).  The pro-endocrine basic 
helix-loop-helix (bHLH) transcription factor neurogenin 3 (Ngn3), a downstream target 
of Hnf6 (Jacquemin et al., 2000), induces expression of Notch ligands, which bind to 
Notch receptors on and activate the Notch pathway in adjacent cells (Heremans et al., 
2002).  Downstream targets of the Notch pathway (e.g. Hairy/enhancer-of-split 1, Hes1) 
4
Figure 1.  β cell differentiation from endoderm. During embryogenesis, the 
pancreas differentiates from foregut endoderm, which also gives rise to the liver and 
duodenum.  Pancreatic progenitors are specified for an endocrine or non-endocrine 
fate, after which the non-endocrine progenitors differentiate into either duct or 
exocrine cells, while the endocrine progenitors differentiate into α, β, δ, PP, or ε cells.  
Transcription factors expressed in each of the cell populations preceding and 
including β cells are listed.  Figure is from Ackermann and Gannon (2007).
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repress Ngn3 expression, which inhibits endocrine differentiation.  Additionally, Hes1 
represses the cell cycle inhibitor p57Kip2, which maintains a proliferative pool of 
pancreatic progenitor cells within the embryonic ductal epithelium (Georgia et al., 2006).  
Therefore, cells in which the Notch signaling pathway is activated maintain their 
proliferative capacity, while cells in which Notch signaling is not activated express Ngn3, 
exit the cell cycle, and differentiate into endocrine cells.  Genetic mouse models of 
impaired Notch signaling, via deletion of Delta-like ligand 1 (Dll1-/-), Recombination 
signal binding protein for immunoglobulin kappa J region (Rbp-Jκ-/-), or Hes1-/-, exhibit 
increased endocrine cell differentiation at the expense of the pancreatic progenitor 
population (Apelqvist et al., 1999; Jensen et al., 2000). 
 Ngn3 is required for endocrine cell differentiation, as evidenced by Ngn3-/- mice, 
which lack all pancreatic endocrine cell types and die postnatally due to severe diabetes 
(Gradwohl et al., 2000).  Additionally, lineage tracing analysis revealed that all endocrine 
cells arise from Ngn3+ cells (Gu et al., 2002).  Ngn3 induces expression of essential β 
cell transcription factors including neurogenic differentiation 1 (Neurod1), also known as 
Beta2 (Huang et al., 2000), and paired box gene 4 (Pax4) (Smith et al., 2003), but is not 
itself expressed in hormone-producing cells.  The bHLH transcription factor NeuroD1 
induces expression of several endocrine genes, including Insulin, and its expression is 
maintained in mature endocrine cells (Naya et al., 1995).  NeuroD1-/- mice are diabetic 
due to severely reduced numbers of all endocrine cell types (Naya et al., 1997), and 
humans with heterozygous mutations in NEUROD1 suffer from a type of diabetes 
referred to as maturity-onset diabetes of the young type 6 (MODY6) (Kristinsson et al., 
2001).  In contrast, ectopic expression of Ngn3 or NeuroD1 in the pancreatic epithelium 
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results in premature and expansive differentiation of endocrine cells, primarily glucagon-
producing α cells, at the expense of the pancreatic progenitor pool, resulting in a 
hypoplastic pancreas (Apelqvist et al., 1999; Schwitzgebel et al., 2000). 
 The basic-leucine zipper (bZIP) transcription factor Musculoaponeurotic 
fibrosarcoma oncogene family protein B (MafB) is expressed in developing insulin+ and 
glucagon+ cells beginning during the first wave of endocrine cell differentiation, and then 
is subsequently down-regulated in β cells, concurrent with up-regulation of MafA in 
these cells (Artner et al., 2006; Nishimura et al., 2006).  MafB can activate transcription 
of the insulin and glucagon genes, and is required for proper differentiation of α and β 
cells (Artner et al., 2007).  Loss of MafB (Mafb-/-) results in impaired differentiation of α 
and β cells, but no change in total endocrine cell number and no alterations in endocrine 
cell lineage allocation, and insulin expression is delayed in these mice mice until the 
onset of MafA expression at e13.5. 
 Endocrine cells produced by the second wave of differentiation can first be 
identified at e13.5, forming endocrine cords adjacent to ducts (Pictet et al., 1972).  These 
cells delaminate from the ductal epithelium, differentiate, proliferate, and then cluster to 
form islets, which contain β cells, α cells, somatostatin-producing δ cells, pancreatic 
polypeptide-producing PP cells, and ghrelin-producing ε cells.  Regulation of 
differentiation down each of these endocrine lineages from a Ngn3+ cell is complex and 
still not completely understood.  However, lineage tracing analyses have revealed that the 
β and α cell lineages diverge early, while β cells and PP cells may differentiate from the 
same lineage (Herrera, 2000).  Additionally, β cells and δ cells share a requirement for 
Pax4, as Pax4-/- mice have increased numbers of α cells at the expense of β and δ cells 
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(Sosa-Pineda et al., 1997).  Pax4 is expressed in early insulin+, but not glucagon+, cells 
and is later restricted to mature β cells, but Pax4 alone is not sufficient to drive Ngn3+ 
cells toward either a β or δ cell fate (Grapin-Botton et al., 2001).  A putative antagonist of 
Pax4 is aristaless related homeobox (Arx), whose expression pattern and loss-of-function 
phenotype directly contrast with that of Pax4 (Collombat et al., 2003).  Arx is expressed 
in pancreatic progenitor cells beginning at e9.5 and is later restricted to mature α and δ 
cells.  Arx-/- mice exhibit increased numbers of β and δ cells at the expense of α cells.  
Furthermore, Arx is up-regulated in Pax4-/- mice, while Pax4 is up-regulated in Arx-/- 
mice.  Thus, Pax4 and Arx function in the differential specification of endocrine cell 
types. 
 Early broad expression of Pdx1 induces expression of the NK homeodomain 
transcription factors Nkx2.2 and Nkx6.1, but while Nkx2.2 expression becomes restricted 
to α, β, and PP cells (Sussel et al., 1998), Nkx6.1 expression becomes tightly restricted to 
β cells (Sander et al., 2000).  Nkx2.2-/- mice reveal that Nkx2.2 is absolutely required for 
β cell differentiation and plays a lesser role in differentiation of α and PP cells (Sussel et 
al., 1998), while Nkx6.1-/- mice have impaired but not complete loss of β cell 
differentiation (Sander et al., 2000).  Several pieces of evidence suggest that Nkx2.2 is 
upstream of Nkx6.1:  initiation of expression of Nkx2.2 precedes that of Nkx6.1 (e9.5 
versus e10.5, respectively); all Nkx6.1+ cells also express Nkx2.2, while not all Nkx2.2+ 
cells express Nkx6.1; Nkx2.2-/- mice lack expression of Nkx6.1; and Nkx2.2-/-;Nkx6.1-/- 
mice exhibit a similar phenotype to Nkx2.2-/- mice. 
 In addition to its early role in pancreas development, Pdx1 plays a role in the 
terminal differentiation of β cells by inducing expression of Insulin, Glucose transporter 2 
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(Glut2), Glucokinase, and Islet amyloid polypeptide (Iapp) (Edlund, 2001), and Pdx1 is 
necessary for maintaining mature β cell function.  MafA has also recently been identified 
as an important regulator of β cell function and a marker of mature β cells (Zhang C et 
al., 2005; Nishimura et al., 2006; Artner et al., 2007).  MafA-/- mice undergo normal 
pancreatic development but develop diabetes postnatally, associated with progressively 
impaired insulin secretion, abnormal islet morphology, and reduced expression of Insulin, 
Pdx1, NeuroD1, and Glut2.  Additionally, insulin has been shown to be a direct 
transcriptional target of MafA (Kataoka et al., 2002; Olbrot et al., 2002; Matsuoka et al., 
2004; Artner et al., 2008). 
 
In Vitro β Cell Differentiation 
 As described above, β cell differentiation in vivo requires that expression of 
specific transcription factors be initiated, maintained, and repressed in a precise temporal 
and sequential manner, which is difficult to control in an in vitro setting.  Furthermore, 
simply inducing insulin expression in a progenitor population does not equate with 
differentiating β cells because an important quality of mature β cells is their ability to 
sense blood glucose levels and appropriately respond by synthesizing and secreting 
proper amounts of insulin.  These functions require expression of several transporter, 
receptor, and exocytosis proteins.  To overcome these obstacles, many different 
approaches are being utilized to generate β cells, as shown in Figure 2:  proliferation of 
existing β cells, differentiation of β cells from embryonic stem (ES) cells, differentiation 
of β cells from pancreatic progenitor cells (residing in pancreatic ductal epithelium), and 
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Figure 2.  Sources of β cells for transplantation. A supply of β cells for 
transplantation may be derived by 1. inducing proliferation of existing β cells, either 
isolated or within islets; 2. by inducing differentiation of ES cells into β cells; 3. by 
inducing differentiation of isolated ductal epithelium into β cells or islets; and 4. by 
inducing transdifferentiation of related cell types, such as exocrine cells, hepatocytes, 
or intestinal enteroendocrine cells, into β cells.  Figure is from Ackermann and 
Gannon (2007).
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transdifferentiation of β cells from related cell types (e.g. pancreatic exocrine cells, 
hepatocytes, and intestinal enteroendocrine cells) (Bonner-Weir and Weir, 2005). 
Although the prospect of deriving β cells from ES cells is intriguing, there has 
been much controversy in the field, and several early studies have since become 
cautionary tales.  For example, initial reports claiming a 10-30% efficiency rate of 
differentiating β cells from ES cells failed to confirm Insulin mRNA expression, which 
was later observed in less than 0.00001% of cells (Rajagopal et al., 2003).  Improved 
results have been obtained by applying what has been learned about β cell differentiation 
in vivo.  For example, transfection of ES cells with Pax4, and to a lesser extent Pdx1, 
results in increased differentiation of insulin-producing cells and increased expression of 
Isl1, Ngn3, Insulin, Iapp, and Glut2 (Blyszczuk et al., 2003).  Currently, the preferred 
method to produce β cells from ES cells is directed differentiation.  Ku et al. showed that 
stepwise application of various growth factors known to influence β cell development 
(FGF, activin, betacellulin, exendin-4, and nicotinamide) induces 2.73% of ES cells to 
differentiate into insulin-producing cells (Ku et al., 2004).  D’Amour et al. developed a 
five-stage protocol to systematically induce differentiation of definitive endoderm, 
primitive gut tube, posterior foregut endoderm, pancreatic endoderm and endocrine 
precursors, and finally insulin-producing cells, along with the four other hormone-
producing cell types (D'Amour et al., 2006).  This method induced 7-12% of ES cells to 
differentiate into insulin-producing cells, although these cells had limited glucose-
stimulated insulin secretion.  More recently, the same group optimized this protocol to 
differentiate ES cells to the fourth stage (pancreatic endoderm and endocrine precursors), 
which is characterized by expression of Pdx1, FoxA2, Hnf6, and Nkx6.1, and they then 
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implanted these cell aggregates into recipient mice (Kroon et al., 2008).  These grafts 
produced insulin within 44 days post-implantation, and by 90 days were producing as 
much insulin as did grafts of 3,000-5,000 adult human islets.  Importantly, the ES cell-
derived grafts appropriately secreted insulin in response to glucose but not in response to 
fasting or hypoglycemia.  Additionally, these grafts were able to maintain glucose 
homeostasis in mice whose endogenous β cells were eliminated.  Histological analysis of 
the grafts after 78 days revealed that hormone+ cells formed islet-like clusters with 
relatively appropriate proportions of each cell type, no endocrine hormones were 
co-expressed within the same cell, and hormone+ cells also expressed mature endocrine 
cell type-specific markers.  Despite these encouraging results, grafts derived from ES 
cells have been shown in some cases to form teratomas after transplantation (Fujikawa et 
al., 2005; Kroon et al., 2008). 
 Isolation and culture of ductal epithelium from adult mouse pancreas also yielded 
insulin+ cells, as well as islets, through islet producing stem cell (IPSC) and islet 
progenitor cell (IPC) intermediates (Ramiya et al., 2000).  Increased islet yield was 
obtained by culturing IPSCs with epidermal growth factor (EGF), hepatocyte growth 
factor (HGF), and nicotinamide.  IPSCs can be maintained in culture long-term 
(>3 years) and can withstand freezing, and the islets derived from them can reverse 
streptozotocin (STZ)-induced diabetes in mice.  Duct cells have also been isolated from 
humans, from the normally-discarded non-islet fraction of pancreatic tissue utilized for 
islet transplantation (Heremans et al., 2002).  Adenoviral infection of these cells with 
Ngn3 or Neurod1 results in differentiation into primarily insulin+ cells (10-fold over that 
observed in control cells), although intracellular insulin content is relatively low.  Similar 
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results were observed when immortalized ductal cell lines from mice or humans were 
transfected with Ngn3 or Neurod1 (Gasa et al., 2004).  However, whether or not the 
insulin+ cells and islets that are derived from these various sources are fully differentiated 
and fully functioning is unknown. 
 
Establishing an Organism’s β Cell Mass 
 β cell mass is increased by β cell neogenesis (differentiation from precursor cells), 
β cell proliferation, and β cell hypertrophy (increased cell size), and is decreased by β cell 
death, primarily via apoptosis, and β cell atrophy (decreased cell size) (Figure 3A) 
(Ackermann and Gannon, 2007).  From embryogenesis to adulthood, there is a net 
increase in β cell mass as the organism’s size increases (Figure 3B), and the majority of 
new β cells are formed by replication (Meier et al., 2008).  β cell differentiation, as 
described above, gives rise to the initial β cells of an organism during embryogenesis, but 
there is much debate regarding whether and to what extent β cell neogenesis occurs in the 
postnatal and adult stages under normal circumstances.  Lineage studies using DNA 
analog incorporation to assess sequential cell division showed that β cells in adult mice 
arise by uniform proliferation of pre-existing β cells, with no contributions from 
specialized populations of progenitor or stem cells (Teta et al., 2007).  However, β cell 
neogenesis has been reported in models of pancreatic injury in adult mice (Xu et al., 
2008; Bonner-Weir et al., 2008). 
 β cell proliferation proceeds at a high rate (approximately 10% per day in mice) 
during late embryogenesis (Bernard-Kargar and Ktorza, 2001) but begins to decline 
postnatally (Scaglia et al., 1997).  During adulthood, β cells proliferate at a low rate that 
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Figure 3.  β cell mass dynamics.  (A) 
β cell proliferation, neogenesis, and 
hypertrophy (enlarged cell size) 
increase β cell mass, while β cell 
apoptosis and atrophy (reduced cell 
size) decrease β cell mass.  (B) Graphs 
represent approximate changes in 
these processes over the course of a 
lifetime in normal individuals (gray 
solid line), in non-diabetic obesity 
(black solid line), in Type II diabetes 
mellitus (T2DM; black dashed line), 
and in Type I diabetes mellitus 
(T1DM; black dotted line), based on 
rodent and human studies.  Embryo 
denotes the period of time prior to 
birth.  Neonate denotes the period of 
time between birth and weaning 
(approximately 3 weeks in the rodent).  
Figure is from Ackermann and 
Gannon (2007).
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may gradually decline with age.  Approximately 1-4% of β cells replicate per day in rats 
between 30 and 100 days old (Finegood et al., 1995), while <1% of β cells replicate per 
day in mice at 1 year of age (Teta et al., 2005).  The differences observed in the rates of β 
cell proliferation at these timepoints is thought to be due to differences in the percentage 
of β cells that are able to be recruited to enter the cell cycle, rather than differences in cell 
cycle lengths.  The mechanism by which more β cells are recruited to enter the cell cycle 
during embryonic versus postnatal and adult stages is currently unknown.  However, 
evidence from several genetic mouse models indicates that the factors that regulate β cell 
proliferation during embryogenesis may differ from those that regulate β cell 
proliferation postnatally (Rane et al., 1999; Georgia and Bhushan, 2004; Kushner et al., 
2005a; Georgia and Bhushan, 2006; Zhang H et al., 2006).  For example, global deletion 
of the cell cycle inhibitor p27Kip1 (p27Kip1-/-) increases β cell proliferation during 
embryogenesis and adulthood, but not during the early postnatal period, resulting in 
increased β cell mass at birth and throughout life (Georgia and Bhushan, 2006).  In 
contrast, β cell-specific deletion of Pdx1 (Pdx1fl/-;RIP-Cre) impairs embryonic β cell 
proliferation and alters islet morphology with increased proportions of α and δ cells at the 
expense of β cells (Gannon et al., 2008). 
 β cell apoptosis occurs at very low rates during embryogenesis, but there is 
evidence that a transient burst of β cell apoptosis occurs at weaning, which may be 
associated with islet remodeling and/or changes in β cell maturation (Scaglia et al., 
1997).  During adulthood, β cell apoptosis again normally occurs at very low rates, 
although it modestly increases in mice fed a high-fat or high-fat/high-protein diet (Linn et 
al., 1999).  Average β cell size is fairly stable during the postnatal period (Scaglia et al., 
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1997), but it increases with age during later adulthood (Montanya et al., 2000) and with 
increased adiposity (Park et al., 2007). 
 Proper development of an organism’s β cell mass requires appropriate nutrition 
during embryogenesis.  Poor maternal nutrition results in intrauterine growth retardation 
(IUGR), low birth weight, and underdeveloped β cell mass in newborn rats, which 
predisposes them to glucose intolerance and diabetes later in life (Breant et al., 2006).  
When IUGR is caused by total caloric restriction, the reduction in β cell mass is due to 
reduced β cell differentiation, with decreased expression of Pdx1, Pax6, and Nkx6.1, 
rather than due to reduced β cell proliferation.  These changes are associated with 
increased levels of glucocorticoids, which can independently reduce fetal β cell mass 
when exogenously administered to the mother.  IUGR caused by protein restriction also 
results in under-developed β cell mass in newborn rats, but this is due to reduced β cell 
proliferation and increased β cell apoptosis, associated with reduced levels of insulin-like 
growth factors (IGFs) (Reusens and Remacle, 2006).  IUGR initiated by surgical ligation 
of uterine arteries resulted in epigenetic modification of the Pdx1 promoter, causing 
reduced islet Pdx1 expression in offspring at birth and during the neonatal period and 
absence of Pdx1 expression in the adult after diabetes onset (Park JH et al., 2008).  In 
contrast, maternal obesity and/or diabetes results in newborn macrosomia (large birth 
weight) and increased β cell mass associated with increased β cell proliferation, likely in 
response to maternal hyperglycemia.  These offspring are also predisposed to obesity, 




Maintaining an Organism’s β Cell Mass 
 Although it was once thought that an organism was born with all of the β cells it 
would ever have, prevailing evidence now shows that new β cells can form throughout 
life.  Several studies have revealed that the primary mechanism by which new β cells 
form during adulthood is via proliferation rather than neogenesis (Dor et al., 2004; 
Georgia and Bhushan, 2004; Teta et al., 2007).  Thus, organisms born with reduced β cell 
mass, as discussed above, have fewer β cells available to enter the cell cycle later in life.  
Under normal circumstances during adulthood, β cells are a slowly-renewing population, 
with steady low levels of proliferation and apoptosis.  However, β cell mass continuously 
expands over the lifespan of an organism (Montanya et al., 2000), likely due to age-
related increases in body weight and insulin resistance.  In rats, β cells achieve this 
progressive increase in β cell mass by increasing their cell size, rather than increasing 
proliferation (Montanya et al., 2000). 
 The ability of an organism to maintain its β cell mass during adulthood is 
paramount to maintaining glucose homeostasis and preventing diabetes.  Table 1 
summarizes the mouse models in which molecular regulators of postnatal β cell mass are 
perturbed, and many of these factors are key regulators of the cell cycle (Figure 4).  
Several genetic mouse models of cell cycle dysregulation impair postnatal β cell 
proliferation, and cause a progressive decline in β cell mass, associated with a 
progressive glucose intolerant and diabetic phenotype.  For example, global inactivation 
of Cyclin-dependent kinase 4 in mice (Cdk4-/-) specifically affects endocrine cells within 
the pancreas, causing diabetes by 2 months of age, and within the pituitary, causing 
reduced body size and infertility (Rane et al., 1999).  The diabetes observed in these mice  
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Table 1.  Molecular Regulators of Postnatal β Cell Mass in Vivo 
 
  Mouse Models Effects References 
Transcription Factors       
Pdx1 Pdx1+/- ↓ β cell mass, ↑ β cell apoptosis (Johnson et al., 2003) 
 Pdx1flox/flox;Rip-Cre ↓ β cell mass (Ahlgren et al., 1998) 
Foxm1 Foxm1flox/flox;Pdx14.3-Cre ↓ β cell mass, ↓ β cell proliferation, ↑-↓ β cell size, ↔ β cell apoptosis (Zhang H et al., 2006) 
Cyclic AMP Response Element 
     Binding Protein 
CBPS436A/+ Tg 
(↑ CREB activity) 
↑ β cell mass, ↑ β cell proliferation, ↔ β cell size, ↔ β cell apoptosis (Hussain et al., 2006) 
 HIP-ICER-Iγ Tg 
(↓ CREB activity) 
↓ β cell mass, ↓ β cell proliferation, ↔ β cell apoptosis (Inada et al., 2004) 
 Rip-dnCREB Tg ↓ β cell mass, ↑ β cell apoptosis (Jhala et al., 2003) 
E2Fs E2F1-/- ↓ β cell mass, ↓ β cell proliferation, ↔ β cell apoptosis (Fajas et al., 2004) 
 E2F1-/-;E2F2-/- ↓ β cell mass, ↑ β cell proliferation (Iglesias et al., 2004) 
Nuclear Factor of Activated T Cells, 
cytoplasmic, calcineurin-dependent 1 
Rip-rtTA;NFATc1nuc ↑ β cell mass, ↑ β cell proliferation (Heit et al., 2006a) 
    
Cell Cycle Proteins       
Cyclin-Dependent Kinases Cdk4R26C/R26C Tg 
(↑ activity) 
↑ β cell mass (Rane et al., 1999) 
 Cdk4-/- ↓ β cell mass (Rane et al., 1999) 
Cyclins Rip-Cyclin D1 Tg ↑ β cell mass, ↑ β cell proliferation, ↔ β cell apoptosis (Zhang X et al., 2005) 
 Cyclin D2-/- ↓ β cell mass, ↓ β cell proliferation, ↔ β cell apoptosis (Georgia and Bhushan, 2004; 
Kushner et al., 2005a) 
 Cyclin D1+/-;Cyclin D2-/- ↓ β cell mass, ↓ β cell proliferation, ↔ β cell apoptosis (Kushner et al., 2005a) 
Cyclin-Dependent Kinase Inhibitors p16INK4a Tg ↓ β cell proliferation (Krishnamurthy et al., 2006) 
 p16INK4a-/- ↑ β cell proliferation (Krishnamurthy et al., 2006) 
 p18INK4c-/- ↑ β cell mass (Pei et al., 2004) 
 p21Cip1-/- ↔ β cell mass, ↔ β cell proliferation, ↔ β cell apoptosis (Cozar-Castellano et al., 2006b) 
 Rip-p27Kip1 Tg ↓ β cell mass, ↓ β cell proliferation, ↔ β cell size (Uchida et al., 2005) 
 p27Kip1-/- ↑ β cell mass, ↑ β cell proliferation, ↔ β cell size (Georgia and Bhushan, 2006) 
Tumor Suppressors pRbflox/flox;Rip-Cre ↑ β cell mass, ↔ β cell proliferation, ↔ β cell size (Vasavada et al., 2007) 
 pRb+/-;p53+/- ↑ β cell mass (Williams et al., 1994) 
 pRb+/-;p53-/- ↑ β cell mass (Williams et al., 1994) 
Growth Factors       
Lactogens Rip-PL1 Tg ↑ β cell mass, ↑ β cell proliferation, ↑ β cell size (Vasavada et al., 2000; Cozar-
Castellano et al., 2006c) 
 PrlR-/- ↓ β cell mass (Freemark et al., 2002) 
Parathyroid Hormone-related Protein Rip-PTHrP Tg ↑ β cell mass, ↔ β cell proliferation, ↔ β cell apoptosis, ↔ β cell size (Porter et al., 1998) 
Growth Hormone GHR-/- ↓ β cell mass, ↓ β cell proliferation, ↓ β cell size (Liu et al., 2004) 
Hepatocyte Growth Factor Rip-HGF Tg ↑ β cell mass, ↑ β cell proliferation (Garcia-Ocana et al., 2000; 
Garcia-Ocana et al., 2001; 
Cozar-Castellano et al., 2006c) 
 c-Metflox/flox;Rip-Cre ↔ β cell mass, ↔ β cell proliferation (Roccisana et al., 2005) 
Epidermal Growth Factor HIP-EGF Tg ↑ β cell mass, ↑ β cell proliferation (Krakowski et al., 1999) 
Keratinocyte Growth Factor HIP-KGF Tg ↑ β cell mass, ↑ β cell proliferation (Krakowski et al., 1999) 
Insulin, Insulin-like Growth Factors IRflox/flox;Rip-Cre ↓ β cell mass (Otani et al., 2004) 
 Rip-IGF-I Tg ↔ β cell mass, ↑ β cell proliferation, ↔ β cell apoptosis, ↔ β cell neogenesis (George et al., 2002) 
 IGF-Iflox/flox;Pdx14.3-Cre ↑ β cell mass, ↑ β cell size (Lu et al., 2004) 
 IGF-IRflox/flox;Rip-Cre ↔ β cell mass (Kulkarni et al., 2002) 
 IGF-II Tg ↑ β cell mass, ↑ β cell proliferation, ↓ β cell apoptosis, ↔ β cell size (Petrik et al., 1999) 
 Rip-IGF-II Tg ↑ β cell mass (Devedjian et al., 2000) 
Fibroblast Growth Factors Pdx1-dnFGFR1c Tg ↓ β cell mass, ↔ β cell apoptosis (Hart et al., 2000) 
 Pdx1-dnFGFR2b Tg ↔ β cell mass (Hart et al., 2000) 
Vascular Endothelial Growth Factors Rip-VEGF-A Tg ↔ β cell mass (Gannon et al., 2002) 
 VEGF-Aflox/flox;Rip-Cre ↔ β cell mass, ↑ β cell size (Inoue et al., 2002) 
Incretins GLP-1R-/- ↔ β cell mass (Ling et al., 2001) 
 GIPR-/- ↑ β cell mass (Pamir et al., 2003) 
Gastrin Rip-Gastrin Tg ↔ β cell mass (Wang et al., 1993) 
 Gastrin-/- ↔ β cell mass, ↔ β cell proliferation (Boushey et al., 2003) 
    
Cell Signaling Proteins      
Insulin Receptor Substrate Rip-Irs2 Tg ↑ β cell mass, ↔ β cell proliferation, ↔ β cell size (Hennige et al., 2003) 
 Irs2-/- ↓ β cell mass, ↑ β cell apoptosis (Withers et al., 1998; Withers et 
al., 1999; Kubota et al., 2000) 
 Irs2flox/flox;Rip-Cre ↓ β cell mass, ↓ β cell proliferation, ↔ β cell apoptosis (Kubota et al., 2004) 
Protein Kinase B/Akt caAkt Tg ↑ β cell mass, ↑ β cell proliferation, ↑ β cell size (Fatrai et al., 2006) 
 Rip-caAkt Tg ↑ β cell mass, ↑ β cell proliferation, ↑ β cell size, ↑ β cell neogenesis (Bernal-Mizrachi et al., 2001) 
 Rip-caAkt Tg ↑ β cell mass, ↑ β cell size, ↑ β cell apoptosis, ↔ β cell proliferation (Tuttle et al., 2001) 
 Rip-kdAkt Tg ↔ β cell mass, ↔ β cell apoptosis, ↔ β cell size (Bernal-Mizrachi et al., 2004) 
p70S6K p70S6K1-/- ↓ β cell mass, ↓ β cell size (Pende et al., 2000) 
Phosphoinositide-Dependent Kinase PDK1flox/flox;Rip-Cre ↓ β cell mass, ↓ β cell proliferation, ↓ β cell size, ↑ β cell apoptosis (Hashimoto et al., 2006) 
    
Others       
Menin Men1+/- ↑ β cell mass, ↑ β cell proliferation (Karnik et al., 2005) 
 Men1flox/flox;Rip-Cre ↑ β cell mass, ↑ β cell proliferation, ↔ β cell apoptosis (Crabtree et al., 2003) 
S-phase kinase-associated protein 2 Skp2-/- ↓ β cell mass, ↓ β cell proliferation, ↑ β cell size (Zhong et al., 2007) 
Pkr-like ER Kinase PERK-/- ↓ β cell mass, ↓ β cell proliferation, ↔ β cell apoptosis, ↔ β cell neogenesis, 
↔ β cell size 
(Harding et al., 2001; Zhang et 
al., 2002; Zhang W et al., 2006) 
Phosphatase and Tensin homologue PTEN+/- ↓ β cell mass, ↓ β cell proliferation (Kushner et al., 2005b) 
 PTENflox/flox;Rip-Cre ↑ β cell mass, ↑ β cell proliferation, ↓ β cell apoptosis, ↔ β cell size (Stiles et al., 2006) 
Calcineurin b1 Cnb1flox/flox;Rip-Cre ↓ β cell mass, ↓ β cell proliferation, ↔ β cell apoptosis (Heit et al., 2006a) 
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Figure 4.  Cell cycle regulation. The G1/S transition is controlled by Cdk2, 4, 5, or 6 
bound to Cyclin D or E, which phosphorylates Rb, releasing the E2F transcription 
factor.  Rb phosphorylation is maintained through the G2/M transition by Cdk2 bound 
to Cyclin A and Cdk1 bound to Cyclin A or B.  Figure is adapted from Dzau et al. 
(2002).
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is associated with severely reduced β cell mass, although β cell mass is comparable to 
that of wild-type mice at postnatal days (P) 1 and 2.  Progression from G1 to S phase in 
the cell cycle requires phosphorylation of the Retinoblastoma protein (Rb) by Cdk4/6 
complexed with a D Cyclin, which releases E2F allowing it to activate transcription of 
necessary cell cycle target genes.  Thus, Cdk6 function is redundant with Cdk4; however, 
mouse β cells do not express detectable levels of Cdk6 (Martin et al., 2003), making 
them uniquely susceptible to cell cycle perturbations caused by loss of Cdk4.  In contrast, 
human islets express Cdk6 but not Cdk4 (Fiaschi-Taesch et al., 2008).  Similarly, global 
deletion of Cyclin D2 (CyclinD2-/-), the predominant D Cyclin expressed in β cells, fails 
to stimulate adequate compensatory up-regulation of Cyclin D1 or D3 within islets and 
drastically impairs postnatal β cell proliferation (Georgia and Bhushan, 2004).  CyclinD2-
/- mice exhibit normal β cell mass at e17.5 but significantly reduced β cell mass 
postnatally, causing progressive glucose intolerance and diabetes. 
 Cdk inhibitor proteins (Cips, Kips, INKs) also play important roles in β cell 
proliferation.  Transgenic over-expression of p27Kip1 within β cells using the rat insulin 
promoter (Rip-p27Kip1) impairs β cell proliferation, resulting in decreased β cell mass and 
diabetes in mice (Uchida et al., 2005).  In contrast, as mentioned before, global deletion 
of p27Kip1 (p27Kip1-/-) increases β cell proliferation under normal circumstances (Georgia 
and Bhushan, 2006).  Loss of p27Kip1 also increases β cell proliferation in genetic models 
of insulin resistance and diabetes (Irs2-/- or db/db) and restores glucose homeostasis in the 
latter model (Uchida et al., 2005).  β cell hyperplasia is also observed in humans with 
focal loss of heterozygosity of p57Kip2, and these subjects suffer from hyperinsulinism of 
infancy (Kassem et al., 2001).  Additionally, mice that express a mutant Cdk4 that cannot 
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be bound and inhibited by p16INK4a (Cdk4R24C/R24C) exhibit postnatal increases in β cell 
proliferation and β cell mass that improve glucose regulation (Rane et al., 1999). 
 Our lab has recently found that FoxM1 also plays an important role in β cell 
proliferation (Zhang H et al., 2006).  FoxM1 is a transcription factor known to regulate 
expression levels of several cell cycle proteins.  Pancreas-wide deletion of Foxm1 using a 
Cre-lox strategy (Foxm1flox/flox;Pdx15.5kb-Cre) in mice results in postnatal defects in β cell 
proliferation, which contribute to a postnatal deficiency in β cell mass and a progressive 
glucose intolerant and diabetic phenotype.  However, β cell mass and islet morphology 
are normal at P1, despite inactivation of Foxm1 early in embryogenesis.  Increased 
nuclear p27Kip1, which is an indirect target of FoxM1, and β cell senescence are 
associated with impaired β cell proliferation in these mice.  Thus, FoxM1 is critical for 
maintaining β cell mass during adulthood by properly coordinating cell cycle progression. 
 One of FoxM1’s transcriptional targets, S-phase kinase-associated protein 2 
(Skp2), mediates degradation of p21Cip1 and p27Kip1 and has also been directly linked to β 
cell proliferation.  Skp2-/- mice exhibit a phenotype similar to that observed in 
Foxm1flox/flox;Pdx15.5kb-Cre mice, with reduced postnatal β cell mass,  reduced β cell 
proliferation, progressive diabetes, β cell hypertrophy and polyploidy, and accumulation 
of nuclear p27Kip1 in β cells (Zhong et al., 2007).  These effects of loss of Skp2 on β cells 
are attributed to increased nuclear p27Kip1, as the metabolic and morphologic phenotypes 
are reversed in Skp2-/-;p27Kip1-/- double knock-out mice. 
 Another regulator of cell cycle genes is the transcriptional coactivator Menin, 
encoded by Men1, mutation of which results in Multiple Endocrine Neoplasia type 1 
(MEN1) in humans (Crabtree et al., 2003).  This syndrome is characterized by 
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hyperplasia of endocrine cell types primarily within the parathyroids, anterior pituitary, 
and pancreas, resulting in tumor formation, most commonly insulinomas composed of β 
cells.  Men1+/- mice display a similar phenotype.  β cell-specific deletion of Men1 
(Men1flox/flox;Rip-Cre) also results in β cell hyperplasia, insulinomas, hyperinsulinemia, 
and hypoglycemia.  Significantly increased β cell proliferation is observed, and this is 
associated with reduced levels of p18INK4c and p27Kip1, both of which are direct targets of 
Menin-mediated histone methylation (Karnik et al., 2005).  Furthermore, a MEN1-like 
phenotype is observed in p18INK4c-/-;p27Kip1-/- mice (Franklin et al., 2000).  Other mouse 
models of impaired and enhanced β cell proliferation have been reviewed by (Cozar-
Castellano et al., 2006a) and (Heit et al., 2006b). 
 Just as impaired β cell proliferation causes a net loss of β cells, increased β cell 
death can have the same effect.  Inherent defects that make β cells more susceptible to 
apoptosis, for example, result in a negative balance of β cell turnover, as observed in 
Pdx1+/- mice, which exhibit normal β cell mass at 3 months of age but are unable to 
appropriately increase their β cell mass as they age (Johnson et al., 2003).  
Haploinsufficiency of Pdx1 makes β cells more susceptible to undergoing apoptosis, 
associated with reduced expression levels of the anti-apoptotic genes BclXL and Bcl-2.  
Increased β cell apoptosis results in insufficient β cell mass and progressive glucose 
intolerance.  A more dramatic phenotype is observed in mice with adult-onset β cell-
specific deletion of Pdx1 (Pdx1flox/flox;Rip-Cre) (Ahlgren et al., 1998).  These mice suffer 
from worsening glucose intolerance due to both progressive loss of β cell mass and 
impaired β cell function.  Mutations of PDX1 in humans result in similar phenotypes; a 
dominant-negative mutation of PDX1 causes MODY4 (Stoffers et al., 1997a), while a 
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heterozygous inactivating mutation of PDX1 predisposes to late-onset Type 2 diabetes 
(Macfarlane et al., 1999).  Thus, Pdx1 is a critical regulator of β cell survival and 
maintenance of β cell mass and function during adulthood. 
 
Dynamic Changes in an Organism’s β Cell Mass 
 In addition to maintaining β cell mass under normal circumstances, as just 
discussed, an organism must also be able to alter its β cell mass in accordance with its 
requirements for insulin.  In states of insulin resistance, such as pregnancy and obesity, β 
cell mass is known to increase (Rhodes, 2005) (Figure 3).  In mice, such β cell mass 
expansion is accomplished primarily by increasing β cell proliferation (Karnik et al., 
2007), whereas β cell neogenesis humans accounts for β cell mass expansion (Butler et 
al., 2003; Cao Minh et al., 2008).  Regardless of the mechanism, when compensatory β 
cell mass expansion is inadequate, diabetes ensues – gestational diabetes in the case of 
pregnancy, and Type II diabetes in the case of obesity.  Although the majority of humans 
do not become diabetic in these circumstances, a significant portion of the population is 
predisposed to β cell failure, for currently unknown reasons.  It is likely that factors that 
regulate β cell proliferation and neogenesis may play a role, although whether the factors 
that regulate β cell mass expansion are the same as those that regulate β cell mass 
maintenance is unclear.  Recent genome-wide association studies have identified several 
polymorphisms in patients with Type II diabetes that correlate with disease risk (Sladek 
et al., 2007; Zeggini et al., 2008).  Some of the identified loci include genes that play 
roles in cellular proliferation, such as TCF7L2, HHEX, EXT2, and CDC123.  TCF7L2 
and HHEX also play important roles in pancreas development, as do other identified loci 
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including NOTCH2.  However, distinct functions of identified loci with regard to Type II 
diabetes are still unclear. 
 During pregnancy, rats exhibit over a 50% increase in β cell mass, which is 
accomplished primarily via an approximate 3-fold increase in β cell proliferation (Scaglia 
et al., 1995).  The chief stimuli of β cell proliferation during pregnancy are placental 
lactogens (PLs), although prolactin (Prl) and growth hormone (GH) also have similar 
effects on β cells and are also elevated during pregnancy.  After delivery, β cell mass 
returns to normal levels within 10 days via increased β cell apoptosis, decreased β cell 
proliferation, and β cell atrophy. 
 To determine the direct role of PLs on β cell mass in non-pregnant animals, 
transgenic mice expressing PL1 within their β cells (Rip-Pl1) were developed (Cozar-
Castellano et al., 2006c).  These mice exhibited hypoglycemia and improved glucose 
clearance due to hyperinsulinemia, which was associated with a doubling of β cell mass.  
This expansion of β cell mass was attributed to a 2-fold increase in β cell proliferation 
and a 20% increase in β cell size.  Similar results were observed in transgenic mice 
expressing HGF within their β cells (Rip-Hgf) (Garcia-Ocana et al., 2000; Garcia-Ocana 
et al., 2001; Cozar-Castellano et al., 2006c).  These mice also exhibited a doubling of β 
cell mass, but the increase in β cell proliferation was not as significant as that in Rip-Pl1 
mice.  Interestingly, islet number was significantly increased in Rip-Hgf mice but not in 
Rip-Pl1 mice versus wild-type mice, suggesting that HGF may stimulate neogenesis. 
  In pregnant female mice, the negative cell cycle regulator Menin normally 
becomes down-regulated within islets, inversely correlated with β cell proliferation 
(Karnik et al., 2007).  β cell-specific over-expression of Menin using the Tet-on system 
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(RIP-rtTA, TRE-Men1) abrogates pregnancy-associated increases in β cell proliferation 
and β cell mass, associated with relatively increased levels of p18INK4c and p27Kip1. 
 Diet-induced obesity results in insulin resistance and β cell mass expansion in 
humans and mice.  The C57Bl/6 mouse strain is notoriously susceptible to these effects, 
exhibiting a 2.2-fold increase in β cell mass and proliferation after four months on a high-
fat diet versus a control diet (Sone and Kagawa, 2005).  However, these mice eventually 
become diabetic and lose their β cell mass due to increased β cell apoptosis and reduced β 
cell proliferation. 
 In genetic models of obesity and insulin resistance, there is also a compensatory 
expansion of β cell mass.  For example, db/db mice, which lack a functional leptin 
receptor, exhibit a 2-fold increase in β cell mass by 8 weeks of age (Wang and Brubaker, 
2002).  This timepoint correlates with the onset of diabetes, which progresses from 
glucose intolerance that is first observed between 4-6 weeks of age.  A similar rat model, 
the Zucker diabetic fatty (ZDF) rat (fa/fa), also has a homozygous mutation in the gene 
encoding the leptin receptor.  ZDF rats exhibit increased β cell mass and increased β cell 
proliferation prior to the onset of diabetes, but increased β cell apoptosis prevents them 
from adequately expanding their β cell mass after the onset of diabetes, despite continued 
high rates of β cell proliferation (Pick et al., 1998).  This phenotype contrasts with what 
is observed in non-diabetic Zucker fatty (ZF) rats, which possess the same mutation as 
ZDF rats and also become obese and insulin resistant but do not develop diabetes due to 
sufficient β cell mass expansion via increased β cell proliferation, neogenesis, and 
hypertrophy (Pick et al., 1998). 
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 Another model of insufficient β cell mass expansion is the insulin receptor 
substrate 2 null mouse (Irs2-/-) (Kubota et al., 2004).  Global inactivation of Irs2 results in 
severe insulin resistance, both centrally in the brain causing obesity, and peripherally, for 
which β cell mass expansion should be able to compensate.  However, because β cells 
require Irs2 for proper proliferation and function, Irs2-/- mice are unable to expand their β 
cell mass, and they develop diabetes by 10 weeks of age.  This phenotype is not observed 
in Irs1-/- mice, despite the fact that these mice exhibit similar insulin resistance, because 
Irs1 is not required for β cell mass expansion.  Deletion of Irs2 specifically within β cells 
and the hypothalamus (Irs2flox/flox;Rip-Cre) causes central insulin resistance and obesity, 
with glucose intolerance developing at 8 weeks of age but without progression to 
diabetes, likely due to the lack of peripheral insulin resistance (Kubota et al., 2004).  
These mice also exhibit reduced β cell proliferation and β cell mass at 8 weeks of age, 
although these impairments are not observed before the onset of insulin resistance 
(between 4 and 8 weeks).  These experiments provide additional evidence that Irs2 is 
required for β cell mass expansion in response to insulin resistance.  Furthermore, over 
expression of Irs2 in β cells (Rip-Irs2) is sufficient to prevent β cell failure in diet-
induced obesity and streptozotocin-induced diabetic models (Hennige et al., 2003). 
 Several downstream effectors of the insulin signaling pathway have been shown 
to play a role in β cell mass expansion in models of insulin resistance.  For example, 
haploinsufficiency of FoxO1 (Foxo1+/-) restores β cell mass and proliferation to nearly 
normal levels in Irs2-/- mice, possibly due to reduced FoxO1-mediated repression of Pdx1 
(Kitamura et al., 2002).  In contrast, expression of constitutively-nuclear FoxO1 prevents 
β cell mass expansion in two other models of insulin resistance (Okamoto et al., 2006). 
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Therapeutic Implications 
In understanding how β cell mass is developed, maintained, and manipulated, we 
seek to better understand diabetes etiology, identify new and optimal therapeutic targets, 
and develop new therapeutic techniques.  Out of necessity, much of the work in this field 
has been and is being performed in lower mammals, and thus much of it must still be 
confirmed in humans.  Furthermore, outside fields, such as gene therapy and 
immunology, must make substantial progress before some clinical interventions can be 
feasible.  However, there remains great optimism regarding the future ability to 
manipulate β cell differentiation and proliferation in vitro to provide an unlimited supply 
of β cells for transplantation into patients with diabetes.  Although studies in this area 
have revealed that it is difficult to achieve full differentiation and maturation of β cells, 
which is essential for clinical application, techniques are continuously being improved.  
Tumor formation, either from ES cell-derived cells or from induction of β cell 
proliferation which may induce transient de-differentiation, is another concern that must 
be considered.  Ultimately, however, the processes of β cell differentiation and 
proliferation will likely one day be controlled in vivo as a means to treat or prevent 
diabetes. 
 
Forkhead Box M1 (FoxM1) 
 
Identification of FoxM1 
 FoxM1 is a member of the forkhead box family of transcription factors, so named 
for their relation to the Drosophila melanogaster gene fork head (fkh).  Mutation of fkh 
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results in formation of ectopic head structures in place of the foregut and hindgut (Weigel 
et al., 1989).  The first mammalian homologue of fkh to be identified was Hepatocyte 
nuclear factor 3α (Hnf3α), which binds to and activates transcription of the liver-specific 
genes Transthyretin (TTR) and α1-antitrypsin (Costa et al., 1989; Lai et al., 1990).  
Hnf3α and fkh were found to share significant sequence similarity within their DNA 
binding domain, which was termed a “fork head domain” (Weigel and Jäckle, 1990).  
Two related mammalian gene products were then identified in the liver and were termed 
Hnf3β and Hnf3γ, the first evidence of a family of forkhead proteins (Lai et al., 1990; Lai 
et al., 1991).  Structural analysis of Hnf3γ’s forkhead domain bound to DNA revealed a 
variation on the helix-turn-helix motif, with three α-helices (H1-3), three β-sheets (S1-3), 
and two loops (W1-2) (Clark et al., 1993) (Figure 5).  As the loops resemble wings 
attached to a helical core, the DNA binding domain was termed a “winged-helix” 
domain. 
 Protein sequence comparisons revealed that Drosophila forkhead most closely 
resembles Hnf3β, with 91% identity (100/110 amino acids) within the DNA binding 
domain (Lai et al., 1991).  Expression pattern comparisons between the two proteins also 
revealed high similarity, suggesting that Hnf3β is the true mammalian orthologue of 
Drosophila forkhead (Monaghan et al., 1993).  Since this time, more than 100 forkhead 
family members have been identified in species ranging from yeast to humans (reviewed 
in Kaufman and Knochel 1996), and due to their diverse means of discovery a unified 
nomenclature was devised (Kaestner et al., 2000).  Currently, there are 44 murine 
forkhead family members, organized into 19 (A-S) phylogenetic subclasses (Tuteja and 
Kaestner, 2007a; Tuteja and Kaestner, 2007b; Montelius et al., 2007). 
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Figure 5.  Winged-helix “forkhead” DNA binding domain structure. The 
characteristic forkhead DNA binding domain is a variation of the helix-turn-helix 
motif, with three α-helices (H1-3), three β-sheets (S1-3), and two loops (W1-2).
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 FoxM1 was originally identified as an M phase phosphoprotein (MPP) by its 
interaction with the Mitotic protein monoclonal 2 antibody MPM2 (Westendorf et al., 
1994).  This antibody recognizes several phosphorylated epitopes, including F-phosphoT-
P-L-Q.  At that time, FoxM1 was referred to as MPP2.  Soon thereafter, FoxM1 was 
simultaneously cloned by three groups looking for new forkhead family members, who 
assigned the names of Trident (Korver et al., 1997a), Winged helix in INS-1 cells (WIN) 
(Yao et al., 1997), and HNF3/forkhead homolog 11 (HFH11) (Ye et al., 1997). 
Trident was cloned from murine thymus and was found by northern blot analysis 
to be expressed broadly within the brain, heart, lung, liver, kidney, and limb of embryos 
but only within the thymus in 6 week old mice (Korver et al., 1997a).  Trident expression 
was also observed within multiple cell lines, and this expression was reduced upon serum 
starvation and stimulated upon serum return, coinciding with initiation of S phase.  The 
DNA binding domain consensus site for Trident was identified as TAAACA. 
WIN was cloned from the rat insulinoma cell line INS-1 and was found by 
northern blot analysis to be expressed in multiple rodent endocrine cell lines, as well as 
embryonic and neonatal, but not adult, pancreas and liver (Yao et al., 1997).  Evaluation 
of e12, e14, e18, neonatal, and adult whole pancreas revealed a progressive decline in 
WIN expression.  Furthermore, WIN expression was detected within the testis and to a 
lesser extent the lung of adult mice, but not within brain, heart, liver, kidney, spleen, or 
skeletal muscle; and within the testis and thymus of adult humans, but not within 
stomach, intestine, pancreas, thyroid, adrenal cortex, adrenal medulla, or the human 
hepatoma cell line HepG2.  Importantly, Yao et al. identified three splice variants of 
human WIN, which they termed classes a, b, and c (Figure 6), and they found that these 
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Figure 6.  Human FOXM1 and mouse Foxm1 cDNA structures. Foxm1 introns
and exons are depicted in the diagram as lines and boxes, respectively.  The human 
FOXM1 cDNA contains two alternatively-spliced exons, producing three transcript 
variants.  Although there exists conflicting variant nomenclature within the literature, 
the NCBI denotes these transcript variants as 1, 2, and 3, and we refer to them as a, b, 
and c, respectively, in accordance with Yao et al. (1997).  Mouse Foxm1 is most 
homologous to human FOXM1b.
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variants were differentially expressed.  Because these variants are derived by alternative 
splicing of two exons that encode portions of the DNA binding and transcription 
activation domains (Figure 7), it was suggested that they may have different 
transcriptional activities and targets.  The consensus binding site for WIN was identified 
as AGATTGAGTA. 
HFH11 was cloned from the human colon carcinoma cell line Caco-2, and it was 
found by northern blot analysis to be expressed in multiple human carcinoma cell lines 
including HeLa (cervical carcinoma), A549, and H441 (both pulmonary adenocarcinoma) 
(Ye et al., 1997).  Interestingly, HFH11 expression was observed within HepG2 cells, in 
contrast to observations made by the group that identified WIN (Yao et al., 1997).  
Further northern blot analysis revealed that HFH11 was expressed at high levels in adult 
human thymus, testis, and intestine (small and large), and to a lesser extent in ovary, 
lung, heart, and placenta.  Only two splice variants of HFH11 were identified by this 
group, and they were termed HFH11A and HFH11B.  As HFH11A is the full-length 
transcript (encoding a 801-amino-acid protein), and HFH11B is missing two exons 
(encoding a 748-amino-acid protein), these variants are analogous to the human WIN 
class a and c variants (Yao et al., 1997).  The consensus binding site for HFH11 was 
identified as TACGTTGTTATTTGTTTTTTTCG. 
 
FoxM1 Gene and Protein 
FOXM1A has been shown to have little, if any, transcriptional activity, while 
FOXM1B and FOXM1C, along with murine FoxM1, which is most homologous to 
FOXM1B, are transcriptional activators (Ye et al., 1997; Leung et al., 2001; Ma et al., 
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Figure 7.  FoxM1 protein structure. This diagram depicts the domains and 
phosphorylation sites present within both mouse FoxM1 and human FOXM1, with the
appropriate corresponding coding exons.  The N-terminal domain is encoded by exon
2 and part of exon 3, and it contains two destruction boxes (D-box), as well as a KEN 
box, all of which are required for FoxM1 degradation.  The DNA binding domain 
(DBD) is encoded by part of exon 3 and exons 4-6.  As exon 6 is alternatively-spliced 
in humans, this may result in the transcript variants having different targets.  The C-
terminal transcription activation domain (TAD) is encoded by exons 7-10 (or 7 and 8 
in the mouse).  The presence of the alternatively-spliced exon 9 within transcript 
variant 1 (FOXM1a) accounts for the different activity observed in FOXM1A versus 
the B and C isoforms.  FoxM1 is phosphorylated by ERK1/2 at a serine residue near 
the nuclear localization signal (NLS), as well as in the TAD near a protein interaction 
(LXL) sequence.  Several Cdk phosphorylation sites are also located within the TAD.
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2005).  The lack of FOXM1A transcriptional activity is due to the presence of an 
additional exon (6 or A2) within the C-terminal transcription activation domain, which 
interferes with its activity (Ye et al., 1997).  Interestingly, FOXM1A is also expressed at 
much lower levels than are either FOXM1B or FOXM1C in many tissues (Yao et al., 
1997).  Additionally, FOXM1c has been shown to be the predominant transcript found in 
human fibroblast cell lines (Ma et al., 2005).  Murine FoxM1 and human FOXM1B share 
78% amino acid sequence identity and 86% sequence similarity. 
FoxM1 is the only isoform within the M subclass of Fox proteins, and beyond the 
characteristic forkhead or winged-helix DNA binding domain, it does not share 
homology with other proteins.  Based on amino acid sequence analysis, FoxM1 is most 
closely related to the P and O Fox subclasses, in both mouse and human (Figures 8, 9). 
 
Transcriptional Regulation of Foxm1 
Currently, little is known regarding transcriptional regulation of Foxm1.  The 
same group that cloned Trident published the only FOXM1 promoter analysis to date 
(Korver et al., 1997b).  This group reported that a 0.3 kb (-296 to +60 bp) fragment of the 
FOXM1 promoter was activated during S-phase compared to G0, and that fragments 
extending to -437 bp, -1411 bp, and -2436 bp upstream of the transcription start site also 
exhibited activation but to a lesser extent.  Furthermore, they identified a putative E-box 
at -49 to -44 bp but did not find a TATA box.  Teh et al. identified FOXM1 as a 
downstream target of Sonic hedgehog (SHH) and Gli1 signaling, and although a direct 
transcriptional link was not established, a putative Gli response element was identified at 
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Figure 8.  NCBI BLAST Tree for mouse FoxM1 protein. The basic local 
alignment search tool (BLAST) on the National Center for Biotechnology 
Information (NCBI) website was queried for the murine FoxM1 protein sequence 
(NP_032047.4) against the mouse refseq_protein database using pairwise alignment.  
The results are displayed in a rectangular arrangement, and they depict the relative 
sequence similarities between FoxM1 and other murine proteins.  (rid7WT536TT012, 
performed on July 16, 2008)
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Figure 9.  NCBI BLAST Tree for human FOXM1 protein. The BLAST tool on 
the NCBI website was queried for the human FOXM1 protein sequence (NP_973731) 
against the human refseq_protein database using pairwise alignment.  The results are 
displayed in a rectangular arrangement, and they depict the relative sequence 
similarities between FOXM1 and other human proteins.  (rid7WTMNA35015, 
performed on July 16, 2008)
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-230 bp upstream of the transcription start site within the FOXM1 promoter (Teh et al., 
2002). 
 
Post-translational Regulation of FoxM1 
FoxM1 is larger than most Fox proteins (predicted molecular weight is 83.3 kDa), 
and it contains unique domains and phosphorylation sites, primarily within the C-terminal 
transactivation domain, many of which have not yet been fully-characterized (Figure 7).  
These include multiple serine/threonine phosphorylation sites for Cdk/Cyclin complexes 
and Mitogen-activated protein kinases (MAPKs).  A nuclear localization signal (NLS) is 
located near the DNA binding domain, and it has been shown that serine phosphorylation 
of FOXM1B by ERK1/2 near the NLS may mediate its nuclear localization and enhanced 
activity in response to MAPK signaling (Ma et al., 2005).  Importantly, activity of 
FOXM1C was not enhanced in response to MAPK signaling, as this isoform lacks the 
phosphorylation site due to alternative splicing of exon 6.  An additional ERK1/2 serine 
phosphorylation site is located within the C terminus of FoxM1 near a Cdk/Cyclin 
complex interaction domain, and mutation of this residue impairs FoxM1 activity, 
possibly by interfering with this important protein-protein interaction.  The domain by 
which FoxM1 interacts with Cdk/Cyclin complexes contains an LXL sequence, which is 
required for binding (Major et al., 2004).  Once bound to FoxM1, Cdks (specifically 
Cdk2 complexed with Cyclin E and Cdk1 complexed with Cyclin B) can phosphorylate 
specific serine/threonine residues within the transcription activation domain, which is 
required for recruitment of the p300/CREB-binding protein (CBP) transcriptional 
coactivators and for FoxM1 transcriptional activity.  As Cdk2/Cyclin E are present during 
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the G1/S transition and Cdk1/Cyclin B are present during the G2/M transition (Dzau et al., 
2002), FoxM1 phosphorylation is maintained as the cell progresses through the cell cycle. 
Interestingly, the Cdk inhibitor p27Kip1 can be found in the Cdk/Cyclin/FoxM1 
complex, where it indirectly inhibits FoxM1 transcriptional activity, likely by reducing 
Cdk-mediated phosphorylation of FoxM1 (Kalinichenko et al., 2004).  FoxM1 is also 
inhibited by the tumor suppressor p19ARF, which binds to FoxM1 via a 19 amino acid 
sequence (p19ARF26-44).  Indeed, this peptide alone can inhibit FoxM1 activity both in 
vitro and in vivo, due at least in part to its ability to target FoxM1 to the nucleolus 
(Kalinichenko et al., 2004; Gusarova et al., 2007).  In addition, FoxM1 has been shown 
to interact with the Rb protein, particularly during G1, but hyper-phosphorylation of Rb 
disrupts this interaction (Major et al., 2004), suggesting the FoxM1 may be negatively 
regulated by Rb.  This hypothesis is supported by the finding that over-expression of the 
human papilloma virus type 16 E7 protein, which inhibits Rb and targets it for 
degradation in addition to binding to FoxM1 directly, enhanced FoxM1 activity in a 
reporter assay (Luscher-Firzlaff et al., 1999). 
FoxM1 is also negatively regulated by proteosome-mediated degradation (Park 
HJ et al., 2008a).  During late mitosis and early G1, FoxM1 is found in a complex with 
the Anaphase-promoting complex/cyclosome (APC/C) E3 ubiquitin ligase and its adaptor 
Cdc20 homolog 1 (Cdh1).  The N terminus of FoxM1 contains two “destruction” 
sequences (D-boxes; RXXL) and a KEN sequence (KEN box), which interact with Cdh1 
and are required for FoxM1 degradation.  Such negative regulation of FoxM1 is 
necessary in order to prevent inappropriate re-entry into S phase. 
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There is also evidence that the N terminus of FoxM1 acts as an auto-inhibitory 
domain by interacting with the C-terminal transactivation domain (Park HJ et al., 2008b; 
Laoukili et al., 2008).  Deletion of the N terminal domain (amino acids 1-232) resulted in 
prolonged and increased transcriptional activity, even in the absence of MAPK signaling 
or Cdk/Cyclin complex binding.  However, activated Cdk/Cyclin complexes disrupted 
the interaction between the N and C termini.  These results suggest that phosphorylation 
of the C terminus by Cdk/Cyclin complexes releases the C-terminal transactivation 
domain from autoinhibition, providing a possible mechanism by which FoxM1 is kept 
inactive during initiation of the G1/S transition. 
 
FoxM1 Targets 
Once within the nucleus and properly activated, FoxM1 drives transcription of 
various genes that coordinate the G1/S and G2/M transitions, as well as karyokinesis and 
cytokinesis (Figure 10) (Costa, 2005; Laoukili et al., 2007).  During the G1/S transition, 
the pocket proteins Rb, p107, and p130 are phosphorylated by Cdk4 and Cdk6, both of 
which must bind D-type Cyclins in order to be active (Massague, 2004).  Phosphorylation 
of the pocket proteins causes dissociation from the E2F transcription factor, allowing E2F 
to activate transcription of S phase-promoting genes, including Cyclin E.  Cyclin E 
complexes with Cdk2, which is required for hyperphosphorylation of Rb.  As mentioned 
before, Rb hyperphosphorylation disrupts its interaction with FoxM1, likely releasing 
FoxM1 from inhibition.  In agreement with this theory, during the G1/S transition, FoxM1 
is required for transcription of Cell division cycle 25 homolog A (Cdc25A), which 







Figure 10.  FoxM1 transcriptional targets are involved in cell cycle regulation.
This diagram depicts key cell cycle regulators.  Transcription factors, including 
FoxM1, are shown in green, Cyclins are shown in purple, Cdks are shown in orange, 
cell cycle inhibitors are shown in red, and FoxM1 transcriptional targets are shown in 
yellow.  FoxM1 targets regulate the G1/S transition, G2/M transition, karyokinesis, 
and cyctokinesis.  Proteins that have been shown to play an important role in β cell 
proliferation are designated with an asterisk (*) .  Figure is adapted from Wang et al.
(2005).
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hyperphosphorylates Rb but also phosphorylates the Cdk inhibitor (CDKI) proteins 
p21Cip1 and p27Kip1, targeting them for recognition by the Skp1-Cullin1-F box (SCF) 
ubiquitin ligase complex, which initiates their proteosome-mediated degradation (Sheaff 
et al., 1997; Carrano et al., 1999; Montagnoli et al., 1999; Bornstein et al., 2003).  The 
SCF ubiquitin ligase complex is composed of three proteins, two of which, Skp2 and Cdk 
subunit 1 (Cks1), confer substrate specificity to the SCF complex and are direct 
transcriptional targets of FoxM1 (Wang et al., 2005).  FoxM1 also indirectly regulates 
p27Kip1 via direct transcriptional activation of Kinase interacting stathmin (Kis), a nuclear 
kinase that phosphorylates p27Kip1 and promotes its nuclear export (Petrovic et al., 2008).  
There is conflicting evidence regarding whether FoxM1 activates Cyclin D1 expression 
(Leung et al., 2001; Wang et al., 2001).  Therefore, it is unclear whether initiation of the 
G1/S transition involves FoxM1; however, progression into S phase does require FoxM1. 
During the G2/M transition, FoxM1 directly activates transcription of Cdc25B, 
which dephosphorylates and activates Cdk1 (Wang et al., 2005).  Cdk1 activity also 
depends on its binding to Cyclin B1, another direct transcriptional target of FoxM1 
(Leung et al., 2001; Wang et al., 2005).  The Cdk1/Cyclin B1 complex was previously 
referred to as the M-phase promoting factor (MPF) (Fung and Poon, 2005), and as 
discussed, this complex phosphorylates and activates FoxM1 (Major et al., 2004), thus 
forming a positive feedback loop.  FoxM1 also directly activates transcription of Polo-
like kinase 1 (Plk1), Aurora B kinase, Centromere protein A (Cenp-A), Cenp-B, Cenp-F, 
and Survivin (Birc5) (Laoukili et al., 2005; Wang et al., 2005).  Plk1 is necessary for 
centrosome duplication and, with Aurora B kinase, mediates attachment of the 
microtubule spindles to kinetochores (Barr et al., 2004).  Plk1 also phosphorylates and 
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activates Cdc25C, which dephosphorylates and activates Cdk1.  Survivin regulates 
Aurora B kinase centromere localization, while Cenp-A, Cenp-B, and Cenp-F are 
involved in kinetochore assembly and chromosome segregation (Howman et al., 2000; 
Laoukili et al., 2005).  FoxM1 also activates transcription of the proliferation-associated 
genes C-myc, C-fos, Hsp70, and Histone H2B/a (Wierstra and Alves, 2006; Wierstra and 
Alves, 2008). 
Other transcriptional targets of FoxM1 that are not directly involved in cell cycle 
regulation include Estrogen receptor α (ERα) (Madureira et al., 2006), Laminin α4 
(Lama4) (Kim et al., 2005), and c-Jun N-terminal kinase 1 (Jnk1) (Wang et al., 2008a).  
Madureira et al. found that FOXM1 expression correlated with ERα expression in breast 
cancer cell lines and that FOXM1 activated the ERα promoter in reporter assays 
(Madureira et al., 2006).  In addition, they found that FOXM1 directly bound to forkhead 
response elements (FHREs) within the proximal region of the ERα promoter in vivo.  
Interestingly, FOXM1 was found to interact in vivo with FOXO3a, a previously-
identified transcriptional activator of ERα.  However, Laoukili et al. found that over-
expression of FoxO3a could not rescue expression of Plk1, Cyclin B1, or Cenp-F in 
Foxm1-/- mouse embryonic fibroblasts (MEFs) (Laoukili et al., 2005). 
Kim et al. found that mice with a global deletion of FoxM1 (Foxm1-/-) exhibit 
defects in development of the pulmonary vasculature (Kim et al., 2005).  They attributed 
these defects to, among other things, alterations in TGF-β signaling and laminin 
expression.  In particular, they found that FoxM1 activated the Lama4 promoter in 
reporter assays, identified two putative FoxM1 binding sites within the Lama4 promoter, 
and determined that endogenous FoxM1 could bind to the Lama4 promoter. 
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Wang et al. found that FoxM1 directly activates transcription of Jnk1 in the 
osteosarcoma cell line U2OS (Wang et al., 2008a).  Activation/phosphorylation of Jnk1 
is associated with many cellular processes, including proliferation, due to the variety of 
transcription factors that it phosphorylates.  Interestingly, Wang et al. found that over-
expression of Jnk1 in Foxm1-depleted U2OS cells rescued the cells from G1/S, but not 
G2/M, blockade.  Furthermore, they found that Jnk1 was required downstream of FoxM1 
for anchorage-independent growth, migration, and invasion of U2OS cells in vitro, at 
least partially via expression of matrix metalloproteinases (MMPs) 2 and 9.  Thus, 
FoxM1 may play roles in other cellular processes in addition to proliferation. 
 
FoxM1 Null Mice 
As previously discussed, FoxM1 is broadly expressed during embryogenesis and 
is restricted to tissues with high rates of cell turnover in the adult, in accordance with its 
role in regulating cell proliferation.  Two groups have generated mice with global 
disruption of the Foxm1 allele (Korver et al., 1998; Krupczak-Hollis et al., 2004).  
Korver et al. generated mice with targeted insertion of a Phosphoglycerate kinase (PGK)-
Neomycin resistance (Neo) cassette into the fourth exon of Foxm1 (Foxm1Neo), which 
codes for the DNA binding domain (Figure 11A).  In contrast, Krupczak-Hollis et al. 
generated mice with deletion of exons 4-8, which code for the DNA binding and 
transactivation domains (Figure 12A).  These mice were generated by crossing mice with 
loxP sequences inserted into the third intron and the 3’ UTR of the Foxm1 locus to mice 
expressing a ubiquitous Cre recombinase (E2A-Cre).  Cre-mediated recombination of the 
floxed Foxm1 alleles within the germline allowed for propagation of a mouse line with a 
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Figure 11.  Foxm1Neo/Neo mice.  (A) A FoxM1 hypomorph was generated by inserting 
a PGK-Neo cassette into exon 4, which codes for the DNA binding domain.  (B)
These mice exhibit variable neonatal lethality and polyploid hepatocytes and 
cardiomyocytes.  A DAPI-labeled section from a neonatal Foxm1Neo/+ heart is shown 





Figure 12.  Foxm1-/- mice.  (A) A Foxm1flox allele was generated by inserting loxP
sequences within the third intron and in the 3’ untranslated region, flanking a PGK-
Neo cassette.  Deletion of the sequence between the loxP sites is accomplished by Cre
recombinase driven by either a global (EIIA) or hepatoblast-specific (AFP) promoter.  
Deletion of the floxed region of Foxm1 results in a null allele.  (B) Global Foxm1-/-
mice exhibit embryonic lethality with edema and hemorrhaging.  Shown here are 




global functionally null Foxm1 allele (Foxm1null).  Comparison of these two lines 
suggests that the Foxm1Neo allele acts as a hypomorph, rather than as a true null. 
Surprisingly, global deletion of Foxm1 in mice (Foxm1-/-) does not have 
catastrophic results, as gross embryological morphology is unaffected (Figure 12B) 
(Krupczak-Hollis et al., 2004).  However, Foxm1 deletion does cause late embryonic 
lethality (between e13.5 and e18.5) due to hepatic and cardiac defects, with severe edema 
and hemorrhaging.  These embryos exhibited significant reductions in hepatoblast 
proliferation and number, but gross liver size was unchanged due to hepatoblast 
hypertrophy.  Part of the hypertrophic phenotype can be explained by the presence of 
polyploid hepatoblasts.  Polyploid cardiomyocytes were also observed (Figure 11B) 
(Korver et al., 1998), which was likely due to endoreduplication (DNA synthesis without 
subsequent cytokinesis) (Wonsey and Follettie, 2005).    Furthermore, Foxm1-/- embryos 
displayed reduced proliferation of mesenchymal and vascular smooth muscle cells and 
defective vasculogenesis within the lungs due to impaired differentiation of mesenchymal 
cells into endothelial cells (Kim et al., 2005), in addition to defects in development of 
intra-hepatic biliary ducts, hepatic vessels, hepatic sinusoids, and the gall bladder 
(Krupczak-Hollis et al., 2004). 
Consistent with the proliferation and polyploid phenotypes observed in Foxm1-/- 
embryos, MEFs collected from these embryos exhibited delayed entry into G2, and those 
cells that did enter mitosis exhibited inappropriate chromosome segregation, resulting in 
frequent aneuploidy and mitotic failure (Laoukili et al., 2005).  These findings were 
associated with reduced expression of Cyclin A2, Cyclin B1, Cyclin B2, Plk1, Aurora B 
kinase, Cdc25B, and Cenp-F in Foxm1-/- MEFs compared to wild-type (WT) MEFs. 
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Mouse Models of Altered FoxM1 Expression in the Liver 
Early deletion of Foxm1 specifically within hepatoblasts using a Cre-lox system 
with an α-fetoprotein (Afp) enhancer driving Cre recombinase expression 
(Foxm1flox/flox;Afp-Cre) yielded similar lethality as observed in global Foxm1 null 
embryos, suggesting that the liver defects in the Foxm1-/- embryos were responsible for 
the lethal phenotype (Krupczak-Hollis et al., 2004).  Additionally, these embryos 
exhibited polyploid hepatoblasts and impaired development of intra-hepatic biliary ducts.  
However, hepatoblast proliferation and number were less-dramatically reduced in these 
embryos than in Foxm1-/- embryos, suggesting that Foxm1 deletion is incomplete in the 
Foxm1flox/flox;Afp-Cre mouse model.  Thus, FoxM1 is necessary for proliferation of 
hepatoblasts, which are bipotential cells that can differentiate into hepatocytes or biliary 
epithelial cells. 
FoxM1 is also required for proliferation of adult hepatocytes, evidenced by 
Foxm1flox/flox;Albumin-Cre mice, which develop normally but exhibit significant 
reductions in hepatocyte proliferation and liver regeneration following partial 
hepatectomy (PHx) (Wang et al., 2002a).  These mice also displayed hepatocyte 
hypertrophy following PHx, which compensated for the reduced amounts of proliferation, 
resulting in regeneration of gross liver size similar to that of Foxm1flox/flox Control mice.  
These findings were associated with increased nuclear p21Cip1 expression, reduced 
expression of Cdc25A, Cdc25B, and Cyclin B1, and reduced hyperphosphorylation of 
Rb, but no changes in Cyclin D (Ccnd) or Cyclin E (Ccne) transcripts. 
As FoxM1 is required for proliferation in some cell types and is highly-expressed 
in embryonic cells and most, if not all, cancer cell lines studied to date, several groups 
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have induced transgenic over-expression of FOXM1 in order to study its role in aging and 
cellular transformation.  Ye et al. found that transgenic liver-specific over-expression of 
FOXM1c (TTR-FOXM1c) accelerated hepatocyte proliferation following PHx (Ye et al., 
1999).  However, the peak amount of hepatocyte proliferation was similar to that 
observed in WT, and hepatocyte proliferation under normal conditions was not affected 
by over-expression of FOXM1c, likely due to the fact that FOXM1 remained localized to 
the cytoplasm unless stimulated by PHx.  These data are consistent with post-
translational modification of FoxM1 being required for nuclear localization, and they 
suggest that the amount of endogenous FoxM1 limits the timeframe in which replication 
can occur, as increasing the expression of FoxM1 allowed for earlier nuclear localization 
and proliferation.  Interestingly, Wang et al. found that over-expression of FOXM1c, 
either by transgenic (TTR-FOXM1c) or adenoviral (Ad-FOXM1c) means, reversed the 
normal age-related decrease in hepatocyte proliferation (Wang et al., 2001; Wang et al., 
2002b).  Using either means of FOXM1C over-expression, this group observed an 
increase in the absolute amount of proliferation in old (12 month old) mice following 
PHx to levels similar to those observed in young (2 month old) mice after the operation.  
Likewise, treatment with human GH (hGH), alone or in conjunction with PHx, induced 
FoxM1 expression and stimulated hepatocyte proliferation in old mice to levels 
comparable to those observed in young, untreated mice (Krupczak-Hollis et al., 2003).  
Interestingly, even without the stimulus of PHx, treatment with hGH dramatically 
stimulated hepatocyte proliferation to a similar extent in young and old mice, in 
comparison to untreated mice.  Importantly, such results were not observed in mice with 
hepatocyte-specific deletion of Foxm1 (Foxm1flox/flox;Albumin-Cre), indicating that 
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FoxM1 acts downstream of the GH signaling pathway to mediate hepatocyte 
proliferation. 
Importantly, over-expression of FOXM1C within the liver (TTR-FOXM1c) was 
not found to be associated with hepatocellular carcinoma (HCC) progression, but was 
associated with increased proliferation of pre-neoplastic and early neoplastic lesions 
induced by diethylnitrosamine/phenobarbital (DEN/PB), resulting in increased size of 
these lesions (Kalinina et al., 2003).  However, FoxM1 was required for formation of 
hepatic adenomas and HCC, as Foxm1flox/flox;Albumin-Cre mice exhibited no tumor 
formation, associated with reduced hepatocyte proliferation but increased hepatocyte size 
(hypertrophy), in response to DEN/PB treatment in comparison to Foxm1flox/flox Control 
mice.  These results suggest that FoxM1 is necessary but not sufficient for initiation and 
progression of HCC (Kalinichenko et al., 2004). 
 
Mouse Models of Altered FoxM1 Expression in the Lung 
FoxM1 has also been shown to play an important role within the lung.  
Kalinichenko et al. exposed transgenic mice that ubiquitously over-expressed FOXM1C 
driven by a fragment of the reverse orientation splice acceptor (Rosa) 26 promoter 
(Rosa26-FOXM1c) to butylated hydroxytoluene, a chemical known to induce lung injury 
that initiates within the epithelial population and then affects the endothelial and smooth 
muscle cells (Kalinichenko et al., 2003).  After exposure, these mice exhibited 
accelerated and enhanced proliferation of all of these cell types within the lungs in 
comparison to WT mice, and these changes were associated with earlier nuclear 
49
localization of FoxM1, increased expression of Cyclin A2, Cyclin B1, Cyclin E, Cyclin 
F, and Cdk1, and decreased expression of p21Cip1. 
As discussed before, endothelial cell differentiation and smooth muscle cell 
proliferation were impaired within the lungs of global Foxm1-/- embryos (Kim et al., 
2005).   However, these embryos died prior to the normal timepoint of completion of 
pulmonary vasculogenesis.  Thus, mice with endothelial cell-specific deletion of Foxm1 
(Foxm1flox/flox;Tie2-Cre) were used to study the role of FoxM1 in mature endothelial cells 
(Zhao et al., 2006).  These mice displayed no phenotype at baseline, indicating that 
FoxM1 is not required for normal endothelial cell turnover.  However, when these mice 
were injected with lipopolysaccharide (LPS), a potent mediator of inflammation that 
induces microvascular injury within the lungs, they exhibited reduced endothelial cell 
proliferation, impaired endothelial barrier repair, increased vascular permeability, and 
increased mortality.  These findings were associated with reduced expression of Cyclin 
B1 and Cdc25C, as well as increased expression of p27Kip1.  Additionally, LPS injection 
into WT mice resulted in a significant increase in Foxm1 expression within the lungs, 
indicating that FoxM1 is normally up-regulated following microvascular injury and that 
this up-regulation is necessary for normal microvascular repair. 
FoxM1 has also been shown to play an important role in lung tumorigenesis.  In 
contrast to the results observed within the liver (Kalinina et al., 2003), Rosa26-FOXM1c 
mice exposed to the tumor-inducing combination of 3-methylcholanthrene and butylated 
hydroxytoluene did exhibit enhanced lung adenoma progression compared to WT mice 
(Wang et al., 2008b).  The adenomas found within the lungs of Rosa26-FOXM1c mice 
were of greater number, size, and proliferative index than those found in WT mice after 
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the same treatment, and they developed more quickly.  However, mice with an inducible 
global deletion of Foxm1 driven by the Myxovirus (influenza virus) resistance 1 promoter 
(Foxm1flox/flox;Mx-Cre), which is activated by exposure to Interferon (IFN) α, IFNβ, or 
double-stranded (ds) RNA,  exhibited reduced number, size, and proliferative index of 
lung tumors after treatment with urethane than did Foxm1flox/flox Control mice after the 
same treatment (Kim et al., 2006).  Additionally, urethane treatment of Foxm1flox/flox 
Control mice stimulated expression FoxM1 within the pulmonary epithelium, whereas 
FoxM1 was undetectable in untreated Foxm1flox/flox Control pulmonary epithelium.  Thus, 
FoxM1 expression levels clearly correlate with tumor burden in the lung. 
 
Mouse Models of Altered FoxM1 Expression in the Colon 
 Similar to the lungs, FoxM1 expression levels within the colon also correlate with 
tumor burden.   Over-expression of FOXM1C in Rosa26-FOXM1c mice exacerbated 
tumor development and progression in response to the carcinogen azoxymethane and 
dextran sodium sulfate (Yoshida et al., 2007).  These mice developed larger and more 
invasive tumors in greater number than those found in WT mice after the same treatment, 
associated with increased proliferation specifically within neoplastic lesions.  
Alternatively, mice with gut-specific deletion of Foxm1 (Foxm1flox/flox;Villin-Cre) 
exhibited reduced tumor development and growth after the same treatment versus 
Foxm1flox/flox Control mice.  The neoplastic lesions that did develop in 
Foxm1flox/flox;Villin-Cre mice exhibited reduced proliferation and never became invasive.  
Both mouse models (Rosa26-FOXM1c  and Foxm1flox/flox;Villin-Cre) exhibited alterations 
in expression of the FoxM1 targets Cyclin B1 and Survivin, as well as Cyclin A2. 
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Mouse Model of Altered FoxM1 Expression in the Prostate 
Transgenic FOXM1C over-expression in Rosa26-FOXM1c mice also accelerated 
the progression of prostate carcinoma initiated in two mouse models of prostate cancer 
(Kalin et al., 2006).  Transgenic (Tg) adenocarcinoma of the mouse prostate (TRAMP) 
mice express the SV40 virus large T and small t tumor antigen oncoproteins in prostate 
epithelial cells, driven by the Probasin promoter.  These proteins inactivate the tumor 
suppressors Rb and p53, resulting in hyperplasia, prostatic intraepithelial neoplasia, and 
invasive prostatic carcinoma.  LADY mice express only the SV40 virus large T antigen 
oncoprotein driven by the same promoter and exhibit a similar progressive phenotype.  
Over-expression of FOXM1C on either the LADY or TRAMP background resulted in an 
increased propensity towards development of prostate carcinoma, as well as increased 
proliferation of prostatic cells within the carcinoma. 
 
Mouse Models of Altered FoxM1 Expression in the Pancreas 
 One of the initial groups that identified FoxM1 (WIN) found it to be highly 
expressed in early embryonic pancreas, and to a progressively lesser extent in later 
embryonic and neonatal pancreas, with undetectable levels of expression in adult whole 
pancreas by northern blot analysis (Figure 13) (Yao et al., 1997).  Our laboratory utilized 
immunohistochemistry to confirm these results and to demonstrate that at all timepoints, 
FoxM1 is more abundant in endocrine than exocrine pancreatic cells (Figure 14A-C) 
(Zhang H et al., 2006).  Mice with a pancreas-wide deletion of Foxm1 
(Foxm1flox/flox;Pdx15.5kb-Cre) exhibited normal pancreas development, but displayed 
postnatal effects of loss of FoxM1, including polyploidy of endocrine and exocrine cells, 
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Figure 13.  FoxM1 expression within the pancreas. Northern blot analysis shows 
that Foxm1 (WIN) is expressed at high levels in embryonic liver and pancreas, but is 
expressed at a lower level in neonatal pancreas, and is undetectable in adult whole 
pancreas and liver.  Figure is from Yao et al. (1997).
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Figure 14.  FoxM1 is highly expressed within the endocrine pancreas and is 
required for normal postnatal β cell growth and proliferation.  FoxM1 protein is 
highly expressed within the endocrine cords (arrowheads) at e15.5 (A) and within the 
developing islets at e18.5 (B).  At these timepoints, FoxM1 is expressed to a lesser 
degree in acinar (a) and ductal (arrow) tissue.  At 9 weeks of age (C), FoxM1 is 
expressed at a low level in a subset of islet (outlined) cells, and to an even lesser 
extent in exocrine cells.  Pancreas-wide deletion of Foxm1 in Foxm1flox/flox;Pdx15.5kb-
Cre mice resulted in reduced growth of postnatal β cell mass (D) and reduced β cell 
proliferation (E) as early as 4 weeks of age.  Pancreas and β cell mass development 
during embryogenesis were not impaired. Figure is adapted from Zhang et al. (2006).
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reduced β cell mass (Figure 14D), reduced islet size, decreased pancreatic insulin content 
and reduced β cell proliferation (Figure 14E).  These β cell effects were associated with 
increased nuclear p27Kip1 and evidence of β cell senescence, and they resulted in a 
progressive diabetic phenotype specifically within male Foxm1flox/flox;Pdx15.5kb-Cre mice.  
Thus, FoxM1 is required for normal postnatal growth of β cell mass and normal β cell 
turnover in the adult mouse. 
 
Therapeutic Implications of FOXM1 Modification 
 As the above studies indicate, FoxM1 is involved in the processes of 
development, regeneration, aging, and tumorigenesis.  Thus, it is a highly desirable target 
for clinical manipulation of these processes.  However, these studies also highlight the 
importance of balancing FoxM1’s beneficial and detrimental effects.  Aberrantly high 
expression of FOXM1 is associated with many human cancers, including HCC (Okabe et 
al., 2001), intrahepatic cholangiocarcinoma (Obama et al., 2005), colorectal carcinoma 
(Douard et al., 2006), basal cell carcinoma (Teh et al., 2002), infiltrating ductal breast 
carcinoma (Wonsey and Follettie, 2005),  and anaplastic astrocytoma and glioblastoma 
(van den Boom et al., 2003; Liu et al., 2006).  A meta-analysis approach also identified 
FoxM1 as being up-regulated in tumors of the bladder, cervix, kidney, ovary, testis, 
pancreas, prostate, small intestine, stomach, trachea, and uterus (Pilarsky et al., 2004).  
These data, combined with the findings that deletion of Foxm1 protects mice against 
various forms of cancer formation and progression makes down-regulating FOXM1 
expression and/or inhibiting its activity a potential treatment for multiple human cancers. 
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 Three potentially therapeutic inhibitors of FoxM1 that have been identified are the 
p19ARF26-44 peptide (Kalinichenko et al., 2004; Gusarova et al., 2007) and the thiazole 
antibiotics Siomycin A and thiostrepton (Radhakrishnan et al., 2006; Gartel, 2007; Kwok 
et al., 2008).  Siomycin A and thiostrepton were identified using a high-throughput 
screen looking for agents that changed FoxM1 activity.  In addition to inhibiting FoxM1 
activity, these compounds also inhibited FoxM1 expression, as FoxM1 is involved in a 
positive autoregulatory loop.  Importantly, both Siomycin A and thiostrepton specifically 
inhibited growth and stimulated apoptosis of cancer cell lines.  p19ARF is an endogenous 
tumor suppressor, so named for its size (19 kDa) and the fact that it is encoded by an 
alternative reading frame within the ARF/INK4a locus that also encodes the CDKI 
p16INK4a, reviewed in (Costa et al., 2005).  p19ARF is normally up-regulated in response to 
tumorigenic stimuli, and it functions to stabilize the p53 tumor suppressor and inhibit the 
functions of E2F, c-Myc, and FoxM1.  However, p19ARF is silenced in many human 
cancers.  Gusarova et al. successfully administered p19ARF26-44 peptide, the portion 
required for its interaction with FoxM1, to mice with HCC and reduced their tumor 
burden, associated with reduced tumor cell proliferation, impaired angiogenesis, and 
increased tumor cell apoptosis (Gusarova et al., 2007).  As these effects were specific to 
HCC areas but not adjacent normal areas, this study indicates that whole-body 
administration of p19ARF26-44 peptide can be used to specifically treat tumors.  
Additionally, these results highlight the two primary therapeutic effects of FoxM1 
inhibitors: reducing proliferation of cancer cells and stimulating their apoptosis via 
mitotic catastrophe (Wonsey and Follettie, 2005). 
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 Despite the concerns regarding tumorigenecity, up-regulation of FoxM1 
expression or activity is of interest for enhancing tissue regeneration and 
preventing/reversing the aging process.  In fact, FOXM1 is significantly down-regulated 
in a human disorder of premature aging termed Hutchinson-Gilford progeria (Ly et al., 
2000), and reduced FoxM1 expression with age has been described in multiple tissues.  
Over-expression of FoxM1 within the liver has been shown to reverse age-associated 
reductions in proliferation (Wang et al., 2002a; Wang et al., 2002b), and it is likely that 
FoxM1 would have such an effect in other tissues as well.  However, because of the 
complexity of FoxM1’s post-translational modifications that are required for both its 
nuclear localization and activation, it is clear that mere over-expression of FoxM1 is not 
sufficient to induce dramatic changes in cellular proliferation. 
 
Overview and Aims of Dissertation 
 Previous studies in our laboratory showed that FoxM1 is highly expressed within 
pancreatic endocrine cells and is required for normal growth and maintenance of 
postnatal β cell mass via regulating postnatal β cell proliferation (Zhang H et al., 2006).  
However, several questions remained, which this thesis sought to address.  First, Zhang et 
al. showed that β cell mass at birth in Foxm1flox/flox;Pdx15.5kb-Cre mice was comparable to 
that of Foxm1flox/flox Control mice (Zhang H et al., 2006), but no analysis of β cell 
proliferation during embryogenesis was performed.  Because other studies have shown 
that several of the factors that regulate β cell proliferation differ between embryonic and 
adult stages, it is possible that FoxM1 is not required during embryogenesis for β cell 
proliferation.  Alternatively, FoxM1 could be required for embryonic β cell proliferation, 
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but neogenesis is able to compensate for this deficiency in Foxm1flox/flox;Pdx15.5kb-Cre 
mice in order to generate a normal β cell mass by birth.  Second, although Zhang et al. 
showed that Foxm1flox/flox;Pdx15.5kb-Cre adult mice exhibited reduced β cell proliferation, 
it is unclear whether FoxM1 is absolutely required for β cell proliferation under all 
conditions, or whether only normal turnover of the β cell population relies on FoxM1.  
Third, because FoxM1 has been primarily described as a regulator of the cell cycle, 
Zhang et al. focused on analysis of β cell proliferation in Foxm1flox/flox;Pdx15.5kb-Cre 
mice, but it is unclear whether the other processes that contribute to β cell mass are also 
affected by loss of FoxM1. 
To address these questions, this thesis sought to determine whether FoxM1 
regulated β cell proliferation and β cell mass during embryogenesis, following pancreatic 
injury, and in response to diet-induced obesity.  Chapter II describes the methods used.  
Chapter III presents data regarding the role of FoxM1 in β cell proliferation, β cell size, 
and β cell neogenesis following 60% partial pancreatectomy (PPx) using 
Foxm1flox/flox;Pdx15.5kb-Cre and Rosa26-FOXM1c mice.  Chapter III also includes 
analyses of FoxM1’s role in embryonic β cell proliferation.  Chapter IV presents data 
regarding using a high-fat diet to induce β cell mass expansion, in order to assess the role 
of FoxM1 in this process.  This chapter also describes preliminary studies of islet 
function in Foxm1flox/flox;Pdx15.5kb-Cre mice.  Chapter V presents an experimental design 
to assess β cell lineage labeling and β cell neogenesis following 60% PPx, as well as 
preliminary results regarding the use of tamoxifen in this system to activate the 
Pdx1PB-CreERT2 fusion protein.  Chapter VI describes the generation of a monoclonal 
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antibody against FoxM1.  Conclusions, implications, and future directions for the studies 




MATERIALS AND METHODS 
 
Mice 
Foxm1flox/flox mice on a mixed background (129SvJ, C57Bl/6) were generously 
provided by Dr. Robert H. Costa (University of Illinois at Chicago) and were described 
by (Wang et al., 2002a).  Briefly, loxP sequences were inserted within the third intron 
and the 3’ untranslated region (UTR) of the Foxm1 allele (Figure 12A).  Thus, upon 
recombination by the P1 phage Cre recombinase protein, exons 4-8, which encode the 
DNA binding and transcription activation domains, will be deleted, yielding a null allele.  
Of note, a PGK-Neo cassette remains within the 3’ UTR of the Foxm1flox allele, flanked 
by an additional loxP sequence.  Therefore, recombination can occur among 3 different 
loxP sequences, and complete recombination results in removal of exons 4-8 of Foxm1 as 
well as the PGK-Neo cassette.  For some experiments, Foxm1flox mice were backcrossed 
for 8 generations to the C57Bl/6JBom strain (Taconic). 
Pdx15.5kb-Cre mice (on a mixed ICR, CBA, C57Bl/6 background) were 
generously provided by Dr. Guoqiang Gu (Vanderbilt University) (Gu et al., 2002).  
These mice express Cre recombinase driven by a 5.5 kb region of the Pdx1 promoter 
(between the SalI and SmaI restriction sites), which includes the endogenous Pdx1 
promoter (Figure 15A). This promoter region directs Cre expression throughout the 
endogenous Pdx1 domain, including the antral stomach, rostral duodenum, and the entire 
pancreatic epithelium, as early as e10.5 (Gannon et al., 2001; Stoffers et al., 1999) 
60
Figure 15.  Pdx15.5kb-Cre transgene. Pdx15.5kb-Cre mice carry a transgene consisting 
of a 5.5 kb region of the Pdx1 promoter, from the SalI restriction site to the SmaI
restriction site, placed upstream of the Cre coding sequence (A). X-gal staining 
reveals that the Pdx15.5kb-Cre transgene mediates recombination of the Rosa26 
reporter allele throughout the entire pancreatic epithelium as early as e11.5 (B)
(arrow), as well as in the remainder of the endogenous Pdx1 expression domain, 
including the antral stomach and rostral duodenum (C) (pan = pancreas, st = stomach, 
int = intestine).  All endodermally-derived cells within the pancreas underwent 
recombination (D) (arrows = islets, asterisks = ducts).  Part A of the figure is from Gu




(Figure 15B-D).  For some experiments, Pdx15.5kb-Cre mice were backcrossed for 8 
generations to the C57Bl/6JBom strain (Taconic). 
Pdx1PB-CreERTM mice (on a mixed B6CBAF1 background) were generated and 
characterized in collaboration with Dr. Chris Wright’s laboratory (Vanderbilt University) 
(Zhang H et al., 2005).  These mice express a Cre recombinase-Estrogen Receptor (ER) 
hormone binding domain fusion protein driven by a 1 kb enhancer fragment of the Pdx1 
promoter (between the PstI and BstI restriction sites) and the Hsp68 minimal promoter 
(Figure 16A).  The hormone binding domain within this fusion protein construct has a 
point mutation (G525R) that makes it selective for binding to tamoxifen but not to 
endogenous estrogen (Littlewood et al., 1995).  The Pdx1PB promoter drives expression 
of  transgenes such as CreERTM specifically within pancreatic endocrine cells as early as 
e11.5 (Gannon et al., 2000; Gannon et al., 2001; Zhang H et al., 2005). 
Rosa26-FOXM1c Tg mice (on a mixed FVB/N, C57Bl/6 background) were 
generously provided by Dr. Robert H. Costa (University of Illinois at Chicago) and were 
described (Kalinichenko et al., 2003).  These mice express a 2.7 kb region of the human 
FOXM1c cDNA (from the translation start site to the HindIII restriction site in the 3’ 
UTR) driven by a -800 bp fragment of the Rosa26 promoter (Figure 17).  The construct 
used to generate these mice was modified from a transgene originally used for liver-
specific over-expression of FOXM1C, in which a 2.7 kb region of FOXM1c cDNA was 
inserted into the second exon of a TTR minigene construct (Ye et al., 1999).  This 
construct contained a mutated TTR translation start site and a 3’ SV40 polyadenylation 
sequence.  Additionally, ~800 bp of the FOXM1c 3’ UTR were deleted from this 
construct, which enhanced mRNA stability. 
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Figure 16.  Pdx1PB-CreERTM transgene. Pdx1PB-CreERTM mice carry a 
transgene consisting of a 1 kb enhancer region of the Pdx1 promoter, from the 
PstI restriction site to the BstI restriction site (A).  The CreERTM fusion protein is 
sequestered in the cytoplasm until binding of tamoxifen stimulates its nuclear 
translocation, allowing for its recombinase activity (B).  Following tamoxifen
injection, the Pdx1PB-CreERTM transgene mediates recombination of the Rosa26
























Figure 17.  Rosa26-FOXM1c transgene. Rosa26-FOXM1c mice carry a 
transgene consisting of an 800 bp region of the Rosa26 promoter driving 
expression of a TTR minigene with inserted FOXM1c cDNA.  Figure is adapted 
from Kalinichenko et al. (2003).
c
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Foxm1+/- mice (on a mixed 129SvJ, C57Bl/6 background) were provided by Dr. 
Robert H. Costa (University of Illinois at Chicago) and were described by (Krupczak-
Hollis et al., 2004).  These mice were generated by crossing Foxm1flox/flox mice with 
E2A-Cre mice, which ubiquitously express Cre recombinase.  Progeny with germline 
recombination of Foxm1flox were propagated to generate a line of mice with a global null 
Foxm1 allele (Foxm1+/-). 
Rosa26-LacZ reporter (R26R) mice on a C57Bl/6J background (B6.129S4-
Gt[ROSA]26Sortm1Sor/J; The Jackson Laboratory) ubiquitously express β-galactosidase 
driven by the endogenous Rosa26 promoter after Cre-mediated excision of a floxed stop 
cassette 5’ of the LacZ gene (Soriano, 1999) (Figure 18). 
LacZ/EGFP (Z/EG) reporter mice on a C57Bl/6J background (B6.Cg-Tg[CAG-
Bgeo/GFP]21Lbe/J; The Jackson Laboratory) ubiquitously express β-galactosidase 
driven by a CMV enhancer/chicken β-actin promoter (Novak et al., 2000) (Figure 19).  
Upon Cre-mediated excision of a floxed stop cassette between the LacZ and EGFP 
coding regions, enhanced green fluorescent protein (EGFP) is expressed in place of 
β-galactosidase. 
For most studies, mice were fed mouse diet 5015 (LabDiet).  For diet studies, 
mice were fed one of three diets: rodent diet 5001 (13.5% total kcal from fat, LabDiet), 
mouse diet 5015 (25.3% total kcal from fat, LabDiet), or high-fat/high-carbohydrate 
mouse diet F3282 (58.7% total kcal from fat, Bio-Serv) beginning at 4 weeks of age, after 
weaning, and continuing for 5-12 weeks.  All mice received food and drink ad libitum 
and were on a 12 hour light-dark cycle.  Z/EG mice on the C57Bl/6 background had 
reduced viability and required additional time prior to weaning.  All mouse studies were 
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Figure 18.  Rosa26-LacZ reporter knock-in.  R26R mice were generated by 
knock-in of a floxed stop cassette (PGK-Neo-PolyA) upstream of a LacZ coding 
sequence into the Rosa26 locus (A).  Cre-mediated recombination of the R26R
allele removes the stop cassette (B).  The Rosa26 promoter drives ubiquitous 
expression, and crossing R26R mice with mice expressing a ubiquitous Cre (E2A-
Cre) results in ubiquitous expression of LacZ, as evidenced by whole-body X-gal 








Figure 19.  Z/EG mice.  (A) The construct used to generate mice that express LacZ in 
the absence of Cre-mediated recombination, followed by expression of EGFP after 
recombination.  (B) Z/EG mice ubiquitously express either LacZ or EGFP.  Cre-
mediated recombination of the Z/EG allele results in expression of EGFP in (C) brain, 
(D) eye, (E) heart, (F) lung, (G) pancreas, (H) intestine, (I) liver, and (J) ovary.  
Figure is adapted from Novak et al. (2000).
A
B
C D E F
G H I J
67
performed in accordance with the Vanderbilt Institutional Animal Care and Use 
Committee guidelines under the supervision of the Division of Animal Care. 
For embryonic analyses, the morning of vaginal plug was considered e0.5. 
 
DNA Extraction and Genotyping 
DNA was extracted from ear-punch (adult mice), tail (late embryonic to adult 
mice), brain (embryos), yolk sac (embryos), or paraffinized tissue sections.  Sections 
were deparaffinized in xylene and washed with 100% ethanol prior to extraction.  All 
samples were digested overnight at 55oC in Lab Tissue Buffer 68.8 (35.2 mM Tris, 
2.5 mM ethylenediaminetetraacetic acid [EDTA], 2.5 mM sodium citrate, 
8.8 mM ammonium sulfate, 5% [v/v] Tween-20) with 0.3 mg/ml Proteinase K and 
0.3 mg/ml RNase A.  Samples were then digested at 37oC for 15 minutes and heat-
inactivated at 95oC for 10 minutes.  Undigested material was removed by centrifugation 
at high speed (16,000 x g) for 10 minutes, and the supernatant was stored at 4oC. 
Genotyping for the Foxm1flox allele was performed as described in (Zhang H et 
al., 2006) using PCR with the following primers:  Foxm1flox forward 5’-TAG GAG ATA 
CAC TGT TAT AT-3’ and Foxm1flox reverse 5’-TGT GGG AAA ATG CTT ACA AAA 
G-3’, which amplify a 180 bp product for wild-type Foxm1 and a 230 bp product for 
Foxm1flox due to insertion of a loxP sequence in the 3rd intron of Foxm1 (Figure 10A).  
Each 10 µl PCR reaction included ~50-100 ng DNA, 250 nM of each primer, 2X FailSafe 
PCR PreMix C (Epicenter Technologies), and 0.5 U REDTaq DNA Polymerase (Sigma-
Aldrich).  The following reaction conditions were used for amplification:  92oC for 6 
minutes (hot-start); 32 cycles of 92oC for 30 seconds (denature), 48oC for 30 seconds 
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(anneal), and 72oC for 1 minute (elongation); and 72oC for 6 minutes.  PCR products 
were separated by 2% [w/v] agarose gel electrophoresis. 
Genotyping for the Foxm1null allele was performed as described in (Zhang H et 
al., 2006) using PCR with the following primers:  Foxm1null forward 5’- TAG GAG ATA 
CAC TGT TAT AT-3’ and Foxm1null reverse 5’-CTC ATG TAG CAT AGA GGG CTG-
3’, which amplify a 510 bp product (Figure 10A).  Primers for the internal control IL-2 
were also included:  IL-2 forward 5’-CTA GGC CAC AGA ATT GAA AGA TCT-3’ and 
IL-2 reverse 5’-GTA GGT GGA AAT TCT AGC ATC ATC C-3’, which amplify a 
324 bp product.  Each 10 µl PCR reaction included ~50-100 ng DNA, 250 nM of each 
Foxm1null primer, 125 nM of each IL-2 primer, 2X FailSafe PCR PreMix C (Epicenter 
Technologies), and 0.5 U REDTaq DNA Polymerase (Sigma-Aldrich).  The following 
reaction conditions were used for amplification:  92oC for 6 minutes (hot-start); 30 cycles 
of 92oC for 30 seconds (denature), 56oC for 30 seconds (anneal), and 72oC for 1 minute 
(elongation); and 72oC for 6 minutes. 
Genotyping for the Cre transgene was performed as described in (Gu et al., 2002) 
using PCR with the following primers:  Cre forward 5’-TGC CAC GAC CAA GTG 
ACA GC-3’ and Cre reverse 5’-CCA GGT TAC GGA TAT AGT TCA TG-3’, which 
amplify a 650 bp product.  Primers for the internal control IL-2 were also included.  Each 
10 µl PCR reaction included ~50-100 ng DNA, 250 nM of each Cre primer, 125 nM of 
each IL-2 primer, 10X PCR Buffer with 15 mM MgCl2 (Applied Biosystems), 200 µM 
dNTP mix, and 0.5 U REDTaq DNA Polymerase (Sigma-Aldrich).  The following 
reaction conditions were used for amplification:  92oC for 6 minutes (hot-start); 32 cycles 
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of 92oC for 30 seconds (denature), 58oC for 30 seconds (anneal), and 72oC for 1 minute 
(elongation); and 72oC for 6 minutes. 
Genotyping for the Rosa26-FOXM1c transgene was performed as described in 
(Ye et al., 1999) using PCR with the following primers:  Rosa26-FOXM1c forward 
5’-AAA GTC CTG GAT GCT GTC CGA G-3’ and Rosa26-FOXM1c reverse 5’-CAG 
ACA TGA TAA GAT ACA TTG ATG-3’, which amplify a 325 bp product.  Each 10 µl 
PCR reaction included ~50-100 ng DNA, 250 nM of each primer, 10X PCR Buffer with 
15 mM MgCl2 (Applied Biosystems), 200 µM dNTP mix, and 0.5 U REDTaq DNA 
Polymerase (Sigma-Aldrich).  The following reaction conditions were used for 
amplification:  92oC for 6 minutes (hot-start); 32 cycles of 92oC for 30 seconds 
(denature), 58oC for 30 seconds (anneal), and 72oC for 1 minute (elongation); and 72oC 
for 6 minutes. 
Genotyping for the Rosa26-LacZ reporter knock-in (R26R) was performed using 
PCR with the following primers:  R26R primer #1 5’-AAA GTC GCT CTG AGT TGT 
TAT-3’, R26R primer #2 5’-GCG AAG AGT TTG TCC TCA ACC-3’, and R26R primer 
#3 5’-GGA GCG GGA GAA ATG GAT ATG-3’, which amplify a 500 bp product for 
the WT R26 allele and a 250 bp product for the R26R allele.  Each 10 µl PCR reaction 
included ~50-100 ng DNA, 400 nM of each primer, and 2X REDExtract-N-Amp PCR 
Ready Mix (Sigma-Aldrich).  The following reaction conditions were used for 
amplification:  93oC for 2 minutes (hot-start); 40 cycles of 93oC for 30 seconds 
(denature), 58oC for 30 seconds (anneal), and 65oC for 1 minute (elongation); and 65oC 
for 5 minutes. 
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Genotyping for the Z/EG reporter transgene was performed using PCR with the 
following primers:  Z/EG forward 5’-AAG TTC ATC TGC ACC ACC G-3’ and reverse 
5’-TCC TTG AAG AAG ATG GTG CG-3’, which amplify a 173 bp product.  Primers 
for the internal control IL-2 were also included.  Each 10 µl PCR reaction included 
~50-100 ng DNA, 250 nM of each primer, 10X PCR Buffer with 15 mM MgCl2 (Applied 
Biosystems), 200 µM dNTP mix, and 0.5 U REDTaq DNA Polymerase (Sigma-Aldrich).  
The following reaction conditions were used for amplification:  94oC for 1.5 minutes 
(hot-start); 35 cycles of 94oC for 30 seconds (denature), 60oC for 1 minute (anneal), and 
72oC for 1 minute (elongation); and 72oC for 2 minutes. 
 
Intraperitoneal Glucose Tolerance Test (IPGTT) 
Mice were fasted overnight for 16 hours, after which their fasting blood glucose 
level was measured using blood obtained from the tail and a FreeStyle glucometer 
(Abbott Diabetes Care).  The mice were then weighed, and 2 mg dextrose/g body weight 
(FisherBiotech) in sterile PBS, pH 7.4 (2.7 mM KCl, 14.7 mM KH2PO4, 136.9 mM 
NaCl, 8.1 mM NaHPO4•7H2O) was injected intraperitoneally, and blood glucose levels 
were measured at 15, 30, 60, 90, and 120 minutes post-injection. 
 
Intraperitoneal Insulin Tolerance Test (IPITT) 
Mice were fasted in the morning for 6 hours, after which their fasting blood 
glucose level was measured using blood obtained from the tail and a FreeStyle 
glucometer (Abbott Diabetes Care).  0.75U/kg insulin (Novolin R, recombinant regular 
human insulin; Novo Nordisk) in 0.9% normal saline was injected intraperitoneally, and 
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blood glucose levels were measured at 15, 30, 60, 90, and 120 minutes post-injection.  
Percent of initial blood glucose was calculated for all time points. 
 
Plasma and Pancreatic Insulin Content 
 For plasma insulin content, blood was collected at 0 and 30 minutes after glucose 
injection during an IPGTT from either the saphenous veins or retro-orbital plexus.  For 
saphenous venous blood collection, the mouse was restrained, the distal-lateral portion of 
the leg was shaved, and the saphenous vein was punctured using a 25 5/8 G needle.  
Blood was collected into heparanized microvette tubes (Sarstedt), which were then placed 
on ice.  For retro-orbital plexus blood collection, the mouse was anesthetized using 
isoflurane, the plexus was punctured using heparinized Natelson Blood Collecting Tubes 
(Fisher), and blood was then transferred to 1.5 ml tubes.  All samples were centrifuged at 
2,000 x g for 15 minutes at 4oC, and the plasma supernatant was transferred and stored at 
-80oC.  At least 25 µl of each sample was analyzed for insulin content at the Hormone 
Assay and Analytical Services Core at Vanderbilt University by liquid-phase 
radioimmunoassay (RIA) using the Rat Insulin RIA Kit (Linco/Millipore).  Plasma 
samples required longer incubation time with diluted antibody for increased sensitivity. 
 For pancreatic insulin content, pancreatic tissue was harvested from the mouse, 
weighed, homogenized in acid-alcohol (1 ml HCl in 110 ml 95% ethanol), and extracted 
in this solution for 3 days at 4oC with agitation (Brissova et al., 2002).  The homogenate 
was then centrifuged at 800 x g for 30 minutes at 4oC, and the supernatant was 
transferred and stored at -20oC.  Samples were analyzed for insulin content at the 
Hormone Assay and Analytical Services Core at Vanderbilt University by liquid-phase 
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RIA using the Rat Insulin RIA Kit (Linco/Millipore).  Samples required dilution 1:1,000 
in buffer prior to an analysis.  Pancreatic insulin content was normalized to pancreas 
weight. 
 
Body Fat Mass Analysis 
 Body composition analysis was performed in the Mouse Metabolic Phenotyping 
Center at Vanderbilt University with the Minispec mq7.5 (Bruker Instruments), which 
utilizes nuclear magnetic resonance (NMR) spectroscopy to assess percentage of body 
weight composed of fat, lean muscle, and free fluid. 
 
60% Partial Pancreatectomy (PPx) 
Mice were anesthetized using isoflurane.  A midline abdominal incision allowed 
exteriorization of the splenic lobe of the pancreas (between the gastro-duodenal junction 
and the spleen).  60% PPx was performed by gently denuding the pancreatic tissue from 
the splenic lobe using cotton-tipped swabs soaked in 0.9% normal saline, leaving the 
main pancreatic duct and splenic artery intact.  For Sham operations, the splenic lobe was 
isolated using cotton-tipped swabs and gently rubbed with a moistened gloved finger for 
1 minute.  Abdominal muscles were sutured using 5-0 vicryl (Ethicon), and the skin was 
stapled using 9.0 mm staples (Reflex Skin Closure Systems).  Following the operation, 
0.1 mg/kg buprenorphine-HCl in 0.9% normal saline was injected subcutaneously for 
analgesia, and 0.8 mg/ml bromo-deoxyuridine (BrdU; Sigma-Aldrich) was administered 
in the drinking water in a light-safe bottle and was replaced on the 4th day.  Mice were 
sacrificed 1 week post-operation by cervical dislocation, and the splenic and duodenal 
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lobes of the pancreas were harvested and analyzed separately.  One day prior to and 7 
days after the operation, IPGTTs were performed. 
 
Tamoxifen Injection 
 The shoulder and nape of the neck area were shaved, and then 8 mg of a 20 mg/ml 
solution of tamoxifen (Sigma-Aldrich) in filter-sterilized corn oil was injected 
subcutaneously.  The injection site was glued with Vetbond tissue adhesive (3M) to 
prevent leakage.  Mice were injected every other day for a total of one, two, or three 
injections.  Control mice were injected with an equal volume of filter-sterilized corn oil. 
 
Islet Isolation 
All islet isolations were performed in the Islet Procurement and Analysis Core at 
Vanderbilt University.  Mice were anesthetized via an intraperitoneal injection of 
0.15 mg/g ketamine-HCl and 0.04 mg/g xylazine (Henry Schein), the abdominal cavity 
was exposed, and 3-4 ml of 0.6% collagenase P (Roche) in Hank’s Balanced Salt 
Solution (HBSS) containing calcium and magnesium (Gibco) was injected into the 
common bile duct.  The pancreas was then harvested and digested in 6.5 ml of the 
collagenase P solution for 4 minutes at 37oC followed by 1.5 minutes at room 







 Islets were cultured overnight in Roswell Park Memorial Institute (RPMI) Media 
1640 (Gibco) supplemented with 1% penicillin-streptomycin and 10% heat-inactivated 
FBS at 37oC in the presence of 5% CO2.  The following day, islets were collected and 
loaded into the perifusion column, and islet equivalent (IEQ) of each sample was 
measured based on islet number and size.  Islets were perifused with perifusion media 
(Dulbecco’s Modified Eagle’s Medium [DMEM] supplemented with 
4.7 mM 4-[2-hydroxyethyl]-1-piperazineethanesulfonic acid [HEPES], 38 mM NaHCO3, 
4.0 mM L-glutamine, 1.0 mM sodium pyruvate, 15.05 µM bovine serum albumin [BSA], 
and 0.0015% phenol red) + 5.6 mM glucose for 39 minutes (baseline) prior to sequential 
stimulation with the following secretagogues in perifusion media: 16.7 mM glucose, 
100 µM isobutylmethylxanthine (IBMX) + 16.7 mM glucose, 300 µM tolbutamide, and 
20 mM KCl.  Each secretagogue was applied for 9 minutes, followed by 21 minutes of 
perifusion media + 5.6 mM glucose to return to baseline prior to subsequent stimulation.  
Perifusate was collected at a rate of 1 ml/min into 3 ml fractions.  Insulin content in each 
fraction was measured using the Rat Insulin RIA Kit (Millipore/Linco) according to 
manufacturer’s protocol. 
 
RNA Isolation and Quantitative Real-Time RT-PCR (qRT-PCR) 
RNA was extracted from freshly-isolated islets or transiently-transfected HeLa 
cells using the RNAqueous kit (Ambion) and DNase-treated using the TURBO DNA-free 
kit (Ambion).  Concentrations of all samples, A260/A280 ratios, and A260/A230 ratios were 
assessed using the ND-1000 Spectrophotometer (NanoDrop).  Islet RNA was analyzed by 
75
the Microarray Shared Resource at Vanderbilt University, where RNA quality was 
further assessed using the 2100 Electrophoresis Bioanalyzer (Agilent). 
For qRT-PCR, cDNA was generated from 20 ng of islet RNA using the 
Superscript III First-Strand Synthesis System for RT-PCR (Invitrogen).  Real-time PCR 
was performed using the iQ5 Real-Time PCR Detection System (Bio-Rad) with iQ Real-
Time SYBR Green PCR Supermix (Bio-Rad) and the following mouse primer sets:  
Foxm1 forward 5’-CAC TTG GAT TGA GGA CCA CTT-3’ and reverse 5’-GTC GTT 
TCT GCT GTG ATT CC-3’, Plk1 forward 5’-TTG TAG TTT TGG AGC TCT GTC G-
3’ and reverse 5’-AGT GCC TTC CTC CTC TTG TG-3’, Cenp-a forward 5’-CAA GGA 
GGA GAC CCT CCA G-3’ and reverse 5’-GTC TTC TGC GCA GTG TCT GA-3’, 
Birc5/Survivin forward 5’-CCG ATG ACA ACC CGA TAG A-3’ and reverse 5’-CAT 
CTG CTT CTT GAC AGT GAG G-3’, Ccnb1 forward 5’-TCT TGA CAA CGG TGA 
ATG GA-3’ and reverse 5’-TCT TAG CCA GGT GCT GCA TA-3’, Ccna2 forward 
5’-CTT GGC TGC ACC AAC AGT AA-3’ and reverse 5’-CAA ACT CAG TTC TCC 
CAA AAA CA-3’, Skp2 forward 5’-GTA TGT TAG GGA ACC ATT TGC GAG-3’ and 
reverse 5’-TTA GAA GGG CAC TTG GAA GAG TT-3’, Cks1 forward 5’-GAC CTC 
AAA GCC CTC GTG T-3’ and reverse 5’-TGA AAC ATA AAT CCA TAA GTC ATC 
A-3’, Aurkb forward 5’-CCC TAC GGC TCA AAG ACG-3’ and reverse 5’-AGC AAG 
CGC AGA TGT CGT-3’, Cdc25b forward 5’-CCC TTC CCT GTT TTC CTT TC-3’ and 
reverse 5’-ACA CAC ACT CCT GCC ATA GG-3’, Ccnd2 forward 5’-CAC CGA CAA 
CTC TGT GAA GC-3’ and reverse 5’-TCC ACT TCA GCT TAC CCA ACA-3’, 
Hprt1 (internal control) forward 5’-AGT CAA CGG GGG ACA TAA AA-3’ and reverse 
5’-TGC ATT GTT TTA CCA GTG TCA A-3’.  The following human primers were also 
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used:  FoxM1 forward 5’-GGA GGA AAT GCC ACA CTT AGC G-3’ and reverse 
5’-TAG GAC TTC TTG GGT CTT GGG GTG-3’.  Samples were assessed in duplicate, 
and results were quantitated using the comparative CT method (Schmittgen and Livak, 
2008) and normalized to control samples. 
Custom TaqMan Low Density Arrays (Applied Biosystems) were designed to 
assess expression of 48 transcripts (Table 2).  cDNA was generated from 40-50 ng of islet 
RNA using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems).  
TaqMan-based qRT-PCR was performed according to manufacturer’s instructions using 
a 7900HT Real-Time PCR System (Applied Biosystems).  Samples were assessed in 
duplicate, and results were quantitated using the comparative CT method and normalized 
to control samples. 
 
Tissue Preparation and Histology 
For paraffin embedding, tissue was fixed in 4% paraformaldehyde in PBS, pH 7.4 
for 1-4 hours at 4oC, washed in PBS at 4oC, stored in 70% ethanol at 4oC, dehydrated in 
an ascending ethanol series at room temperature, cleared twice with xylene at room 
temperature, infiltrated with xylene:paraffin (1:1, v/v) and then 100% paraffin at 56oC, 
embedded in paraffin, and sectioned at 5 µm.  Sections were then deparaffinized in 
xylene, rehydrated in a descending ethanol series, and washed in PBS. 
For frozen embedding, tissue was fixed in 4% paraformaldehyde in PBS, pH 7.4 
for 1-4 hours at 4oC, washed in PBS, partially dehydrated with 30%  [w/v] sucrose 
overnight at 4oC, embedded in Tissue-Tek Optimal Cutting Temperature (OCT) 























Assay IDGene SymbolCommon Name
Table 2.  Transcripts assessed by Custom TaqMan Low Density Array. Hs 
indicates homo sapiens.  Mm indicates Mus musculus.  g1 indicates that primers may 
detect genomic DNA.  m1 indicates that primers span an intron and will not detect 
genomic DNA.  s1 indicates that transcript consists of only one exon and thus primers 
will detect genomic DNA.  mH indicates that intron-spanning primers were designed 
to detect a transcript belonging to a family with high sequence homology.  gH
indicates that the primers were designed to detect a transcript belonging to a family 






























Table 2 — continued
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stored at -80oC.  Sections were then thawed at room temperature for 15-30 minutes, 
permeabilized in PBS with 0.1% (v/v) Triton-X-100 for 45 minutes or in PBS with 
0.2% (v/v) Triton-X-100 for 10 minutes, and washed in PBS. 
The following primary antibodies were incubated with 5% normal donkey serum 
(NDS) and 1% BSA in PBS at 4oC overnight:  guinea pig anti-insulin (1:1,000; Linco), 
guinea pig anti-glucagon (1:1,000; Linco), rabbit anti-cytokeratin (1:1,000; 
DakoCytomation), rabbit anti-phospho-histone H3 (1:250; Upstate Cell Signaling 
Solutions), rabbit anti-Cre (1:10,000; Novagen), and chicken anti-β-galactosidase 
(1:1,000; AbCam).  The rat anti-BrdU primary antibody (1:400; Accurate Chemical & 
Scientific) was incubated with 5% NDS and 1% BSA in PBS at room temperature 
overnight.  The mouse anti-Neurogenin3 primary antibody (Ngn3; 1:100; Developmental 
Studies Hybridoma Bank, The University of Iowa) was incubated in 1% blocking 
solution (Invitrogen TSA Kit #2) at 4oC overnight.  The anti-Cre and anti-β-galactosidase 
antibodies were used exclusively on cryosections. 
The following secondary antibodies were incubated with 1% BSA in PBS for 
1 hour at room temperature:  peroxidase-conjugated donkey anti-guinea pig (1:250; 
Jackson Laboratories), Cy2-conjugated donkey anti-guinea pig, Cy2-conjugated donkey 
anti-rabbit, Cy3-conjugated donkey anti-guinea pig, Cy3-conjugated donkey anti-rabbit, 
Cy3-conjugated donkey anti-rat, Cy3-conjugated donkey anti-chicken (all 1:500; Jackson 
Laboratories).  For Ngn3 labeling, peroxidase-conjugated goat anti-mouse seconday 
antibody (1:100; Invitrogen) was incubated in 1% blocking solution (Invitrogen) for 
1 hour at room temperature. 
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Detection of cytokeratin required pre-treatment with 20 µg/ml Proteinase-K 
(DakoCytomation) in PBS for 5 minutes at room temperature.  Detection of Ngn3 
required slow-boil microwave antigen retrieval with Tris-EGTA (TEG) buffer, pH 9.0 
(10 mM Tris, 500 µM ethylene glycol tetraacetic acid [EGTA]) and tyramide signal 
amplification with TSA Kit #2 (Invitrogen).  Detection of phospho-histone H3 required 
microwave antigen retrieval at 1200 W in 10 mM sodium citrate, pH 6.5 for 4 minutes 
and permeabilization with 0.2% (v/v) Triton-X-100 in PBS for 10 minutes.  Detection of 
BrdU required pre-treatment with 1.5 N HCl for 20 minutes at 37oC, sodium borate 
buffer (0.85% [w/v] boric acid, 0.15% [w/v] sodium borate) for 1 minute at room 
temperature, and 0.005 mg/ml trypsin (Sigma-Aldrich) with 0.005 mg/ml CaCl2 in 
0.5 M Tris-HCl, pH 7.5 for 3 minutes at 37oC. 
For screening of mouse anti-FoxM1 sera (Vanderbilt Monoclonal Antibody Core) 
by immunohistochemistry (IHC), the HistoMouse-SP Kit (Zymed) was used according to 
manufacturer’s protocol.  Sera was incubated overnight at 4oC at dilutions ranging from 
1:50 to 1:250 in PBS with 5% NDS and 1% BSA.  The TSA Kit #2 (Invitrogen) was also 
used for screening, following manufacturer’s protocol.  In some cases, microwave 
antigen retrieval was performed with 10 mM sodium citrate, pH 6.5 or with TEG buffer, 
pH 9.0. 
Coverslips were mounted with Permount (Fisher) for bright-field microscopy or 
with anti-fade mounting media (50% glycerol [v/v] and 2% N-propylgalate [w/v] in PBS, 
pH 7.4) for fluorescent microscopy.  Nuclei were fluorescently labeled with 
1.5 µg/ml 4’,6’-diamidino-2-phenylindole (DAPI; Molecular Probes) in mounting media. 
81
5-bromo-4-chloro-3-indolyl-B-D-galactoside (X-gal) staining was performed on 
paraformadehyde-fixed tissue or whole embryos.  After washing with PBS, samples were 
permeabilized for 30 minutes at 4oC and again for 30 minutes at room temperature with 
permeabilization solution (2 mM MgCl2, 0.01%  [w/v] sodium deoxycholate, and 
0.02% [v/v] NP-40 in PBS).  Samples were then incubated overnight at room temperature 
in X-gal staining solution (0.1% [w/v] X-gal, 2 mM MgCl2; 5 mM potassium 
ferricyanide; 5 mM potassium ferrocyanide; 20 mM Tris, pH 7.4). 
 
In Situ Hybridization 
 Foxm1 probes were generated from a fragment of rat Foxm1 cDNA (EcoRI-PstI 
sub-clone, 500 bp) in the pGEM-1 vector, a generous gift from Robert H. Costa 
(University of Illinois at Chicago) (Ye et al., 1997).  The anti-sense probe was generated 
using SP6 RNA polymerase and EcoRI-digested plasmid DNA, while the sense probe 
was generated using T7 RNA polymerase and HindIII-digested plasmid DNA.  Probes 
were labeled with non-radioactive digoxigenin-UTP (DIG) using the DIG RNA Labeling 
Kit (Roche) and purified using G-50 sephadex columns (Amersham).  Labeling 
efficiency was determined by spot-testing according to instructions in the DIG RNA 
Labeling Kit. 
 Paraffin sections were deparaffinized in xylene, rehydrated in a descending 
ethanol series, and washed in PBS.  Sections were then post-fixed in 
4% paraformaldehyde in PBS, pH 7.4 for 20 minutes on ice, treated with 
15 µg/ml Proteinase K in PBS for 7 minutes at room temperature, post-fixed again in 
4% paraformaldehyde in PBS, pH 7.4 for 20 minutes on ice, and treated with acetylation 
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agent (86 mM triethanolamine, 26 mM acetic anhydride) for 10 minutes at room 
temperature.  Tissue was then hybridized with an appropriate dilution of each probe in 
hybridization solution (40% [v/v] formamide, 20X SSC, 50X Denhardt’s reagent 
[Fisher], 250 µg/ml heparin [Sigma], 1 mg/ml tRNA [Sigma]) at 65oC overnight.  Slides 
were then washed in 5X SSC for 5 minutes at 60oC, 0.2X SSC for 1 hour at 60oC and 
then 5 minutes at room temperature, and maleic acid buffer, pH 7.5 (100 mM maleic 
acid, 150 mM NaCl, 175 mM NaOH) for 5 minutes at room temperature.  Slides were 
then blocked in 1% blocking reagent (Roche) in maleic acid buffer for 1 hour at room 
temperature and incubated with anti-DIG primary antibody (1:5,000; Roche) in maleic 
acid buffer for 1 hour at room temperature.  Slides were then washed two times for 
15 minutes each in maleic acid buffer at room temperature and in Tris solution 
(100 mM Tris, pH 9.5; 100 mM NaCl, 5 mM MgCl2) for 5 minutes at room temperature.  
Slides were then developed in detection buffer, pH 9.5 (2 mM Tris, 2 mM NaCl) with 
nitro blue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate (NBT/BCIP) tablets 
(Roche) for 4 hours to overnight at room temperature, followed by serial washes in 
deionized H2O and Tris-EDTA (TE) buffer, pH 8.0 (10 mM Tris-HCl, 1 mM EDTA) 
before mounting. 
 
β Cell Mass Analysis 
Sections 250 µm apart (3-15 sections per tissue sample, depending on tissue size) 
were incubated with anti-insulin primary antibody followed by peroxidase-conjugated 
anti-guinea pig secondary antibody, which was visualized using the DAB Peroxidase 
Substrate Kit (Vector Laboratories).  Sections were counterstained with eosin, and a 
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digital image was created using a Nikon Coolscan 9000 and NikonScan v4.0.2.  
MetaMorph v6.1 software (Molecular Devices) was used to measure the total insulin+ 
area and the total pancreatic area of each section.  β cell mass was calculated by dividing 
the total insulin+ area of all sections by the total pancreatic areas of all sections and 
multiplying this ratio by the pancreatic wet weight. 
 
Proliferation Analyses 
For adult β cell proliferation analyses, evenly-spaced sections (250-1250 µm 
apart, 2-8 sections per tissue sample, depending on tissue size) were labeled with anti-
insulin and anti-BrdU primary antibodies and DAPI.  Images of all insulin+ cells on each 
section were captured at 400X magnification on an Olympus BX41 microscope with a 
digital camera using Magnafire (Optronics), and cells were counted using MetaMorph 
v6.1.  Percent proliferating β cells was calculated by dividing the number of insulin/BrdU 
double-positive cells by the total number of insulin+ cells.  α cells were identified by 
glucagon labeling, and proliferation was measured in the same manner.  Ductal cells were 
identified by cytokeratin labeling on sections 250-750 µm apart, and images were 
captured at 200X magnification.  Acinar cells were identified by morphological 
characteristics on 200X images from sections 750 µm apart. 
For embryonic β cell proliferation analyses sections 125 µm apart (6-9 sections 
per tissue sample) were labeled with anti-insulin and anti-phospho-histone H3 primary 




Islet Size, β cell Size, and β cell Nucleus Size Analyses 
Using the same pictures analyzed for β cell proliferation, the cross-sectional area 
of each insulin+ cell group was circumscribed and measured using MetaMorph.  Average 
cross-sectional β cell size per islet was calculated by dividing the total area of the islet by 
the number of β cell nuclei within it.  β cell nuclear size was measured by circumscribing 
the DAPI+ cross-sectional area within insulin+ cells. 
 
β cell Apoptosis Analysis 
 Apoptotic β cells were identified on sections 750-1250 µm apart (2-4 sections per 
tissue sample) by terminal deoxynucleotidyl transferase-mediated dUTP nick-end-
labeling (TUNEL) using the BD ApoAlert DNA Fragmentation Assay Kit (BD 
Biosciences-Clontech), followed by labeling with anti-insulin primary antibody and 
DAPI.  Images of all insulin+ cells on each section were captured at 400X magnification.  
Percentage of apoptotic β cells was calculated by dividing the number of insulin/TUNEL 
double-positive cells by the total number of insulin+ cells. 
 
R26R Recombination Analysis 
 Evenly-spaced cryosections (2-3 sections per tissue sample, 250-750 µm apart, 
depending on tissue size) were labeled with anti-β-galactosidase and anti-insulin primary 
antibodies.  Nuclei were labeled with DAPI in mounting media.  Images of all insulin+ 
cells on each section were captured at 400X magnification, and cells were counted using 
MetaMorph v6.1.  The percent of recombined β cells was calculated by dividing the 
85
number of β-galactosidase/insulin double-positive cells by the total number of insulin+ 
cells. 
 
Generation of an Anti-FoxM1 Monoclonal Antibody 
 
Sub-cloning of Foxm1 cDNA Fragments 
 Full-length murine Foxm1 cDNA in pYX-Asc in DH5α E. coli was obtained from 
Open Biosystems (clone 6417436, accession number BC065067) (Figure 20).  The DH5α 
E. coli were grown on Luria Broth (LB)-Ampicillin agar plates overnight at 37oC, and 
isolated colonies were cultured overnight in Terrific Broth (TB; 1.2% [w/v] tryptone, 
2.4% [w/v] yeast extract, 0.4% [v/v] glycerol, 17 mM KH2PO4, 72 mM K2HPO4) with 
100 µg/ml Ampicillin at 37oC with shaking at 225 rpm prior to plasmid purification. 
Three fragments of the Foxm1 cDNA were amplified by PCR, using primers that 
added a BamHI restriction site and start (ATG) codon to the 5’ end and a stop (TAG) 
codon and SalI restriction site to the 3’ end of each amplicon.  The following primer sets 
were used:  Fragment 1 forward 5’-GGA TCC ATG AGA ACC AGC CCC C-3’ and 
reverse 5’-GTC GAC CTA CTC AGA CAC AGA GTC CTG-3’, Fragment 2 forward 
5’-GGA TCC ATG AAT CGC TAC TTG ACA TTG GAC C-3’ and reverse 5’-GTC 
GAC CTA CTG AGG GCA GCT GAG-3’, Fragment 3 forward 5’-GGA TCC ATG 
GAA GAG GGA GGA CCT TTC-3’ and reverse 5’-GTC GAC CTA AGG GAT GAA 
CTG AGA CCA G-3’.  Fragment 1 primers amplified a 714 bp product, consisting of bp 
172-870 of the Foxm1 cDNA (NM_008021).  Fragment 2 primers amplified an 849 bp 
product, consisting of bp 1108-1938 of the Foxm1 cDNA.  Fragment 3 primers amplified  
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Figure 20.  pYX-Asc vector. Murine Foxm1 cDNA was obtained from 
OpenBiosystems in the pYX-Asc vector.  Figure from OpenBiosystems website.
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a 522 bp product, consisting of bp 1939-2445 of the Foxm1 cDNA.  Each 50 µl PCR 
reaction included 1 µg DNA, 200 nM of each primer, 10X PCR Buffer with 15 mM 
MgCl2 (Takara), 400 µM dNTP mix, and 2.5 U Taq DNA Polymerase (Takara).  The 
following conditions were used for amplification:  95oC for 2 minutes (hot-start); 
30 cycles of 95oC for 30 seconds (denature), 61oC for 30 seconds (anneal), and 72oC for 1 
minute (elongation); and 72oC for 10 minutes.  PCR products were separated on a 
0.8% [w/v] agarose gel with 50 ng/ml ethidium bromide and 1 mM guanosine and 
extracted using the QIAquick Gel Extraction Kit (Qiagen).  DNA was stored at -20oC. 
 Each PCR-amplified Foxm1 fragment was cloned into the pCR2.1-TOPO vector 
using the TOPO-TA Cloning Kit (Invitrogen) (Figure 21).  Transformed OneShot TOP10 
E. coli (Invitrogen) were grown overnight on LB-Ampicillin agar plates at 37oC.  Isolated 
colonies were then cultured overnight in TB with 50 µg/ml Kanamycin at 37oC with 
shaking at 225 rpm prior to plasmid purification.  Positive clones for each Foxm1 
fragment were identified by restriction digest with EcoRI followed by gel electrophoresis, 
which produced a vector band at 4 kb and Foxm1 Fragment 1-, 2-, and 3-specific bands at 
714, 849, and 522 bp, respectively.  Clones were verified by sequencing using M13 
reverse and T7 primers (Vanderbilt DNA Sequencing Facility). 
 Verified clones were cultured in TB with 50 µg/ml Ampicillin overnight at 37oC 
with shaking at 225 rpm prior to plasmid purification.  Each Foxm1 fragment was excised 
from pCR2.1-TOPO with BamHI and SalI, gel extracted, and sub-cloned into the maltose 
binding protein (MBP)-tagged expression vector pAT107b, provided by the Vanderbilt 
Monoclonal Antibody Core (Figure 22).  Transformed DH5α E. coli were grown on 
LB-Kanamycin agar plates overnight at 37oC, and isolated colonies were cultured in TB 
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Figure 21.  pCR-TOPO2.1 vector. Murine Foxm1 cDNA fragments generated by 
PCR were sub-cloned into the pCR-TOPO2.1 vector and then excised using 
restriction digest with EcoRI. Figure from Invitrogen website.
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Figure 22.  pAT107b vector.  Murine Foxm1 cDNA fragments were sub-cloned into 
the multiple cloning site of the pAT107b expression vector, via ligation at the EcoRI
and NotI restriction sites.  The pAT107b vector adds an MBP tag and an 8X
polyhistidine tag to each cDNA clone, which can be cleaved by digestion with 3C 
protease.
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with 50 µg/ml Kanamycin overnight at 37oC with shaking at 225 rpm prior to plasmid 
purification.  Positive clones for each Foxm1 fragment were identified by restriction 
digest with BamHI and NotI followed by gel electrophoresis, which produced a vector 
band at 6.5 kb and Foxm1 Fragment 1-, 2-, and 3-specific bands at 722, 857, and 529 bp, 
respectively.  Putative Foxm1 Fragment 1 clones were verified by restriction digest with 
SalI and EcoRV, which produced bands of 6780 and 452 bp.  Putative Foxm1 Fragment 2 
clones were verified by restriction digest with BamHI and PvuII, which produced bands 
at 6528 and 831 bp.  Putative Foxm1 Fragment 3 clones were verified by restriction 
digest with SalI and PstI, which produced bands of 6869 and 168 bp. 
 Verified clones were used to transform BL21 CodonPlus (DE3)-RIPL E. coli 
(Stratagene), which were then grown on LB-Kanamycin agar plates overnight at 37oC. 
 
Plasmid Purification 
 Plasmid mini-preps were performed on 1 ml overnight cultures.  Cultures were 
pelleted by centrifugation at 1,000 x g for 1 minute, resuspended/lysed in 100 µl Alkaline 
Lysis Solution I (50 mM glucose; 25 mM Tris-HCl, pH 8.0; 10 mM EDTA, pH 8.0), and 
mixed with 200 µl of Alkaline Lysis Solution II (0.2 N NaOH, 1% [w/v] sodium dodecyl 
sulfate [SDS]).  Then 150 µl Alkaline Lysis Solution III (3 M potassium acetate, 
11.5% [v/v] glacial acetic acid) was added to each sample, and samples were vortexed.  
Lysate was cleared by centrifugation at high speed (16,000 x g) for 10 minutes, and then 
transferred to 900 µl of 95% ethanol.  Precipitated DNA was pelleted by centrifugation at 
high speed (16,000 x g) for 5 minutes, washed with cold 70% ethanol, and resuspended in 
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55 µl TE buffer with 200 ng/µl RNase A.  For sequencing, plasmid mini-preps were 
performed using the Plasmid Mini Kit (Qiagen) according to manufacturer’s protocol.   
 Plasmid maxi-preps were performed using the Plasmid Maxi Kit (Qiagen) 
according to manufacturer’s protocol.  DNA was resuspended in 100 µl TE buffer with 
200 ng/µl RNase A. 
 
Spectrophotometry 
 DNA concentration was measured by optical density (OD) absorption at 260 nm 
(A260) using a SmartSpec 3000 spectrophotometer (Bio-Rad) and a quartz cuvette.   
A conversion factor of 50 µg/ml dsDNA per absorption unit (AU) was used.  Nuclease-
free water was used as a blank and to dilute the samples appropriately to attain A260 
between 0.1 and 1.5 for accuracy. 
 Bacterial growth was determined by OD absorption at 600 nm (A600) using a 
SmartSpec 3000 spectrophotometer (Bio-Rad) and disposable polystyrene cuvettes.   
A conversion factor of 5 x 108 cells/ml per AU was used.  LB (1% [w/v] tryptone, 
0.5% [w/v] yeast extract, 171 mM NaCl) was used as a blank and to dilute the cultures 
appropriately to attain A600 between 0.1 and 1.5 for accuracy. 
 
Restriction Digests 
 Restriction enzymes were obtained from New England Biolabs and used 
according to the manufacturer’s instructions.  Restriction digests were performed in 
20 µl reactions using 10 µg DNA, 2 µl each restriction enzyme (4 U per µg DNA), 
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2 µl appropriate 10X buffer, 0.2 µl BSA if necessary, and nuclease-free H2O.  Reactions 
were incubated at 37oC for 2 hours to overnight. 
 
DNA Ligation 
 Ligations of insert and vector were performed using the Quick Ligation Kit (New 
England Biolabs).  Each ligation step consisted of two control reactions (vector alone, 
insert alone) and two ligation reactions (1:1 [v/v] vector:insert, 1:7 [v/v] vector:insert).  
Each 20 µl reaction contained 1 µl Quick Ligase, 10 µl 2X Quick Ligase Buffer, 
appropriate volume of vector and insert, and nuclease-free H2O.  Reactions were 
incubated at room temperature for 5 minutes and chilled on ice prior to use.  Ligation 
products were stored at -20oC. 
 
Bacterial Transformation 
DH5α E. coli were transformed by adding 2 µl  purified plasmid or 10 µl  ligation 
products to 100 µl cells in 14 ml round-bottom tubes (Falcon) on ice, mixing gently, 
incubating on ice for 2 minutes, incubating at 42oC for 1 minute, and incubating again on 
ice for 2 minutes.  Transformed cells were then spread onto LB agar plates with 
appropriate antibiotic. 
OneShot TOP10 E. coli were transformed according to manufacturer’s protocol 
(Invitrogen).  Transformed cells were then spread onto LB agar plates with appropriate 
antibiotic. 
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BL21 CodonPlus (DE3)-RIPL E. coli were transformed according to 
manufacturer’s protocol (Stratagene).  200 µl transformed cells were then spread onto LB 
agar plates with appropriate antibiotic. 
 
Induction of Recombinant FoxM1 Expression in Bacteria 
 Transformed BL21 CodonPlus (DE3)-RIPL E. coli were cultured in LB with 
50 µg/ml Kanamycin and 50 µg/ml Chloramphenicol overnight at 37oC with shaking at 
225 rpm.  The cultures were then diluted to an OD A600 of 0.1-0.2 AU with LB with 
50 µg/ml Kanamycin and 50 µg/ml Chloramphenicol and cultured at 37oC with shaking 
at 225 rpm until the OD A600 reached ~0.5 AU.  Bacteria were induced to express 
recombinant FoxM1 by adding isopropyl-β-D-thiogalactopyranoside (IPTG) to a final 
concentration of 1 mM and culturing for 2-6 hours with shaking at 225 rpm at 37oC, 
32oC, 29oC, or 25oC. 
Small samples of each culture prior to and after induction were collected, 
centrifuged at high speed (16,000 x g) for 2 minutes to remove media, and resuspended in 
protein gel sample buffer (50 mM Tris, pH 6.8; 1% [w/v] SDS; 5% [w/v] sucrose; 
0.004% [w/v] bromophenol blue; 120 mM β-mercaptoethanol) for SDS-polyacrylamide 
gel electrophoresis (PAGE) analysis.  Bacteria (pellets and resuspended) were stored at  
-20oC. 
 
Purification of Recombinant FoxM1 Antigen 
 Bacterial cultures induced to express recombinant FoxM1 were centrifuged at 
5,000 x g for 10 minutes at 4oC to remove media.  Cells were resuspended/lysed in 
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Bacterial Protein Extraction Reagent (B-PER; Pierce Biotechnology) with NaCl (final 
concentration 150 mM), EDTA (final concentration 2 mM), and 2.5% (v/v) Protease 
Inhibitor Cocktail (Sigma-Aldrich) for use with bacterial cell extracts (Sigma-Aldrich), 
vortexed, and mixed for 10 minutes at 4oC.  The insoluble fraction was pelleted by 
centrifugation at 15,000 x g for 15 minutes at 4oC.  Soluble and insoluble fractions were 
stored at -20oC. 
 FoxM1 fragment-MBP fusion proteins were purified from soluble lysate by 
binding to Amylose Resin (New England Biolabs) and eluting with Maltose 
Monohydrate (Supelco).  The amylose resin was prepared for binding by brief 
centrifugation at low speed to remove the ethanol in which it was stored, washed twice 
with 2 volumes of column buffer (20 mM Tris-HCl, pH 7.4; 150 mM NaCl; 
2 mM EDTA; 0.1% [v/v] NP-40), resuspended in 1 volume of column buffer, and stored 
at 4oC.  Soluble lysate was mixed 20:1 with prepared amylose resin at 4oC for 1 hour, 
then briefly centrifuged at <6,000 x g, and the unbound fraction was removed.  Pelleted 
bound resin was washed five times with 2 volumes of column buffer.  MBP-bound 
proteins were eluted by resuspending pellet in 10 mM maltose in column buffer, mixing 
for 10 minutes at 4oC, and centrifuging briefly at <6,000 x g.  The eluted fraction was 
removed and stored at -20oC. 
Small samples of crude lysate, insoluble fraction, soluble fraction, unbound 
fraction, bound fraction, eluted fraction, and non-eluted fraction were collected, mixed 
with 2X protein gel sample buffer for SDS-PAGE analysis of induction and purification 
efficiencies, and stored at -20oC. 
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Mice in Vanderbilt Monoclonal Antibody Core 
 Balb/c and A/J mice were injected with purified MBP-tagged FoxM1 fragments.   
A total of 50 µg of FoxM1 Fragment 1-MBP and Fragment 3-MBP were mixed with 
sterile PBS in a final volume of 100 µl.  Two injections of 50 µl each were injected per 
mouse, one subcutaneous and the other intraperitoneal.  Mice were injected 
approximately once every 30 days.  Prior to the initial injection and two weeks after the 
second and consecutive boosts, blood was collected from either the tail vein or the retro-
orbital plexus.  Serum was collected after coagulation and centrifugation.  Enzyme-linked 
immunosorbent assay (ELISA) was performed by the Monoclonal Antibody Core to 
assess sera reactivity with MBP, Fragment 1-MBP, and Fragment 3-MBP. 
 
Transient Transfection of Mammalian Cells 
 Full-length murine Foxm1 cDNA was sub-cloned from the pYX-Asc vector to the 
pcDNA3.1+ vector by digestion with EcoRI and NotI.  DH5α E. coli were transformed 
with ligation products and grown on LB-Ampicillin agar plates overnight at 37oC.  
Isolated colonies were cultured in TB with 200 µg/ml Ampicillin overnight at 37oC prior 
to plasmid purification.  Positive clones were identified by restriction digest with EcoRI 
and NotI, which produced bands of 5,428 and 4,390 bp; restriction digest with EcoRV, 
which produced bands of 9,938 and 420 bp; and restriction digest with NheI, which 
produced bands of 7,279 and 2,539 bp.  Clones were verified by sequencing using T7 
primer (Vanderbilt DNA Sequencing Facility). 
 Verified clones were used to transiently transfect HeLa cells, generously provided 
by Shuangli Guo, Post-Doctoral Fellow in Dr. Roland Stein’s laboratory (Vanderbilt 
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University).  4 µg plasmid prep was complexed with Lipofectamine Reagent (Invitrogen) 
by mixing 1:4 (w/v) DNA:Lipofectamine in Opti-MEM I Reduced Serum Medium 
(Invitrogen) and incubating for 30 minutes at room temperature.  Negative controls 
lacked DNA.  HeLa cells were transfected at ~50% confluence, after washing twice with 
Dulbecco’s PBS and incubating for 10-15 minutes with Opti-MEM at 37oC.  
DNA:Lipofectamine complexes in Opti-MEM were incubated with cells for 5 hours at 
37oC, then growth medium was added, and the cells were incubated for 20 hours at 37oC 
prior to RNA and protein extraction. 
 
Protein Extraction 
 Total protein was extracted from mouse tissue (embryonic liver, embryonic heart 
and lungs, embryonic whole body, or adult islets).  Tissue was homogenized in lysis 
buffer (20 mM HEPES, 400 mM NaCl, 752 µM spermidine, 250 µM EDTA, 
2 mM EGTA, 1% [v/v] NP-40, 25% [v/v] glycerol, 2 mM dithiothreitol [DTT], 
1 mM phenylmethylsulphonyl fluoride [PMSF], 0.04% [v/v] protease inhibitor cocktail), 
then centrifuged at high speed (16,000 x g) for 10 minutes at 4oC.  Supernatant was 
stored at -80oC. 
 Nuclear and cytoplasmic protein fractions were extracted from transfected HeLa 
cells.  Cells were incubated with lysis buffer (100 mM Tris-HCl, pH 8.0;  
0.5% [v/v] NP-40) for 5 minutes on ice with vortexing, then centrifuged at high speed 
(16,000 x g) at 4oC for 5 minutes.  The supernatant (cytoplasmic fraction) was collected 
and stored at -80oC.  The pellet was resuspended in nuclear extraction buffer  
(20 mM HEPES, pH 7.5; 400 mM NaCl; 1 mM DTT; 2 mM Na3VO4; 1 mM EDTA;  
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1 mM EGTA, pH 8.0; 1 mM PMSF), incubated for 20 minutes on ice with vortexing, 
then centrifuged at high speed (16,000 x g) at 4oC for 5 minutes.  The supernatant 
(nuclear fraction) was collected and stored at -80oC. 
 
Protein Quantification 
 Extracted protein samples were quantitated using the DC Protein Assay Kit (Bio-
Rad).  Samples and BSA standards were assessed in duplicate using a microplate reader 
to measure A750. 
 
SDS-PAGE, Western Immunoblotting 
 Protein samples were mixed with 4X NuPAGE LDS Sample Buffer (Invitrogen), 
boiled at 95-100oC for 5 minutes, chilled, and subjected to denaturing electrophoresis on 
NuPAGE Novex 4-12% Bis-Tris Mini Gels using 3-morpholinopropanesulfonic acid,  
3-(N-morpholino) propanesulfonic acid (MOPS) SDS Running Buffer, and the Xcell 
SureLock Mini cell electrophoresis system (all from Invitrogen) according to 
manufacturer’s protocol.  SeeBlue Plus2 Pre-Stained Standard (Invitrogen) was used as a 
molecular weight marker. 
 For analysis of recombinant protein induction and purification, gels were stained 
with Bio-Safe Coomassie G250 Stain (Bio-Rad) according to manufacturer’s protocol. 
For western immunoblotting, protein was transferred from gel to Hybond-P 
polyvinylidene difluoride (PVDF) membrane (Amersham) using the Xcell II Blot Module 
(Invitrogen), following manufacturer’s protocol.  Membranes were then blocked in 
5% [w/v] non-fat milk in Tris-buffered saline, pH 7.4 (TBS; 20 mM Tris, 137 mM NaCl) 
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for 1 hour at room temperature and incubated with primary antibody in 3% [w/v] non-fat 
milk overnight at 4oC, washed for 30 minutes in TBS with 0.1% (v/v) Tween 20 (TBS-T) 
at room temperature, and incubated with species-specific peroxidase-conjugated 
secondary antibody in 3% non-fat milk for 1 hour at room temperature.  Following  
30 minutes to 1 hour of washing in TBS-T, antibody detection was performed using ECL 
Western Blotting Detection Reagents (Amersham) and BioMax or X-Omat scientific 
imaging film (Kodak). 
Primary antibodies used for western immunoblotting included:  rabbit anti-FoxM1 
(1:1,000; a gift from Robert H. Costa [University of Illinois at Chicago]) (Wang et al., 
2005), rabbit anti-MPP2 (C-20) (1:200; Santa Cruz Biotechnology), mouse anti-FoxM1 
sera (1:1,000; Vanderbilt Monoclonal Antibody Core).  Secondary antibodies included:  
peroxidase-conjugated goat anti-mouse IgG (1:5,000; Promega) and peroxidase-
conjugated goat anti-rabbit IgG (1:5,000; Promega). 
 
Statistical Analyses 
Data were analyzed by unpaired t-test, one-way ANOVA with Bonferroni’s post-
tests, or two-way ANOVA with Bonferroni’s post-tests, as appropriate, using GraphPad 
Prism v5.01.  P<0.05 was considered significant.  Specific analyses performed and 




INVESTIGATING THE ROLE OF FOXM1 IN β CELL REGENERATION AND 





As type I and type II diabetes result from an absolute or relative deficiency in β 
cell number, respectively, understanding how β cell number is determined and can be 
manipulated may lead to new therapeutic options.  While transplantation of cadaveric 
islets remains promising, additional sources of islets or β cells are required to make this 
treatment more widely available (Shapiro et al., 2006). Diabetic patients would also 
benefit from in vivo manipulation of their β cell population.  Although β cells proliferate 
slowly after birth (Finegood et al., 1995), increased β cell proliferation can be stimulated 
under various conditions, including obesity, pregnancy, injury, and growth factor over-
expression.  In adult rodents and humans, β cell replication is the primary mechanism by 
which new β cells are formed (Dor et al., 2004; Teta et al., 2007; Meier et al., 2008), and 
there is much debate regarding whether and how new β cells arise de novo in the adult.  
However, a recent study in mice has conclusively shown that new β cells are generated 
from facultative adult progenitor cells (neogenesis) in response to pancreatic injury, in a 
manner reminiscent of embryonic endocrine cell differentiation (Xu et al., 2008).  
Additionally, lineage tracing studies using the duct marker carbonic anhydrase II (CAII) 
showed that duct ligation stimulates differentiation of both acinar and endocrine cells 
from duct cells in adult mice, similar to what occurs during development (Bonner-Weir et 
al., 2008).  Furthermore, patients with type I diabetes exhibit evidence for continued β 
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cell production in the face of immune destruction (Meier et al., 2005; Meier et al., 2006), 
providing support for the ability of human β cells to regenerate. 
Partial pancreatectomy (PPx) has been used by several groups as a method of 
pancreatic injury that stimulates regeneration (Bonner-Weir et al., 1983; Leahy et al., 
1988; De Leon et al., 2003; Lee et al., 2006; Peshavaria et al., 2006; Joglekar et al., 
2007; Teta et al., 2007).  However, there are important differences in the actual 
techniques used in these studies, with tissue removal ranging from 50-90% and the 
process of tissue removal being either excision (including removal of the main pancreatic 
duct and splenic artery) or denuding (leaving the main pancreatic duct and splenic artery 
relatively intact).  Although it is difficult to directly compare results among such studies, 
it seems that the greater amount of tissue removed creates a stronger stimulus for 
regeneration, and that denuding the tissue results in more de novo differentiation than is 
observed following pure excision of tissue, although both techniques stimulate 
proliferation.  Additionally, removal of 90% of pancreatic tissue results in hyperglycemia 
(Bonner-Weir et al., 1983; Sharma et al., 1999), which is an independent stimulus for β 
cell proliferation, while 60% PPx does not induce hyperglycemia (Leahy et al., 1988; 
Peshavaria et al., 2006).  This study aimed to determine FoxM1’s role in β cell 
proliferation and regeneration under normoglycemic conditions using 60% PPx, in which 
tissue from the splenic lobe of the pancreas is denuded from the main pancreatic duct and 
splenic artery. 
 FoxM1 is an important regulator of postnatal β cell proliferation, but loss of 
FoxM1 in Foxm1flox/flox;Pdx15.5kb-Cre (FoxM1∆panc) mice does not affect embryonic 
pancreas or β cell development (Zhang H et al., 2006).  These outcomes mirror those 
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reported for widespread deletion of other cell cycle regulators (Cdk4, Cyclin D), with 
postnatal endocrine cell-specific effects causing diabetes (Rane et al., 1999; Georgia and 
Bhushan, 2004; Kushner et al., 2005a).  Female FoxM1∆panc mice remain glucose tolerant 
despite significantly reduced β cell mass and thus are the focus of this study, allowing for 
analysis of β cell proliferation and regeneration without the confounding effects of 
hyperglycemia. 
 To determine whether FoxM1 is required for new β cell formation during 
regeneration, 60% PPx was performed on adult female FoxM1∆panc mice and Control 
(Foxm1flox/flox) littermates (Figure 23A,B).  Importantly, Foxm1 and some of its 
transcriptional targets were up-regulated within islets following PPx during the period of 
peak regeneration, and endocrine cell proliferation and regeneration of β cell mass 
following PPx were specifically impaired in FoxM1∆panc mice.  Furthermore, loss of 




60% PPx up-regulated Foxm1 and select targets within islets while maintaining 
normoglycemia. 
 
FoxM1 mRNA and protein are relatively low in adult islets (Figure 24A) (Zhang 
H et al., 2006), but it was unknown whether up-regulation occurs upon stimulation of 
endocrine cell proliferation.  Indeed, Foxm1 expression was up-regulated 2-fold in 
Control islets 6 days after PPx versus Sham (Figure 24B), suggesting that FoxM1 plays a 
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Figure 23.  60% partial pancreatectomy (PPx).  (A) Exocrine and endocrine tissue 
were removed from the splenic lobe of the pancreas, leaving the main pancreatic duct 
intact.  The splenic (regenerating) and duodenal (expanding) lobes were analyzed 
separately.  It was expected that the regenerating lobe would undergo both
proliferation and neogenesis, while the expanding lobe would undergo only 
proliferation.  (B) Eight week old female mice underwent either a PPx or a Sham 
operation, in which no tissue was removed.  One day prior to the operation, IPGTT 
was performed.  Mice recovered for one week, during which they were given BrdU in 
the drinking water.  After 7 days, IPGTT was performed again, and the mice were 
sacrificed for tissue harvest. 
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Figure 24.  Expression of Foxm1 and targets in Control islets.  (A) qRT-PCR 
revealed that Foxm1 expression was relatively low in adult islets, compared to 
postnatal day 4 (P4) whole pancreas.  (B) After 60% PPx, expression of Foxm1 (blue) 
and several of its targets (green) were up-regulated within islets compared to after a 
Sham operation.  Other FoxM1 targets were not up-regulated after PPx (red), nor were 
cell cycle regulators that are not FoxM1 targets (black).  Results were normalized to 
Hprt1 levels and then to control samples.  Error bars represent SEM.  Unpaired t-test 
with Welch’s correction was used in A, and with no corrections in B, to measure 












corresponded with the peak of β cell proliferation following PPx (Peshavaria et al., 
2006). 
Other transcripts of interest were then screened for differences in expression after 
60% PPx versus Sham, using Custom TaqMan Low-Density Arrays.  Although 
preliminary, these screens revealed that many transcripts were up-regulated within islets 
following PPx, most notably Aurkb, Birc5/Survivin, Ccna2, Ccnb1, Ccnb2, Cenp-a, Plk1, 
and Sox9 (Figure 25).  Other transcripts, including Cdc25b, Ctgf, Nkx2.2, and Skp2 were 
up-regulated to a similar extent as was Foxm1.  qRT-PCR was used to validate these 
findings, and this analysis confirmed that several of FoxM1’s known transcriptional 
targets were up-regulated, including Plk1, Cenp-a, Birc5/Survivin, and Ccnb1 (Figure 
24B).  Other targets, including Skp2, Cks1, and Cdc25b, displayed a trend of up-
regulation following PPx versus Sham but were not significantly altered.  A similar trend 
was observed for Ccna2 but not for Ccnd2, both of which have been linked to β cell 
proliferation (Georgia and Bhushan, 2004; Inada et al., 2005; Kushner et al., 2005a), but 
neither of which is a known FoxM1 target. 
 To determine whether FoxM1 is necessary for endocrine cell regeneration 
following pancreatic injury, FoxM1∆panc and Control female littermates underwent PPx or 
Sham operation at 8 weeks of age.  In agreement with previous reports showing that 60% 
PPx does not induce hyperglycemia (Leahy et al., 1988; Peshavaria et al., 2006), IPGTTs 
performed 7 days following 60% PPx or Sham confirmed that Control and FoxM1∆panc 
female mice remained glucose tolerant, although there was a trend toward slightly higher 
glucose levels in both genotypes after PPx versus Sham (Figure 26A,B). 
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Figure 26.  Glucose tolerance was maintained in Control and FoxM1∆panc mice
following 60% PPx.  (A) IPGTTs were performed in FoxM1∆panc and Control female 
mice 1 week after 60% PPx or a Sham operation.  (B) Area under the curve (AUC) for 
glucose was calculated based on blood glucose levels during IPGTT in FoxM1∆panc
and Control female mice 1 week after 60% PPx or a Sham operation.  Error bars 
represent SEM.  Two-way ANOVA with Bonferroni’s post-tests was used to measure 
significance.  n=5-7 per group.
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Regeneration of β cell mass within the splenic lobe was specifically impaired in 
FoxM1∆panc mice. 
 
Similar to FoxM1∆panc male mice (Zhang H et al., 2006), FoxM1∆panc female mice 
also exhibited ~40% reduced β cell mass at 9 weeks of age compared to littermate 
Controls (1.07 mg versus 1.62 mg), although FoxM1∆panc female mice remained 
normoglycemic. This ~40% reduction in β cell mass was unchanged after a Sham 
operation (Figure 27A), but was specifically due to a reduction in β cell mass within the 
splenic, not duodenal, pancreatic lobe (Figure 27C,E).  Furthermore, the reduction in β 
cell mass was specific to the endocrine compartment of the pancreas, as neither total 
pancreatic weight nor weights of the individual lobes was different between Control and 
FoxM1∆panc mice (Figure 27B,D,F).  There was also no significant difference in total 
pancreatic area on sections (data not shown).  Consistent with previous findings (Spooner 
et al., 1970), a significant majority of β cell mass was located within the splenic lobe of 
Control mice after a Sham operation versus the duodenal lobe (Figure 27C,E) (P<0.01). 
PPx effectively eliminated most of the tissue from the splenic lobe, although a 
relatively small amount of acinar and endocrine tissue remained attached to the main 
pancreatic duct after the procedure (Figure 27D, 28A,C).  Within 7 days, a significant and 
equivalent amount of tissue regenerated in both FoxM1∆panc and Control mice (Figure 
27D, 28B,D), suggesting that overall pancreas regeneration during this time period was 
not impaired by Foxm1 deletion.  β cell mass regeneration within the splenic lobe, 
however, was impaired in FoxM1∆panc mice, as β cell mass in these mice did not 
significantly increase within 7 days following PPx, in contrast to Control littermates 
(Figure 27C).  There were no significant alterations in tissue weight or β cell mass within 
the duodenal lobe of Control or FoxM1∆panc mice following 60% PPx (Figure 27E,F). 
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Figure 27.  β cell mass and pancreas weight in Control and FoxM1∆panc mice after 
60% PPx or a Sham operation.  (A) Total β cell mass and (B) pancreas weight.  (C)
Splenic lobe β cell mass and (D) weight.  (E) Duodenal lobe β cell mass and (F)
weight. Error bars represent SEM.  Two-way ANOVA with Bonferroni’s post-tests 
was used to measure significance.  ns=not significant.  n=4-6 per group.
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Figure 28.  Regeneration of the splenic lobe was observed within 7 days after 
60% PPx in Control and FoxM1∆panc mice. Sections through the splenic lobe of 
Control (A, B) and FoxM1∆panc pancreata (C, D) at either Day 0 (A, C) or Day 7 (B, 
D) following PPx were labeled with anti-insulin antibody (brown) and counterstained 
with eosin.  The majority, but not all, of the endocrine and exocrine tissue was 
removed by the PPx operation, and an increased amount of tissue was observed 7 days 
later in both groups of mice.  Larger islets were observed in Control mice than in 
FoxM1∆panc mice, and in both groups of mice there was evidence of islet neogenesis
within newly-differentiating portions of the splenic lobe (arrowheads, insets).
Scale bar = 1 mm.
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β cell proliferation was reduced in FoxM1∆panc mice compared to Controls after 
60% PPx. 
 
Because β cells are replenished primarily by self-replication (Dor et al., 2004), 
and FoxM1 is important for postnatal β cell proliferation (Zhang H et al., 2006), it 
seemed likely that reduced β cell proliferation contributed to the impaired β cell mass 
regeneration observed in FoxM1∆panc mice.  Indeed, PPx dramatically stimulated β cell 
proliferation in both pancreatic lobes of Control mice, and these effects were significantly 
blunted in FoxM1∆panc mice (Figure 29A-F).  Moreover, β cell proliferation within the 
duodenal lobe of FoxM1∆panc mice did not significantly increase after PPx. 
β cell proliferation in the splenic lobe of FoxM1∆panc mice did increase 
significantly following PPx versus Sham, despite Foxm1 deletion (Figure 29E), due to 
increased proliferation of β cells within small endocrine cell clusters (8 or fewer insulin+ 
cells) and definitive islets (9 or more insulin+ cells) (Figure 30A,C).  However, β cell 
proliferation within definitive islets was significantly reduced in FoxM1∆panc versus 
Control mice (Figure 30C).  Because there was no significant impairment in β cell 
proliferation in small endocrine cell clusters in FoxM1∆panc mice, we hypothesized that 
these represented newly-formed β cells that did not require FoxM1 for proliferation.  This 
hypothesis was supported by the finding that embryonic β cell proliferation did not 
require FoxM1 (Figure 31A,B).  Additionally, proliferation of β cells within small 
endocrine cell clusters after PPx was specifically stimulated in the regenerating splenic 
lobe (Figure 30A), but not duodenal lobe (Figure 30B).  These data suggest that just as 
perinatal β cells can proliferate in the absence of FoxM1, newly-differentiated β cells in 
the adult can undergo several rounds of FoxM1-independent replication prior to 
switching to FoxM1-dependent proliferation. 
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Figure 29.  β cell proliferation was reduced in FoxM1∆panc mice after 60% PPx.  
Low levels of β cell proliferation were observed in the splenic lobes of Control (A)
and FoxM1∆panc (C) mice after a Sham operation.  PPx enhanced BrdU incorporation 
into all pancreatic cell types within the splenic lobe of Control mice (B), but 
incorporation into endocrine cells was reduced in FoxM1∆panc mice (D).  β cell 
proliferation was quantified for both the splenic (E) and duodenal (F) pancreatic 
lobes. Error bars represent SEM.  Two-way ANOVA with Bonferroni’s post-tests 


















Figure 30.  β cell proliferation was only reduced in definitive islets, but not small 
endocrine cell clusters, in FoxM1∆panc versus Control mice after 60% PPx.  β cell 
proliferation within small endocrine cell clusters (<8 β cells) after PPx versus Sham 
was similarly enhanced in the splenic lobes of FoxM1∆panc and Control mice (A), but 
was not significantly altered in the duodenal lobes (B).  β cell proliferation within 
definitive islets (>9 β cells) after PPx was enhanced in the splenic lobe of Control 
mice, and this effect was partially inhibited in FoxM1∆panc mice (C). PPx also 
significantly stimulated β cell proliferation within definitive islets in the duodenal 
lobe of Control, but not FoxM1∆panc, mice (D). Error bars represent SEM.  Two-way 
ANOVA with Bonferroni’s post-tests was used to measure significance.  ns=not 
significant.  n=4-5 per group
113
Table 3.  Summary of β cell proliferation results for Control and FoxM1∆panc
mice after Sham versus PPx.
↓↔Duodenal Lobe
↓↔Splenic Lobe
FoxM1∆panc PPx vs. Control PPx
↔↔Duodenal Lobe
↔↔Splenic Lobe
FoxM1∆panc Sham vs. Control Sham
↔↔Duodenal Lobe
↑↑Splenic Lobe
FoxM1∆panc PPx vs. Sham
↑↔Duodenal Lobe
↑↑Splenic Lobe








Figure 31.  β cell proliferation was unaffected in FoxM1∆panc embryos versus 
Control littermates. Phospho-histone H3 labeling at e17.5 (A) and e18.5 (B) was 
used to measure β cell proliferation.  Error bars represent SEM.  Unpaired t-test was 
used to measure significance.    n=2-3 per group.
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PPx stimulated β cell proliferation within definitive islets of Control mice to the 
same extent (7-fold) in both the splenic and duodenal lobes versus Sham (Figure 30C,D).  
In contrast, proliferation in the splenic lobe of FoxM1∆panc mice increased only 5-fold, 
while the increase within the duodenal lobe was not significant, suggesting that 
proliferation of pre-existing β cells was impaired in the absence of FoxM1.  The 
increased BrdU incorporation within definitive islets in the splenic lobe of FoxM1∆panc 
mice 7 days after PPx versus Sham (Figure 30C) may represent proliferation that 
occurred at an earlier stage of new islet development.  These results are summarized in 
Table 3. 
Similar to the results observed for the β cell population, α cell proliferation was 
also stimulated by PPx in Control mice, and this effect was significantly blunted in 
FoxM1∆panc mice (Figure 32A).  In contrast, acinar (Figure 32B) and ductal cell (Figure 
32C) proliferation were not impaired in FoxM1∆panc mice compared to Control mice after 
PPx.  In fact, acinar proliferation was enhanced in FoxM1∆panc mice, perhaps in part as a 
compensatory mechanism due to reduced islet regeneration.  However, no differences in 
gross splenic lobe weight nor acinar cell number were apparent between the two 
genotypes (Figure 27D and data not shown).  These results indicate that FoxM1 is 
specifically required for endocrine cell proliferation in the pancreas following PPx. 
 
FoxM1∆panc mice exhibited increased β cell and nucleus size compared to Controls. 
 
Sham-operated FoxM1∆panc mice exhibited larger average β cell size in both 
pancreatic lobes (Figure 33A,B) versus Control littermates, due in part to increased β cell 
nucleus size (Figure 33C,D).  However, enlarged nuclei alone could not account for the 
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Figure 32.  α cell proliferation was reduced in FoxM1∆panc mice after 60% PPx, 
but acinar and ductal cell proliferation were not impaired.  BrdU incorporation 
into α cells (A), acinar cells (B), and duct cells (C) was measured in Control and 
FoxM1∆panc mice after PPx or Sham.  Error bars represent SEM.  Two-way ANOVA 
with Bonferroni’s post-tests was used to measure significance.  n=3-5 per group
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Figure 33.  FoxM1∆panc mice exhibited increased β cell and nucleus size. After a 
Sham operation, FoxM1∆panc mice exhibited increased β cell size in both the splenic
(A) and duodenal (B) pancreatic lobes.  Increased β cell size was also observed after 
PPx in the splenic lobe of FoxM1∆panc mice versus Controls but was significantly 
reduced compared to after a Sham operation. The average β cell size in Control 
pancreata was unchanged by PPx.  FoxM1∆panc mice also exhibited increased β cell 
nucleus size in the splenic (C) but not duodenal (D) lobe, which was unchanged by 
PPx.  Error bars represent SEM.  Two-way ANOVA with Bonferroni’s post-tests was 
used to measure significance.  n=4-5 per group.
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total increase in β cell size observed.  Thus, cellular hypertrophy also contributed, likely 
as a compensatory measure due to reduced β cell number.  Although PPx did not alter β 
cell size in Control mice, average β cell size was significantly reduced specifically within 
the splenic lobe of FoxM1∆panc mice after PPx, likely due to new β cell formation. 
 
Islet size in FoxM1∆panc mice was reduced compared to Control mice following 60% 
PPx. 
 
Although PPx reduced total β cell number within the splenic lobe, islets present 
within this lobe 7 days after PPx were of the same average size as after a Sham operation 
in Control mice (Figure 34A).  However, FoxM1∆panc islets were significantly smaller 7 
days after PPx compared to Sham.  There was also a trend for the average islet size 
within the duodenal lobe of Control mice to increase following PPx versus Sham, but no 
islet expansion was observed in the duodenal lobe of FoxM1∆panc mice (Figure 34B).  
These data suggest that Foxm1 deletion impairs islet growth after PPx.  Of note, islets 
within the splenic lobe of Control mice after Sham operation were approximately twice 
as large as islets within the duodenal lobe (P<0.05), which may be due to a greater 
proportion of small endocrine cell clusters versus definitive islets normally found in the 
duodenal versus splenic lobe (P<0.05) (Figure 34C,D).  Interestingly, after PPx 
FoxM1∆panc mice exhibited an increased proportion of small endocrine cell clusters versus 
definitive islets within their splenic lobe in comparison to Control mice (Figure 34C), 
which likely contributed to their reduced average islet size.  No differences were 
observed in the proportion of small endocrine cell clusters between Control and 
FoxM1∆panc mice after Sham operation or within the duodenal lobe under any condition 
(Figure 34D).  These data are consistent with the hypothesis that new insulin+ cell 
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Figure 34.  FoxM1∆panc mice exhibited impaired islet growth after 60% PPx.
There was no significant difference in average islet size between Control and 
FoxM1∆panc mice after a Sham operation or PPx in either the splenic (A) or duodenal 
(B) pancreatic lobes.  Following PPx, the average islet size in the splenic lobe of 
Control pancreata was similar to that observed in Sham-operated mice, but 
FoxM1∆panc islets were significantly reduced in size.  Within the duodenal lobe, 
Control mice trended toward increased average islet size after PPx, but no increase 
was observed in FoxM1∆panc mice.  (C) FoxM1∆panc mice specifically exhibited an 
increased proportion of small insulin+ cell clusters (1-8 β cells) within the splenic lobe 
after PPx, but (D) no differences were observed within the duodenal lobe. Error bars 
represent SEM.  Two-way ANOVA with Bonferroni’s post-tests was used to measure 
significance.  n=4-5 per group
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clusters form in the splenic/regenerating lobes after PPx, and that subsequent growth of 
these clusters is impaired by loss of FoxM1. 
 
β cell neogenesis following 60% PPx was not impaired in FoxM1∆panc mice. 
Islet density was significantly less in the splenic lobe of FoxM1∆panc mice versus 
Controls after a Sham operation (Figure 35A), but no differences were observed in the 
duodenal lobe between the two genotypes (Figure 35B).  Interestingly, the density of 
insulin+ cell groupings in the splenic lobe of both FoxM1∆panc and Control mice trended 
toward an increase 7 days after PPx versus Day 0 (Figure 35A), and insulin+ cells were 
observed within foci of regeneration in the splenic lobes of both groups of mice (Figure 
28B,D).  However, islet density in the duodenal lobe was unchanged by PPx in either 
genotype.  These data suggest that generation of new insulin+ cell groups, or neogenesis, 
occurs specifically in the splenic lobe after PPx and is not impaired in FoxM1∆panc mice. 
In support of these findings, Ngn3, a marker of endocrine progenitor cells (Gradwohl et 
al., 2000), was observed in ductal epithelial cells in both Control (Figure 35C) and 
FoxM1∆panc (Figure 35D) mice following PPx.  Importantly, Ngn3 expression was only 
observed in ductules within the regenerating portion of the splenic lobe, but not within 
differentiated pancreas tissue.  Furthermore, no difference in the number of Ngn3+ ductal 
epithelial cells was detected between Control and FoxM1∆panc mice following PPx.  
 
FOXM1c over-expression did not enhance β cell mass regeneration following 60% 
PPx. 
 
To determine whether FoxM1 over-expression affects pancreas and β cell 
regeneration following PPx, Rosa26-FOXM1c Tg mice were used, which constitutively 
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Figure 35.  FoxM1∆panc mice did not exhibit impaired β cell neogenesis after 60% 
PPx. (A) The number of insulin+ cell groupings per section (islet density) was 
reduced within the splenic lobe of FoxM1∆panc mice compared to Control littermates 
after a Sham operation, but at Day 0 and Day 7 following PPx, the number of insulin+
cell groupings per section was equivalent between FoxM1∆panc and Control mice.  7 
days after PPx, there was a trend in both groups of mice to show increased numbers of 
insulin+ cell groupings per section within the splenic lobe compared to Day 0.  (B) No 
differences in islet density were observed between any groups of mice in the duodenal 
lobe.  (C) Ngn3 expression was detected only after PPx within cytokeratin+ (CK+) 
ductal epithelial cells located within foci of regeneration in the splenic lobes of both 
Control and (D) FoxM1∆panc mice.  Error bars represent SEM.  Two-way ANOVA 















and ubiquitously over-express human FOXM1c (Kalinichenko et al., 2003).  Despite 
FOXM1c over-expression within islets (Figure 36A), Tg mice exhibited no significant 
differences in glucose tolerance (Figure 36B) nor β cell mass following PPx (Figure 37A) 
compared to wild-type (WT) littermates.  Furthermore, no differences in pancreatic tissue 
weight (Figure 375B), average islet size (Figure 37C), or islet density (Figure 37D) were 
observed between Tg and WT mice in either lobe.  Preliminary analyses also revealed no 
obvious differences in β cell proliferation within the splenic/regenerating lobe of Tg and 
WT mice after PPx (Figure 37E).  Additionally, no significant changes in transcript levels 
of the FoxM1 targets Plk1 or Cenp-a, or of the cell cycle regulator Ccnd2, were observed 
in Rosa26-FOXM1c Tg versus Control islets (data not shown). 
 
Discussion 
 FoxM1 is highly expressed within pancreatic endocrine cells during 
embryogenesis and is down-regulated with age (Figure 14A-C) (Zhang H et al., 2006), 
corresponding with reduced β cell proliferation. Our laboratory previously showed that 
mice with Foxm1 deleted throughout the pancreatic epithelium (FoxM1∆panc) exhibit 
impaired growth and maintenance of postnatal β cell mass secondary to reduced postnatal 
β cell proliferation, associated with increased nuclear-localized p27Kip1 and premature 
cellular senescence (Zhang H et al., 2006).  Several of FoxM1’s direct transcriptional 
targets inhibit p27Kip1 by promoting its ubiquitination and subsequent degradation (Skp2, 
Cks1) (Wang et al., 2005) or its nuclear export (KIS) (Petrovic et al., 2008). The study 
presented here showed that FoxM1∆panc mice have impaired β cell mass regeneration 
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Figure 36. Over-expression of FOXM1C had no effect on glucose tolerance.  (A) 
Real-time qRT-PCR with primers specific to human FOXM1c was performed on 
RNA extracted from isolated islets from 9 week old WT and Rosa26-FOXM1c Tg
mice.  (B) Tg mice did not display any significant differences in glucose tolerance 
after a sham operation or PPx.  Error bars represent SEM.  Unpaired t-test was used to 
measure significance for A. Two-way ANOVA with Bonferroni’s post-tests was used 
to measure significance for B.  n=2-3 WT, 4-5 Tg.
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Figure 37. Over-expression of FOXM1C had no effect on β cell regeneration 
after 60% PPx.  No differences were observed in β cell mass (A), pancreas weight 
(B), average islet size (C), or average number of insulin+ cell groupings per section 
(islet density) (D) after PPx in either the splenic or duodenal pancreatic lobes of Rosa-
FOXM1c Tg mice compared to WT littermates.  Islet size and number were obtained 
from the same images used to measure β cell mass. (E) β cell proliferation in the 
splenic lobe after PPx was also similar between Rosa-FOXM1c Tg and WT mice.  
Error bars represent standard error of the mean (SEM).  Unpaired t-test was used to 
measure significance.  n=2-3 WT, 4-5 Tg for A-D.  n=2 per group for E.
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following PPx, due to reduced β cell proliferation, but there was no evidence that 
neogenesis was affected by loss of FoxM1. 
 60% PPx is a normoglycemic pancreatic injury model that stimulates regeneration 
by (1) differentiation and proliferation and (2) hyperplasia of pre-existing tissue.  This 
study revealed that Foxm1 and some of its targets were up-regulated within islets 
following PPx during a period of enhanced α and β cell proliferation, leading to the 
hypothesis that FoxM1 is required for injury-stimulated endocrine cell proliferation.  
Indeed, FoxM1∆panc mice exhibited impaired α and β cell proliferation and impaired β cell 
mass regeneration following PPx.  PPx stimulated β cell proliferation in both the splenic 
(regenerating) and duodenal (expanding) lobes of Control mice, but not in the duodenal 
lobe of FoxM1∆panc mice.  Thus, hyperplasia of pre-existing β cells after injury requires 
FoxM1. 
Interestingly, PPx-stimulated β cell proliferation was blunted but not completely 
inhibited within the splenic lobe of FoxM1∆panc mice, due at least in part to impaired 
proliferation of β cells in definitive islets, but not small endocrine cell clusters, in the 
absence of FoxM1.  Of course, small clusters of insulin+ cells are not necessarily newly-
formed, as a certain amount of such clusters are normally present in the adult pancreas.  
Furthermore, because islet size and insulin+ cell number were quantified using two-
dimensional histology, it is possible that some of the clusters included in these analyses 
were in fact the edges of larger islets.  However, because Control and FoxM1∆panc mice 
were analyzed in a similar manner, it is unlikely that this method skewed the data based 
on genotype, although comparisons between Sham, Day 0, and Day 7 may have been 
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affected.  To avoid this caveat, three-dimensional analyses of re-constituted confocal z-
stacks could be used to more accurately determine cluster and islet size. 
The proliferation data presented here suggest that another pathway(s), which may 
mimic that utilized during embryonic pancreas development, compensates for loss of 
FoxM1 during regeneration, as FoxM1 was also not required for embryonic β cell 
proliferation.  Thus, pre-existing β cells seemingly exhibit a stronger requirement for 
FoxM1 than do new β cells formed by neogenesis.  Although it is currently unclear which 
factors are required for β cell proliferation during embryogenesis and following islet 
neogenesis, this study supports the hypothesis that neogenesis in the adult is similar to 
embryonic β cell development, both with regard to re-expression of Ngn3 and initial 
FoxM1-independent proliferation. 
 Because BrdU was administered over 7 days, this study may have under-
estimated the effects of Foxm1 deletion on endocrine cell proliferation.  Previous studies 
have shown that Foxm1-/- cells can undergo multiple rounds of DNA synthesis without 
karyo- or cytokinesis (endoreduplication), resulting in polyploid nuclei (Krupczak-Hollis 
et al., 2004).  Evidence of polyploid β cells and exocrine cells were observed in 
FoxM1∆panc mice, and these cells would have been counted as proliferating cells in this 
study, but would not have actually resulted in increased cell number.  This phenomenon 
could partially explain the increased BrdU incorporation in β cells without significant β 
cell mass regeneration within the splenic lobe of FoxM1∆panc mice after PPx compared to 
Sham, although it most likely would not be restricted to one lobe.  Labeling with 
phospho-histone H3 may yield different results, as this protein is specifically 
phosphorylated during mitosis (Dai et al., 2005), and such labeling would be a useful 
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addition to these experiments.  However, it may be necessary to analyze phospho-histone 
H3 labeling at multiple time points following PPx, as the time course of stimulated β cell 
proliferation may vary between Control FoxM1∆panc mice. 
 Additionally, incomplete Foxm1 recombination could have resulted in mosaic 
expression, allowing some β cells to continue proliferating in FoxM1∆panc mice.  
However, this is unlikely because Pdx15.5kb-Cre was previously shown to recombine the 
Rosa26-LacZ reporter allele within all endodermally-derived pancreatic cells and to yield 
a significant reduction in FoxM1 protein by e15.5 (Zhang H et al., 2006).  Additionally, 
Foxm1 transcripts were significantly reduced in FoxM1∆panc neonatal pancreas (Figure 
38A) and even more dramatically in adult islets (Figure 38B).  These tissues contain non-
endodermally-derived mesenchymal, endothelial, and neuronal cells, which would not 
undergo Foxm1 recombination, and thus likely account for remaining transcript 
expression.  Verification of FoxM1 protein expression, or the lack thereof, could not be 
performed because antibodies to detect FoxM1 protein in mouse tissue do not currently 
exist. 
Proliferation of α and β cells, but not acinar or ductal cells, was reduced in 
FoxM1∆panc mice versus Control littermates following PPx, suggesting that FoxM1 is 
required specifically within endocrine cells.  These data concur with other studies 
showing that endocrine cells are particularly susceptible to perturbations in cell cycle 
regulation (Georgia and Bhushan, 2004; Kushner et al., 2005a; Mettus and Rane, 2003; 
Rane et al., 1999).  The current study utilized qRT-PCR on islet RNA to assess changes 
in Foxm1 expression following PPx.  Lack of an anti-FoxM1 antibody precludes precise 
identification of the cell population(s) in which FoxM1 expression or localization 
128
Figure 38.  Foxm1 transcript levels were dramatically reduced in FoxM1∆panc
mice versus Control littermates. Real-time qRT-PCR was performed on RNA 
isolated from postnatal day 4 FoxM1∆panc and Control pancreata (A) and from isolated 
islets from 9 week old mice (B).  Foxm1 transcript levels were reduced by 63% in 
postnatal day 4 FoxM1∆panc pancreata and by 77% in adult FoxM1∆panc islets.  Error 
bars represent SEM.  Unpaired t-test with Welch’s correction was used to measure 
significance.  n=3-5 per group.
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changes with time and after PPx.  Such studies will in the future allow for better 
understanding of cell type-specific requirements for FoxM1 and may help to explain the 
differing effects of FoxM1 absence that were observed between endocrine and exocrine 
cells following PPx.  However, the expression analyses described here identified several 
potentially important regulators of pancreatic endocrine cell proliferation and 
regeneration that are themselves regulated by FoxM1 (Plk1, Cenp-a, Birc5/Survivin, 
Ccnb1). 
This study also presented evidence of β cell neogenesis following 60% PPx, 
including Ngn3+ duct cells, insulin+ cells within regenerating tissue, and increased islet 
density.  Although each finding alone is not sufficient to support neogenesis, all pieces of 
data together strongly indicate the occurrence of neogenesis.  Importantly, these findings 
were equivalent between Control and FoxM1∆panc mice, revealing that β cell neogenesis 
in the adult mouse does not require FoxM1.  Because neither β cell mass at birth (Zhang 
H et al., 2006) nor embryonic β cell proliferation were altered in FoxM1∆panc mice, it is 
clear that β cell neogenesis during development also does not require FoxM1.  Peshavaria 
et al. (Peshavaria et al., 2006) showed increased small endocrine cell clusters by 2 days 
post-PPx, which normalized by 7 days.  Although the definition of “cluster” in that work 
was based on insulin+ area, while here “cluster” was defined by number of insulin+ cells 
(in order to avoid confounding effects of β cell size on cluster area), the data presented 
here are consistent the findings of Peshavaria et al., as Control mice at 7 days post-PPx 
exhibited a normal proportion of small endocrine cell clusters.  However, FoxM1∆panc 
mice had an increased proportion of small endocrine cell clusters at 7 days post-PPx, 
indicating that formation of these clusters is not impaired in the absence of FoxM1, but 
130
significant growth is.  These data support the hypothesis that initial proliferation of 
newly-differentiated β cells does not require FoxM1, but that these cells later switch to a 
FoxM1-dependent state.  Unfortunately, current technology precludes real-time 
monitoring of β cell proliferation and islet growth.  However, this study highlights the 
importance of β cell proliferation as a mechanism of β cell mass regeneration, as 
neogenesis, without adequate proliferation, was not sufficient to regenerate a significant 
amount of β cell mass in FoxM1∆panc mice after 60% PPx. 
As β cell regeneration after partial duct ligation mimics embryonic β cell 
differentiation with Ngn3 re-expression (Xu et al., 2008), it is not surprising that similar 
processes occur following 60% PPx, although perhaps to a lesser extent.  In comparison 
to results published for ductal ligation (Xu et al., 2008), relatively few ductule cells were 
found to express Ngn3 at 7 days after PPx (0-3 positive cells per 200X field of view).  
However, analysis at an earlier timepoint, such as 1-2 days after PPx when there is a 
significant increase in small insulin+ cell clusters (Peshavaria et al., 2006), would likely 
reveal more Ngn3+ cells, as Ngn3 expression is transient in endocrine progenitors. 
This is the first study to show Ngn3 re-expression following PPx, in contrast to 
several previous studies that concluded that after PPx, neogenesis and Ngn3 re-
expression did not occur.  However, the partial pancreatectomy procedures used in these 
studies were performed in a manner that likely precluded true regeneration.  Lee et al. 
performed 50% PPx, in which the entire splenic lobe and pancreatic duct were surgically 
excised, and they reported no re-expression of Ngn3 in the remaining tissue by 
immunohistochemistry and Ngn3-EGFP knock-in analyses (Lee et al., 2006).  As we 
only observed Ngn3 expression in foci of regeneration within the splenic lobe after 60% 
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PPx, these results are not surprising.  The data presented here and by others (Bonner-
Weir et al., 1993; Sharma et al., 1999) reveal the importance of leaving the main 
pancreatic duct and splenic artery in order to stimulate differentiation of new pancreas 
tissue.  Teta et al. also utilized 50% PPx, in conjunction with sequential thymidine analog 
labeling to assess proliferation, and they concluded that no specialized progenitors gave 
rise to new β cells in the adult because individual β cells only rarely incorporated more 
than one thymidine analog after PPx (Teta et al., 2007).  Again, complete removal of the 
splenic lobe and main pancreatic duct likely precluded differentiation of new pancreas 
tissue in this model.  Furthermore, our results do not indicate that newly-formed β cells 
(in small clusters) undergo more proliferation than do pre-existing β cells (in definitive 
islets) in Control mice after 60% PPx.  Dor et al. performed 60-70% PPx in a manner 
similar to that described here, but they did not analyze the splenic and duodenal lobes 
separately (Dor et al., 2004).  Based on β cell lineage labeling results, in which β cells 
were labeled with a heritable marker prior to PPx and no significant dilution of this label 
was observed after PPx, they concluded that neogenesis did not give rise to new β cells.  
Because the splenic lobe comprises only a small percentage of total pancreas weight and 
β cell mass after PPx (~20% after 7 days), and because the contribution of neogenesis and 
regeneration to new β cell formation is relatively small following PPx, it would be 
unlikely to detect any significant changes in the β cell lineage label using this technique 
without analyzing the splenic and duodenal lobes separately.  The current study removed 
tissue from the splenic lobe, leaving the main pancreatic duct intact.  This lobe was 
analyzed separately, and only specific foci of regeneration within the splenic lobe 
exhibited evidence of neogenesis.  In contrast, the duodenal lobe, which was the sole or 
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primary source of tissue analyzed in the aforementioned studies, exhibited significant 
hyperplasia with no evidence of neogenesis after 60% PPx, in agreement with these other 
published works.  Thus, this study does not contradict but adds to the current knowledge 
regarding the potential for pancreas regeneration and β cell neogenesis. 
FOXM1C over-expression did not affect β cell regeneration following PPx, which 
could have been due to differences in activity between human FOXM1C and murine 
FoxM1, although both are transactivators.  Rosa26-FOXM1c Tg mice were used for these 
experiments because mice over-expressing murine Foxm1 or the more closely-related 
human FOXM1b have not yet been generated.  However, these results suggest that over-
expression of FoxM1 is not sufficient to elevate β cell proliferation, emphasizing that the 
β cell cell cycle is under tight negative regulatory control, even after injury.  As reviewed 
(Cozar-Castellano et al., 2006a), β cells express all of the cell cycle “brakes” studied thus 
far, but only some “accelerators”.  Thus, it may be more difficult than initially anticipated 
to stimulate β cell proliferation in vivo or in vitro as a therapeutic option for diabetic 
patients.  Because FoxM1 positively regulates cell cycle accelerators and negatively 
regulates cell cycle brakes, it is of particular interest.  However, because over-expression 
of FOXM1C did not seem up-regulate target genes in mouse islets in vivo, FoxM1 may 
not be a limiting factor for β cell proliferation.  Alternatively, it may be necessary to 
directly activate FoxM1 in addition to over-expressing it in order to stimulate β cell 
proliferation.  Thus, better understanding of post-translational and inhibitory regulators of 




INVESTIGATING THE ROLE OF FOXM1 IN β CELL HYPERPLASIA 
IN RESPONSE TO DIET-INDUCED OBESITY 
 
Introduction 
 Obesity is a primary risk factor for developing Type II diabetes (Staff, 2007), and 
it has been well-characterized that increased adiposity leads to insulin resistance, as 
reviewed in (Kahn et al., 2006).  Insulin resistance is known to stimulate β cell 
compensation via enhanced insulin secretory function and expansion of β cell mass in 
order to produce more insulin in an attempt to maintain normoglycemia.  Genetic mouse 
models of insulin resistance have been generated by deletion of the insulin receptor (IR) 
(Okada et al., 2007; Cohen et al., 2007), Irs1 (Tamemoto et al., 1994; Araki et al., 1994), 
or Irs2 (Withers et al., 1998; Kubota et al., 2000; Kubota et al., 2004).  Spontaneous 
mutations in the genes encoding leptin (ob/ob) (Lindstrom, 2007) or the leptin receptor 
(db/db) (Chen et al., 1996) also resulted in obesity and insulin resistance.  Additionally, 
mouse models of diet-induced obesity have been shown to exhibit insulin resistance.  In 
particular, high-fat diets cause the most dramatic effects on body weight and insulin 
resistance, and the C57Bl/6 mouse strain is most susceptible to these effects (Collins et 
al., 2004). 
 In rodents, β cell mass expansion in response to insulin resistance occurs 
primarily via increased proliferation (Zhong et al., 2007) and secondarily via β cell 
hypertrophy (Lingohr et al., 2002).  C57Bl/6 mice fed a high-fat diet exhibit 2.2-fold 
increases in β cell mass and proliferation within four months compared to mice fed a 
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control diet (Sone and Kagawa, 2005).  Rodent studies have shown that both 
hyperglycemia and hyperlipidemia stimulate β cell proliferation, both under acute and 
chronic conditions (Bonner-Weir et al., 1989; Steil et al., 2001).  Furthermore, 
hyperinsulinemia stimulated by peripheral insulin resistance can act through the 
insulin/IGF-1 receptor on β cells to stimulate proliferation and promote survival (Bernal-
Mizrachi et al., 2001).  Additionally, incretins, such as glucagon-like peptide 1 (GLP-1) 
and gastric inhibitory peptide (GIP), which are secreted by intestinal cells after feeding, 
can promote β cell proliferation and survival (Drucker, 2006).  All of these stimuli also 
enhance β cell insulin secretory function.  However, chronic exposure to these stimuli 
eventually results in β cell failure, characterized by apoptosis and senescence, reduced 
proliferation and β cell mass, and diabetes. 
In contrast, obese humans undergo only an approximate 50% expansion of β cell 
mass compared to lean individuals (Butler et al., 2003).  Such expansion is primarily due 
to β cell neogenesis, with β cell proliferation being difficult to observe under any 
condition, which is consistent with the low replicative capacity of human versus rodent β 
cells, as discussed in (Butler et al., 2007).  Although Type II diabetes in humans 
progresses in a similar manner as in obese rodents (Rhodes, 2000), the majority of obese 
humans do not develop Type II diabetes (Mokdad et al., 2001; Kahn et al., 2006) 
suggesting that diet alone is not responsible, and that primary β cell dysfunction may play 
a role in pre-disposing some people to developing the disease.  Type II diabetes, although 
a complex multifactorial disorder, is subject to high genetic risk and has been linked to 
several gene mutations, some of which likely affect β cell function (Permutt et al., 2005; 
Sladek et al., 2007; The Wellcome Trust Case Control Consortium, 2007).  Thus, 
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identification of factors that play a role in regulating β cell mass expansion may give 
some insight into the pathogenesis of Type II diabetes, as well as provide putative 
therapeutic targets. 
 While FoxM1 has been identified as an important regulator of β cell proliferation 
and β cell mass growth after weaning in mice under normal conditions (Zhang H et al., 
2006), it was unknown whether FoxM1 was similarly required for β cell proliferation and 
β cell mass expansion stimulated by diet-induced obesity and insulin resistance.  To 
address this question, FoxM1∆panc mice were placed on a high-fat/high-carbohydrate diet, 
and their physiological and islet responses were analyzed in comparison to Control 
littermates and to mice on a chow diet with moderate fat content (Figure 39). 
 In response to the high-fat diet, FoxM1∆panc female mice became obese to the 
same extent as did Control female littermates.  Both Control and FoxM1∆panc mice on the 
high-fat diet displayed glucose intolerance, which was more prominent in FoxM1∆panc 
mice, but all mice on the chow diet remained glucose tolerant.  FoxM1∆panc mice on the 
high-fat diet displayed reduced insulin secretion in response to glucose.  Part of this 
impairment was explained by reduced β cell mass in FoxM1∆panc mice, which was also 
observed in chow-fed mice.  However, no expansion of β cell mass was observed in 
Control mice in response to the high-fat diet, despite their ability to increase insulin 
secretion.  Thus, the impaired insulin secretion observed in FoxM1∆panc mice may be due 
at least in part to β cell dysfunction rather than just reduced β cell number.  
Unfortunately, the failure of Control mice to under β cell mass expansion, and the lack of 
a significant increase in β cell proliferation, in response to the high-fat diet rendered this 
study inconclusive as to the role of FoxM1 in obesity-induced β cell mass compensation. 
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Figure 39.  Diet-induced obesity.  (A) High-fat/high-carbohydrate diets induce 
obesity, which causes insulin resistance in insulin target tissues such as liver, muscle, 
and fat.  Insulin resistance results in an increased demand for insulin, which stimulates 
increased β cell insulin secretory function and β cell mass expansion.  (B) Four week 
old mice were placed on either a high-fat/high-carbohydrate diet or a moderate-fat 
chow diet for 12 weeks.  IPGTTs were performed at the start of the study and every 4 
weeks thereafter.  Insulin secretion was measured at 0 and 30 minutes during the 
IPGTT at 8, 12, and 16 weeks of age.  At 15 weeks old, mice were subjected to IPITT 
and NMR body composition analysis and then given BrdU in the drinking water for 1 
week.  Mice were sacrificed at 16 weeks of age, after 12 weeks on the respective 
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 The most likely reason this study failed was because the FoxM1∆panc and Control 
mice were on a mixed strain background.  Therefore, a pilot study was performed to 
determine whether isogenic C57Bl/6 mice responded in the predicted ways to diet-
induced obesity, and then FoxM1∆panc and Control mice were backcrossed to the C57Bl/6 
background in order to repeat the study.  These experiments verified that female mice on 
the C57Bl/6 strain background underwent β cell mass expansion in response to the high-
fat diet. 
 Despite these setbacks, several interesting findings came from these studies that 
will be interesting to investigate further.  First, a potential insulin secretory defect in 
FoxM1∆panc mice was identified by measuring plasma insulin levels before and after a 
glucose challenge.  Preliminary results from islet perifusion and transcript expression 
analyses suggest that loss of FoxM1 may have other β cell effects in addition to 
regulating proliferation.  Second, preliminary analysis of islet transcript expression 
suggested that Foxm1 and some of its transcriptional targets were up-regulated within 
islets in response to the high-fat diet.  Thus, follow-up of these studies is likely to yield 




FoxM1∆panc and Control Mice on a Mixed Background 
High-fat diet induced obesity in mixed background FoxM1∆panc and Control mice. 
 
 FoxM1∆panc and Control female littermates weighed the same amount at the outset 
of the study at 4 weeks of age (Figure 40A), prior to randomization into the two diet 
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Figure 40.  High-fat diet induced obesity in FoxM1∆panc and Control littermates.  
(A) Absolute body weight increased more dramatically in FoxM1∆panc and Control 
mice fed the high-fat diet versus the chow diet over the 12 week study period, from 
age 4 weeks (after weaning) to age 16 weeks.  (B) Average fold-change in body 
weight over the 12 week study period was significantly greater in FoxM1∆panc and 
Control mice fed the high-fat diet versus the chow diet. Error bars represent SEM.  
Two-way ANOVA with Bonferroni’s post-tests was used to measure significance.  
**P<0.01, ***P<0.001 HFD vs Chow. n=10-12 per group. 
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groups.  However, feeding of the high-fat diet (HFD; 58.7% fat) induced obesity in both 
Control and FoxM1∆panc mice versus mice on a chow diet (mouse diet 5015, 25.3% fat), 
with body weights of the high-fat diet fed groups diverging from the chow-fed groups as 
early as 8 weeks of age, after being on the diet for 4 weeks.  By the end of the study 
period, both Control and FoxM1∆panc mice on the high-fat diet exhibited significantly 
increased body weights versus chow-fed mice (Figure 40A), and total weight high-fat 
diet-fed mice was ~30% greater than that of mice fed the chow diet (Figure 40B).  
Importantly, no significant differences in weight gain were observed between Control and 
FoxM1∆panc mice, regardless of diet or gender. 
 To confirm that increased weight gain in mice on the high-fat diet versus chow 
was associated with increased adiposity, body composition analysis was performed at the 
end of the study period, after 12 weeks on the respective diets.  In comparison to the 
chow diet, high-fat diet resulted in significantly increased body fat mass in both Control 
and FoxM1∆panc mice (Figure 41A).  In addition, percent body weight composed of fat 
was also significantly increased by the high-fat diet, at the expense of lean muscle mass 
(Figure 41B).  Again, these changes were similar between Control and FoxM1∆panc mice. 
 
High-fat diet induced glucose intolerance in mixed background FoxM1∆panc and 
Control mice. 
 
 At four weeks of age, all mice were glucose tolerant (Figure 42A).  However, 
after being fed the high-fat diet for only four weeks, both Control and FoxM1∆panc mice 
began to exhibit glucose intolerance, defined as significantly higher blood glucose levels 
during IPGTT compared to mice on the chow diet (Figure 42B).  Additionally, 
FoxM1∆panc mice displayed significantly higher blood glucose levels at the later 
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Figure 41.  High-fat diet induced increased adiposity in FoxM1∆panc and Control 
littermates. (A) NMR spectroscopy reavealed that absolute weight of body fat was 
significantly greater in FoxM1∆panc and Control mice fed the high-fat diet versus the 
chow diet at the end of the 12 week study period.  Lean mass (muscle) and weight of 
free fluid were not significantly altered.  (B) Percent total body weight composed of 
fat was significantly increased in FoxM1∆panc and Control mice fed the high-fat diet 
versus the chow diet at the end of the 12 week study period, while percent body 
weight composed of lean mass was reduced. Error bars represent SEM.  Two-way 
ANOVA with Bonferroni’s post-tests was used to measure significance.  n=8-9 per 
group.
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Figure 42.  High-fat diet induced glucose intolerance in FoxM1∆panc and Control 
littermates.  (A) IPGTT at 4 weeks of age showed that all mice at the beginning of 
the study displayed similar glucose tolerance.  (B) IPGTT at 8 weeks of age, after 
being fed either the high-fat or chow diet for 4 weeks, showed that high-fat diet-fed 
mice displayed significant glucose intolerance, while mice fed the chow diet remained 
glucose tolerant.  Error bars represent SEM.  Two-way ANOVA with Bonferroni’s
post-tests was used to measure significance.  **P<0.01, ***P<0.001 HFD vs Chow; 
†P<0.05, ††P<0.01 FoxM1∆panc HFD vs Control HFD. n=10-12 per group.
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timepoints during IPGTT, indicating that loss of FoxM1 within the pancreas exacerbates 
high-fat diet-induced glucose intolerance.  However, because glucose tolerance is 
determined by a combination of β cell function and peripheral insulin sensitivity, it was 
unclear what was affected by diet and what was affected by genotype. 
 
High-fat diet induced insulin resistance in mixed background FoxM1∆panc and Control 
mice. 
 
To assess peripheral insulin resistance, IPITTs were performed after 11 weeks on 
the respective diets.  Surprisingly, no differences in insulin tolerance were observed 
between Control and FoxM1∆panc mice on either diet and high-fat diet did not 
significantly alter insulin tolerance in either group of mice (Figure 43A).  However, use 
of the Homeostasis Model Assessment (HOMA) (fasting plasma insulin x fasting blood 
glucose / 22.5), an indirect measure of insulin sensitivity (Matthews et al., 1985), 
revealed a trend for both Control and FoxM1∆panc mice to display insulin resistance as 
early as 4 weeks on the high-fat diet (Figure 43B).  Importantly, no differences in IPITT 
or HOMA were observed between Control and FoxM1∆panc mice on either diet. 
 
FoxM1∆panc mice on a mixed background exhibited impaired insulin secretion on the 
high-fat diet. 
 
In order to better assess β cell function, insulin secretion was measured during 
IPGTTs at 0 and 30 minutes after glucose injection.  In agreement with published results, 
Control mice displayed an approximate 2-fold increase in plasma insulin levels at 30 
minutes versus 0 minutes after glucose injection after both 4 weeks (Figure 44A) and 12 
weeks (Figure 44B) on the chow diet.  At the 4 week timepoint, no significant differences 
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Figure 43.  High-fat diet did not induce significant insulin resistance.  (A) IPITT 
at 15 weeks of age showed no significant differences in insulin tolerance between 
Control or FoxM1∆panc mice fed the high-fat diet for 11 weeks versus those fed the 
chow diet.  However, (B) HOMA calculation at 8 weeks of age, after being fed either 
a high-fat or chow diet for 4 weeks, revealed a trend for the high-fat diet-fed mice to 
display insulin resistance.  Error bars represent SEM.  Two-way ANOVA with 
Bonferroni’s post-tests was used to measure significance.  n=7-9 per group.
144
Figure 44.  FoxM1∆panc mice fed the high-fat diet exhibited impaired insulin 
secretion.  (A) Insulin secretion in Control mice on either diet and in FoxM1∆panc
mice on the chow diet increased two-fold by 30 minutes after glucose injection during 
IPGTT at 8 weeks of age, after 4 weeks on the respective diets. However, FoxM1∆panc
mice on the high-fat diet did not secrete more insulin at 30 minutes after glucose 
injection than at baseline.  (B) After 12 weeks on the high-fat diet, Control mice 
exhibited increased fasting and 30-minute plasma insulin levels versus mice fed the 
chow diet, but no such increase was observed in FoxM1∆panc mice.  (C) Calculation of 
the insulinogenic index revealed a trend for high-fat diet-fed FoxM1∆panc mice to 
display reduced β cell insulin secretory function after 4 weeks and (D) 8 weeks on the 
diet.  Error bars represent SEM.  Two-way ANOVA with Bonferroni’s post-tests was 
used to measure significance. †P<0.05, ††P<0.01, †††P<0.001 FoxM1∆panc HFD vs
Control HFD. n=10-12 per group.
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were observed between Control and FoxM1∆panc mice on the chow diet at 0 or 30 
minutes, nor on the high-fat diet at 0 minutes (Figure 44A).  However, FoxM1∆panc mice, 
after 4 weeks on the high-fat diet, exhibited impaired insulin secretion in response to 
glucose, with no significant increase in plasma insulin levels at 30 minutes versus 0 
minutes, resulting in the 30 minute plasma insulin level in these mice being significantly 
reduced compared to Control mice on the high-fat diet.  This impairment in insulin 
secretion worsened by 12 weeks on the high-fat diet, as plasma insulin levels in 
FoxM1∆panc mice at this timepoint were only 50% of those of Control mice at both 0 and 
30 minutes after glucose injection (Figure 44B).  In comparison to mice on the chow diet, 
Control mice on the high-fat diet exhibited higher plasma insulin levels at both 0 and 30 
minutes, whereas FoxM1∆panc mice did not secrete more insulin on the high-fat versus 
chow diet. 
 Comparing the results for blood glucose levels and plasma insulin levels at 0 and 
30 minutes after glucose injection allowed for calculation of the insulinogenic index 
(change in plasma insulin / change in blood glucose), which is a measure of β cell 
secretory function (Wareham et al., 1995).  After both 4 weeks (Figure 44C) and 12 
weeks (Figure 44D) on the high-fat diet, FoxM1∆panc mice displayed reduced 
insulinogenic indices compared to Control mice, although these differences were not 
statistically significant.  Thus, based on insulin secretion and insulinogenic index 
calculations, FoxM1∆panc mice appear to exhibit defective insulin secretion when placed 




FoxM1∆panc mice on a mixed background exhibited reduced β cell mass compared to 
Controls, and high-fat diet did not stimulate β cell mass expansion. 
 
 As obesity-induced insulin resistance and hyperglycemia have been shown to 
stimulate β cell proliferation and expansion of β cell mass, it was of interest to determine 
whether FoxM1 was required for these processes.  Additionally, it was possible that 
FoxM1∆panc mice displayed reduced insulin secretion on the high-fat diet because of 
impaired β cell mass compensation.  At 16 weeks of age, although pancreas weight was 
similar to that of Control mice (Figure 45A), FoxM1∆panc mice displayed an approximate 
40% reduction in β cell mass on both the chow and high-fat diets (Figure 45B).  
Surprisingly, high-fat diet did not significantly alter pancreas weight or β cell mass in 
either genotype. 
 As a corollary to β cell mass, pancreatic insulin content was assessed in Control 
and FoxM1∆panc mice after 12 weeks on the chow and high-fat diet.  Indeed, pancreatic 
insulin content results were similar to those of β cell mass, with FoxM1∆panc mice 
exhibiting a 40% reduction versus Control mice when on the chow diet (Figure 45C).  
Additionally, high-fat diet had no effect on pancreatic insulin content in either group of 
mice. 
 
High-fat diet did not stimulate significant β cell proliferation or apoptosis. 
 
 To determine whether high-fat diet had any effects on β cell proliferation that 
were not appreciated by analysis of β cell mass, BrdU incorporation into β cells was 
assessed during the 12th week on the diet.  No significant differences in β cell 
proliferation were observed between Control and FoxM1∆panc mice fed the chow diet, but 
β cell proliferation was significantly reduced in FoxM1∆panc mice compared to Controls 
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Figure 45.  FoxM1∆panc mice exhibited reduced β cell mass and pancreatic insulin 
content compared to Controls, and neither was altered by high-fat diet.  (A)
Pancreas weight did not significantly differ between Control and FoxM1∆panc mice on 
either diet. However, (B) β cell mass and (C) pancreatic insulin content in 
FoxM1∆panc mice at 16 weeks of age were reduced by ~40% compared to Control 
mice on either diet.  High-fat diet did not cause any changes in β cell mass or 
pancreatic insulin content in either genotype.  Error bars represent SEM.  Two-way 
ANOVA with Bonferroni’s post-tests was used to measure significance.  n=10-12 per 
group for A, n=5-6 per group for B and C.
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when fed the high-fat diet (Figure 46A).  Additionally, there was a trend for Control mice 
on the high-fat diet to exhibit increased β cell proliferation, whereas no such trend was 
observed for FoxM1∆panc mice on the high-fat versus chow diet. 
It was surprising that high-fat diet did not stimulate significant β cell proliferation 
in Control mice, but it was possible that such stimulation occurred at an earlier timepoint, 
and that by 12 weeks on the diet, significant β cell compensation could no longer be 
observed.  Therefore, BrdU incorporation into β cells was assessed during the 5th week on 
the diet, but again no differences in β cell proliferation between Control mice fed the 
high-fat diet versus the chow diet were apparent (Figure 46B).  Additionally, it was 
possible that the high-fat diet stimulated β cell apoptosis that counter-balanced any 
hyperplasia or expansion that occurred.  To this end, TUNEL labeling of β cells after 12 
weeks on the diets was measured, but very few TUNEL+ β cells were observed in any 
group of mice (Figure 46C).  Thus, high-fat diet did not appear to increase β cell 
apoptosis. 
Together, these results suggested that mice on a mixed C57Bl/6 strain background 
do not exhibit β cell hyperplasia or β cell mass expansion in response to diet-induced 
obesity. 
 
FoxM1∆panc mice on a mixed background displayed enlarged β cell size but reduced 
islet size. 
 
Although this set of experiments did not allow for assessment of FoxM1’s 
involvement in β cell hyperplasia and β cell mass expansion in response to diet-induced 
obesity, several interesting results were observed when comparing Control and 
FoxM1∆panc mice on either diet.  Similar to what was reported in Chapter III, FoxM1∆panc 
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Figure 46.  FoxM1∆panc mice exhibited reduced β cell proliferation after 12 weeks 
on the high-fat diet, but high-fat diet did not significantly stimulate β cell 
proliferation in Control mice. (A) BrdU incorporation into β cells was significantly 
reduced in FoxM1∆panc mice compared to Control mice after 12 weeks on the high-fat, 
but not chow, diet.  High-fat diet did not significantly stimulate β cell proliferation in 
Control mice compared to chow diet, but did result in decreased β cell proliferation in 
FoxM1∆panc mice. (B) BrdU incorporation into β cells of Control and FoxM1∆panc
mice after 5 weeks on the high-fat diet was similar to results observed after 12 weeks.  
(C) TUNEL labeling identified only a small number of β cells undergoing apoptosis 
in either Control or FoxM1∆panc mice after 12 weeks on either the high-fat or chow 
diet.  Error bars represent SEM.  Two-way ANOVA with Bonferroni’s post-tests was 
used to measure significance for A and C. n=5-6 per group for A, n=3 Controls and 1 
FoxM1∆panc for B, n=2-3 per group for C.
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mice exhibited enlarged β cell size compared to Control mice on both the chow and high-
fat diets (Figure 47A).  Interestingly, high-fat diet did not result in significant increases in 
β cell size in either genotype.  As discussed in Chapter III, FoxM1∆panc mice on the chow 
diet display enlarged nuclei due to endoreduplication, which partially accounts for the 
observed increase in cell size.  Although β cell nucleus size was not directly measured in 
this study, it is likely that similar results would be obtained. 
Despite having larger β cells, however, average islet size in FoxM1∆panc mice was 
reduced compared to Controls on both diets, and high-fat diet did not cause any changes 
in islet size versus chow diet (Figure 47B).  The reduction in average islet size observed 
in FoxM1∆panc mice could in part be attributed to an increased proportion of small 
endocrine cell clusters versus definitive islets in these mice compared to Controls (Figure 
47C).  Additionally, islet density was significantly reduced in FoxM1∆panc mice compared 
to Controls after being fed the high-fat diet (Figure 47D). 
 
Isogenic C57Bl/6 Mice Pilot Study 
 To confirm that isogenic C57Bl/6 female mice would undergo β cell hyperplasia 
and β cell mass expansion in response to the high-fat diet used in the above studies, and 
to determine whether a chow diet with reduced fat content would serve as a better 
control, pilot studies were performed using C57Bl/6JBom mice fed three different diets 
for 12 weeks:  rodent diet 5001 (13.5% fat), mouse diet 5015 (25.3% fat), or high-




Figure 47.  FoxM1∆panc mice exhibited enlarged β cell size but reduced islet size 
and density compared to Control littermates. (A) β cell size was significantly 
larger, while (B) islet size was significantly smaller, in FoxM1∆panc mice compared to 
Control mice after 12 weeks on either the chow or high-fat diet.  High-fat diet did not 
significantly alter β cell or islet size versus chow diet. (C) The proportion of small 
endocrine cell clusters versus definitive islets was greater in FoxM1∆panc mice than 
Controls after 12 weeks on either the high-fat or chow diet and was not significantly 
altered by high-fat diet. (D) Islet density was significantly reduced in FoxM1∆panc
mice compared to Controls after 12 weeks on the high-fat, but not chow diet.  Error 
bars represent SEM.  Two-way ANOVA with Bonferroni’s post-tests was used to 
measure significance.  n=5-6 per group.
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High-fat diet induced obesity and glucose intolerance in C57Bl/6 mice. 
 
 Female C57Bl/6JBom littermates were weaned at four weeks of age, at which 
time their weights were similar (Figure 48A), prior to being placed on one of the three 
study diets.  As early as four weeks after being fed the high-fat diet, the mice began to 
diverge in weight, which was exacerbated with age.  While no significant differences in 
weight gain were observed between mice on the two chow diets, mice on the low-fat 
5001 chow diet displayed a consistent trend towards less weight gain than mice on the 
moderate-fat 5015 chow diet. 
 In accordance with body weight, mice on the high-fat diet exhibited glucose 
intolerance as early as eight weeks of age, after only four weeks on the diet.  Area under 
the curve (AUC) calculations, utilizing blood glucose levels during IPGTT, revealed that, 
despite all mice initially being normoglycemic, mice fed the high-fat diet displayed 
significantly higher blood glucose levels during IPGG than mice in either chow diet 
group at later timepoints (Figure 48B).  Again, no significant differences were observed 
in AUC measurements between mice on the two chow diets. 
 
High-fat diet stimulated β cell mass expansion in C57Bl/6 mice. 
 
 Mice fed the high-fat diet had larger pancreata than mice on either chow diet 
(Figure 49A), and these pancreata contained an increased percentage of insulin+ tissue 
(Figure 49B).  Together, these two phenomena resulted in mice on the high-fat diet 
exhibiting increased β cell mass versus mice on the chow diets (Figure 49C).  Again, no 
differences in these parameters were apparent between mice on the two chow diets, 
although they did follow the body weight results, with mice on the low-fat 5001 chow 
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Figure 48.  High-fat diet induced obesity and glucose intolerance in C57Bl/6 
female mice. (A) Fasting body weight was measured every four weeks during the 
study, beginning at 4 weeks of age after weaning.  All mice weighed approximately 
the same amount at 4 weeks of age, and subsequently the high-fat diet-fed group 
gained weight more rapidly and to a greater extent than either of the chow diet-fed 
groups.  (B) Area under the curve (AUC) for glucose during IPGTT was calculated 
every four weeks during the study.  While mice fed either chow diet maintained a 
stable AUC at all timepoints, high-fat diet-fed mice displayed glucose intolerance at 
8, 12, and 16 weeks of age.  Error bars represent SEM.  Two-way ANOVA with 
Bonferroni’s post-tests was used to measure significance.  *P<0.05, **P<0.01, 
***P<0.001 vs HFD.  n=4-5 per group.
154
Figure 49.  High-fat diet stimulated pancreas growth and β cell mass expansion
in C57Bl/6 female mice. Although sample size was too small to reach significance, 
mice fed the high-fat diet exhibited a consistent trend towards increased (A) pancreas 
weight, (B) percent insulin+ area within the pancreas, (C) β cell mass, and (D) BrdU
incorporation into β cells. Error bars represent SEM.  One-way ANOVA with 
Bonferroni’s post-tests was used to measure significance.  n=2 per group.
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diet demonstrating the lowest values for pancreas weight, insulin+ area, and β cell mass.  
A similar trend was observed for β cell proliferation, with mice on the high-fat diet 
displaying increased BrdU incorporation into β cells than mice on either chow diet 
(Figure 49D). 
 
High-fat diet stimulated Foxm1 expression in C57Bl/6 islets. 
 
 qRT-PCR was used to assess whether diet-induced obesity altered Foxm1 
expression within islets.  Indeed, Foxm1 transcript levels mirrored the changes observed 
in β cell mass and proliferation, with mice fed the high-fat diet expressing a higher level 
of Foxm1 transcripts compared to mice fed either of the chow diets (Figure 50).  
Additionally, enhanced expression of the FoxM1 targets Plk1 and Aurkb was also 
observed, while there was no change in Ccnd2, which is not a known FoxM1 target. 
 Despite the small sample size for some of the analyses performed in this pilot 
study, it demonstrated that the high-fat diet used in the previous studies could elicit 
changes in β cell mass, β cell proliferation, and islet Foxm1 expression in isogenic 
C57Bl/6 female mice.  Additionally, this study suggested that the low-fat 5001 chow diet 
may be a better control diet to use in future studies.  Thus, it was deemed worthwhile to 
pursue investigating FoxM1’s role in β cell hyperplasia in response to diet-induced 
obesity, using mice on a congenic C57Bl/6 background. 
 
Foxm1flox/flox Mice on a C57Bl/6 Background 
 Based on the results of the two aforementioned studies, Foxm1flox and 
Pdx15.5kb-Cre mice were backcrossed eight generations to the C57Bl/6JBom strain, and 
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Figure 50.  High-fat diet up-regulated Foxm1 and some of its targets in C57Bl/6 
female mice. Foxm1, Plk1, and Aurkb, but not Ccnd2, transcripts were up-regulated 
in mice fed the high-fat diet compared to mice fed either of the control diets. Error 
bars represent SEM.  n=1-2 per group.
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the original study of FoxM1’s role in β cell adaptation to diet-induced obesity was 
repeated with a shorter end-point of eight weeks, as prior studies had demonstrated that 
many parameters were altered by high-fat diet feeding within this time period. 
 Unfortunately, during the course of the study, it was discovered that the  
Pdx15.5kb-Cre transgene had been silenced in the mouse colony prior to the beginning of 
the study.  This was confirmed for the mice in this study, which had genotyped positive 
for the Cre transgene (Figure 51A) but still had the full-length floxed Foxm1 allele and 
no null allele upon genotyping pancreas tissue from sections (Figure 51B).  Additionally, 
Cre expression was undetectable in islet nuclei (Figure 51C).  Thus, FoxM1∆panc mice 
were actually not included in the experiment, and all results reported here represent 
Foxm1flox/flox mice on either the high-fat diet or the low-fat 5001 chow diet. 
 
High-fat diet induced obesity and glucose intolerance in Foxm1flox/flox mice on the 
C57Bl/6 background. 
 
 At four weeks of age, after weaning, Foxm1flox/flox female mice on the C57Bl/6 
background were randomized into either the high-fat diet or low-fat chow diet groups.  
All mice has similar body weights at the beginning of the study, but within eight weeks 
mice fed the high-fat diet gained significantly more weight than did mice fed the chow 
diet (Figure 52A).  Similarly, all mice exhibited similar glucose tolerance at four weeks 
of age (Figure 52B,C), but eight weeks of high-fat diet feeding resulted in glucose 
intolerance compared to mice fed the chow diet, evidenced by increased blood glucose 




Figure 51. Foxm1flox/flox;Pdx15.5kb-Cre mice on the C57Bl/6 background did not 
undergo Cre-mediated recombination of Foxm1.  (A) Despite approximately half 
of the mice included in the study genotyping positive for the Cre transgene, (B) floxed
Foxm1 alleles were still present in pancreas tissue from all mice, while Foxm1 null 






























Figure 52.  High-fat diet induced obesity and glucose intolerance in Foxm1flox/flox
C57Bl/6 female mice. (A) Fasting body weight at 4 weeks of age was similar 
between all mice, but the high-fat diet-fed group subsequently gained more weight 
than the chow-fed group.  (B) Area under the curve (AUC) for glucose during IPGTT 
increased over the 8 week study period to a greater extent in high-fat diet-fed mice 
versus chow-fed. (B) IPGTT at 4 weeks of age revealed no differences in glucose 
tolerance between the mice at the beginning of the study, (C) but after 8 weeks on the 
high-fat diet, Foxm1flox/flox C57Bl/6 mice exhibited hyperglycemia versus chow-fed 
mice.  Error bars represent SEM.  Two-way ANOVA with Bonferroni’s post-tests was 
used to measure significance. **P<0.01, **P<0.001.  n=11-12 per group.
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High-fat diet stimulated β cell mass expansion in Foxm1flox/flox mice on the C57Bl/6 
background. 
 
 Although pancreas weight was not significantly different in mice on the high-fat 
versus chow diet (Figure 53A), the percent of pancreas tissue composed of β cells was 
significantly increased in high-fat diet-fed mice versus chow diet-fed mice (Figure 53B).  
This resulted in an approximate 50% increase in β cell mass in Foxm1flox/flox female mice 
on the high-fat diet compared to chow diet within eight weeks (Figure 53C). 
 
Investigating Insulin Secretory β Cell Function in FoxM1∆panc Mice on a Mixed 
Background 
 
 Because FoxM1∆panc mice fed a high-fat diet exhibited reduced plasma insulin 
levels after a glucose challenge, it was of interest to determine whether this was due to a 
primary β cell defect associated with loss of FoxM1.  To this end, a preliminary islet 
perifusion study was performed on isolated islets from nine week old female FoxM1∆panc 
and Control littermates.  Comparison of islet responses to various secretagogues (high 
glucose, tolbutamide, IBMX, and KCl) revealed an approximate 50% reduction in insulin 
secretion from FoxM1∆panc islets compared to Control islets (Figure 54).  Of course, this 
study compared islets from only one FoxM1∆panc mouse and one Control littermate, 
necessitating the need for further study.  Unfortunately, the aforementioned silencing of 
the Pdx15.5kb-Cre transgene has precluded such studies from being performed as of yet. 
 An additional approach used to determine whether FoxM1∆panc islets exhibited 
non-proliferative defects was islet transcript expression analysis.  For these analyses, a 
combination of routine qRT-PCR and higher-throughput arrays were utilized.  Again, 
islet RNA was isolated from nine week old female FoxM1∆panc and Control littermates.  
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Figure 53.  High-fat diet stimulated β cell mass expansion in Foxm1flox/flox
C57Bl/6 female mice. (A) High-fat diet did not alter pancreas weight versus chow 
diet.  However, (B) percent insulin+ area within the pancreas and (C) β cell mass were 
significantly increased in high-fat diet-fed mice versus chow-fed mice.  Error bars 
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Figure 54.  Preliminary analysis revealed a possible insulin secretory defect in 
FoxM1∆panc islets.   50.05 IEQ of each genotype were loaded onto perifusion columns 
and exposed to either 5.6 mM glucose (baseline) or one of four secretagogues (16.7 
mM glucose, 16.7 mM glucose + IBMX, Tolbutamide, or KCl).  Insulin concentration 
in the perifusate was measured by RIA.  Insulin secretion in response to all 


















qRT-PCR revealed no significant differences in expression of the islet hormones 
Insulin1, Insulin2, or Glucagon, or of the mature islet transcription factors Pdx1, MafA, 
or Arx (Figure 55).  However, FoxM1∆panc islets expressed reduced levels of the 
transcription factor Pax4.  Additionally, the FoxM1 target CenpA was reduced in 
FoxM1∆panc islets, although other proliferation markers (Plk1, Aurora B kinase, and 
Cyclin D2) were not significantly altered.  Thus, FoxM1∆panc islets do not express less 
insulin than Control islets, so the putative insulin secretory defect was likely due to 
downstream defects in insulin secretion. 
 To further investigate this hypothesis, Custom TaqMan Low Density Arrays were 
utilized to analyze expression of many targets, including islet hormones, transcription 
factors, cell cycle regulators (including some FoxM1 targets), and factors involved in 
insulin vesicle secretion.  These analyses confirmed the reduced CenpA expression in 
FoxM1∆panc islets identified by qRT-PCR, but contradicted the Pax4 results, with Pax4 
transcript levels being higher in FoxM1∆panc islets analyzed by the arrays (Figure 56).  In 
fact, CenpA and Pax4 were the most dramatically-altered transcripts using this technique.  
Additionally, the Cdk inhibitors p16INK4a and p21Cip1 were up-regulated in FoxM1∆panc 
islets, concurring with a proliferative defect.  The array data also suggested that some 
factors involved in insulin secretion (Vamp2, Rab3a, Rab27a, and Myosin5a) may be 
down-regulated in FoxM1∆panc islets, while Munc13b may be up-regulated.  However, 
because of technical issues several RNA samples could not be analyzed, and thus, these 




Figure 55.  Real-time qRT-PCR analysis of transcript expression in FoxM1∆panc
and Control islets. Error bars represent SEM.  Unpaired t-tests were used to measure 




















































































































































Diet-induced obesity has been utilized in many rodent studies as a means to 
stimulate β cell proliferation.  However, not all mouse strains are affected in the same 
manner by a high-fat diet, and the C57Bl/6 strain is particularly susceptible to weight 
gain, glucose intolerance, and β cell compensation (Black et al., 1998; Funkat et al., 
2004; Andrikopoulos et al., 2005).  Some of these distinctions may be due to significant 
differences in islet mass, number, and function that have been identified among various 
mouse strains (Bock et al., 2005; Andrikopoulos et al., 2005).  Therefore, it is not 
entirely surprising that Control mice on a mixed background (129SvJ, ICR, CBA, 
C57Bl/6) did not undergo significant β cell mass expansion in response to the high-fat 
diet.  However, these mice were outbred from the C57Bl/6 strain, and other groups have 
observed diet-induced β cell mass expansion in mouse strains other than C57Bl/6 (Gupta 
et al., 2007). 
In addition, different responses to high-fat diet are observed between male and 
female mice on the same genetic background.  In general, male rodents are more 
susceptible to obesity and diabetes than are female rodents, due at least in part to 
estrogenic effects on body weight regulation, insulin sensitivity, and β cell mass and 
function (Geary et al., 2001; Louet et al., 2004; Choi et al., 2005; Contreras et al., 2002).  
Thus, many published studies regarding effects of high-fat diet utilized only male mice.  
However, the majority of FoxM1∆panc male mice develop glucose intolerance and 
diabetes under normal conditions by six to nine weeks of age, associated with islet 
necrosis and fatty infiltration of the pancreas (Zhang H et al., 2006), which could mask 
any diet-induced effects.  Despite these concerns, FoxM1∆panc and Control male mice 
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were included in the aforementioned high-fat studies.  However, the majority of male 
mice, regardless of genotype, displayed glucose intolerance or diabetes when fed the 
high-fat diet, and FoxM1∆panc male mice consistently displayed impaired insulin 
secretion, regardless of diet.  Therefore, only results from the female arm of the study 
were included here, as they are representative of both groups of data but lack the 
confounding effects of pre-existing hyperglycemia.  Interestingly, Control male mice did 
undergo β cell mass expansion (2-fold) in response to the high-fat diet, revealing that β 
cell compensation occurred in male, but not female, mice on this particular mixed 
background. 
To circumvent this conundrum, FoxM1∆panc mice were backcrossed onto the 
C57Bl/6 strain background before repeating the study.  However, an alternative approach 
would be to use FoxM1∆islet male mice (Foxm1flox/flox;Pdx1PB-CreERTM), in which Foxm1 
is specifically deleted within islet endocrine cells (primarily β cells) after injection of 
tamoxifen (Zhang H et al., 2005).  By delaying Foxm1 deletion until just before the start 
of the study and restricting Foxm1 deletion to islets, the confounding effects of pre-
existing hyperglycemia and exocrine defects (Zhang H et al., 2006) could be avoided, 
which may allow for better analysis of FoxM1’s role in β cell mass expansion in response 
to diet-induced obesity.  These studies have not yet been undertaken, but the necessary 
mice are readily available. 
Another caveat to this study is that the high-fat and chow diets used were not 
matched for micronutrients.  Thus, it is possible that some of the effects observed in 
response to the diets (or lack thereof) were due to differences in components of the diets 
other than fat.  Additionally, it is becoming clearer that different types of fat sources have 
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different effects on body composition and insulin resistance (Rivellese et al., 2002).  
Although the fat source in both the high-fat diet and mouse diet #5015 was lard, which is 
known to induce insulin resistance, it is possible that this fat source does not stimulate β 
cell compensation in the same manner as other fat sources.  Future studies should aim to 
use matched diets with optimal fat sources in order to avoid these potential confounding 
factors, although the high-fat diet used in this study did stimulate β cell mass expansion 
in C57Bl/6 mice, and such effects would need to be verified for other diets. 
 When considering the use of other diets or other mouse models for diet-induced 
obesity studies, it will be important to verify that obesity actually correlates with insulin 
resistance, as the studies presented here have shown that obesity alone is not sufficient to 
stimulate β cell mass expansion.  To this end, it may be worthwhile in future experiments 
to utilize hyperinsulinemic-euglycemic clamps to assess insulin resistance, rather than 
IPITTs or HOMA calculations.  Although HOMA has been shown to correlate well with 
clamp-determined insulin sensitivity (Lee et al., 2008), hyperinsulinemic-euglycemic 
clamps are considered the reference standard in humans and rodents (Ayala et al., 2006).  
However, the clamps are technically difficult and would need to be an end-point analysis, 
as opposed to HOMA, which can be assessed repeatedly in the same mouse and relatively 
easily.  Additionally, consideration should be given to administering glucose for IPGTTs 
based on lean body mass, rather than total body mass, as glucose levels in high-fat diet-
fed mice were likely inflated in this study due to increased adiposity. 
 Although preliminary results presented here suggest that Foxm1 transcript levels 
are up-regulated in mouse islets after exposure to a high-fat diet, these results will need to 
be confirmed, and ideally up-regulation within β cells specifically will need to be 
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assessed.  Such studies have not yet been performed because of the lack of an acceptable 
anti-FoxM1 antibody.  Once such an antibody is available, immunohistochemistry could 
be used to assess FoxM1 expression within particular cell types, both under normal and 
high-fat diet-fed conditions.  Additionally, because nuclear localization of FoxM1 is 
essential for its transcriptional activity, and phosphorylation has been shown to regulate 
such localization and activity (Ma et al., 2005), it will be important to determine whether 
sub-cellular localization of FoxM1 in different cell types is altered under various 
conditions.  Importantly, mice fed diets with differing fat contents exhibit altered sub-
cellular localization of another forkhead transcription factor, FoxD3 (Dr. Trish Labosky, 
Vanderbilt University; personal communication), and nuclear exclusion of FoxO is 
associated with insulin resistance (Okada et al., 2007).  Therefore, localization of FoxM1 
may also change in response to a high-fat diet, and an antibody will be necessary in order 
to detect such a change.  Chapter VI discusses the ongoing efforts to generate a 
monoclonal anti-FoxM1 antibody for use in western immunoblotting and/or 
immunohistochemistry in order to perform these experiments. 
 This study aimed to determine whether FoxM1 was required for β cell 
proliferation and β cell mass expansion in response to diet-induced obesity and insulin 
resistance, using mice with a pancreas-wide deletion of Foxm1 (FoxM1∆panc) fed a high-
fat diet.  However, Control mice failed to exhibit β cell mass expansion or increased β 
cell proliferation after being fed the high-fat diet, preventing any conclusions from being 
made regarding FoxM1’s role in these processes.  This series of studies revealed that 
female mice on a congenic C57Bl/6 strain background, but not those on a mixed 
background, responded to the high-fat diet as expected.  Although FoxM1∆panc mice were 
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backcrossed to the C57Bl/6 background, the Pdx1-Cre transgene became silenced, and 
new mice will have to be backcrossed before the experiments can be repeated.  The 
mechanism of gene silencing has not yet been determined, but it occurred in two different 
colonies of mice, on both the original and backcrossed strain backgrounds, during a 
similar timeframe.  Thus, perhaps after a certain number of generations, the transgene 
underwent epigenetic modification, chromatin remodeling, and/or RNAi-mediated 
silencing. 
Additionally, these studies indicated that FoxM1∆panc mice suffered from reduced 
insulin secretion when fed the high-fat diet, suggesting that FoxM1 may be important for 
the compensatory enhancement of β cell function that normally occurs in response to 
diet-induced obesity and insulin resistance.  Importantly, the impairment in insulin 
secretion was not due to reduced Insulin gene transcription or reduced Insulin protein 
expression per β cell mass.  Together with preliminary islet perifusion experiments that 
showed reduced insulin secretion in response to all secretagogues, these results suggest 
that loss of FoxM1 impairs general insulin secretion.  These results are intriguing, 
particularly because mice with a global deletion of Skp2 (Skp2-/-), which is a direct 
FoxM1 transcriptional target, also exhibited reduced insulin secretion in response to 
glucose without a reduction in insulin protein expression per β cell mass, as well as 
impaired β cell mass expansion in response to diet-induced obesity (Zhong et al., 2007).  
Therefore, FoxM1 may regulate β cell mass expansion and β cell function through Skp2, 
although loss of FoxM1 may produce more dramatic effects than observed in Skp2-/- 
mice, as other transcriptional targets are likely affected as well.  Thus, further study of 
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 There is much interest in generating new β cells both in vivo and in vitro in order 
to enhance or replace a patient’s own β cell population.  However, a definitive source of 
new β cells in the adult pancreas, and indeed whether new β cells can even be derived 
from adult human tissue, has not been conclusively determined.  Several studies have 
shown that replication of pre-existing β cells is the primary mechanism by which β cell 
mass expansion and regeneration occurs during adulthood (Dor et al., 2004; Teta et al., 
2007; Meier et al., 2008) (Chapter III).  However, because β cells differentiate from 
Ngn3+ precursors located within the ductal epithelium during development (Gradwohl et 
al., 2000; Gu et al., 2002), it is hypothesized that β cells may be able to be derived from 
duct cells in the adult.  In support of this hypothesis, several groups have found that after 
pancreatic injury there are increased numbers of insulin+ cells within or directly adjacent 
to ducts (Bonner-Weir et al., 1993; Hayashi et al., 2003); the pancreatic progenitor and β 
cell marker, Pdx1, is up-regulated in duct cells (Sharma et al., 1999); and Ngn3 is up-
regulated (Xu et al., 2008) (Chapter III).  Furthermore, ductal epithelium isolated from 
mice and humans has been induced to differentiate into insulin-producing cells in vitro 
(Ramiya et al., 2000; Heremans et al., 2002). 
 In hopes of identifying a definitive β cell precursor population in the adult mouse, 
lineage tracing studies have been performed in which a particular cell population is 
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labeled with a heritable marker that will distinguish it and its progeny at a later timepoint 
upon histological analysis.  Such studies have been performed using conditional Cre 
expression to recombine a marker, such as the Rosa26 reporter (Soriano, 1999) (Figure 
18), in particular cell populations during development in order to determine into which 
cell types they differentiate.  For adult lineage tracing, it is often necessary to use 
inducible, conditional Cre-mediated recombination to label a cell population at a specific 
timepoint.  For this purpose, CreERTM-expressing mouse lines are used, in which Cre 
recombinase is fused to a mutated form of the estrogen receptor ligand binding domain 
that renders it responsive to tamoxifen, but not endogenous estrogen (Littlewood et al., 
1995).  Binding of CreERTM to tamoxifen disrupts its interaction with heat shock proteins 
that sequester it in the cytoplasm, allowing for nuclear translocation of the fusion protein 
and Cre-mediated recombination of floxed target alleles (Figure 16B). 
 Several distinct CreERTM mouse lines have been utilized for lineage tracing after 
pancreatic injury, although interpretation of the results are somewhat unclear.  Most 
recently, adult duct cells were labeled by CreERTM-mediated recombination of the 
Rosa26 reporter locus, under the control of the carbonic anhydrase II (CAII) promoter, 
and labeled islet cells were observed following duct ligation (Bonner-Weir et al., 2008).  
Thus, duct cells can contribute to formation of new islet cells, but the frequency of such 
occurrence was not reported, and no images were provided in the manuscript for 
interpretation.  Interestingly, lineage tracing of acinar cells using the elastase I promoter 
driving expression of CreERTM showed that acinar cells did not give rise to endocrine 
cells after 70-80% partial pancreatectomy (PPx), treatment with exendin-4, cerulein-
induced pancreatitis, or duct ligation (Desai et al., 2007).  Finally, β cells themselves 
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have been lineage-labeled using the rat insulin promoter (RIP) to drive CreERTM-
mediated recombination of the Z/AP reporter (Dor et al., 2004).  In this study, a pulse-
chase experiment was performed, in which β cells were labeled in adult mice by 
tamoxifen injection (pulse), and maintenance or dilution of this label within the β cell 
population over time and after 70% PPx (chase) was assessed (Figure 57A).  In both 
cases, the percent of labeled β cells remained constant, indicating that non-β cells 
(unlabeled) do not give rise to β cells. 
However, several caveats existed in the Dor et al. (2004) study that could have 
confounded the results.  First, tamoxifen-induced recombination of the Z/AP reporter was 
significantly less than 100% (ranging from 30-60%, depending on the dose of tamoxifen 
administered), requiring extrapolation of the results to conclude that no new β cells are 
derived from non-β cells.  Second, because the actual portion of the pancreas that 
undergoes regeneration is quite small in comparison to the remaining portion of the 
pancreas, which undergoes expansion of pre-existing tissue (see Chapter III), and because 
the regenerating portion was not analyzed separately, it is possible that the results were 
skewed by including only pre-existing islets and no new islets.  Third, it was unclear 
whether tamoxifen was still present during the “chase” periods, as no phamacokinetic 
studies have been performed in rodents using doses as high as used in this study.  
Because the RIP would be activated in newly-differentiated β cells, regardless of their 
origin, these cells would express CreERTM, and if tamoxifen had not yet been cleared 
from the bloodstream, the fusion protein would be translocated to the nucleus, 
recombination of the reporter allele would occur, and expression of the marker would 
have been interpreted as the cell being derived from a pre-existing β cell.  Although the 
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β cells come 
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Figure 57.  Pulse-chase lineage labeling of β cells. (A) Lineage labeling of β cells is 
accomplished by CreER-mediated recombination of a heritable reporter label (pulse) 
that can be assessed over a period of time (chase).  (B) Experimental design of β cell 
lineage labeling experiments in Pdx1PB-CreERTM;R26R mice.  Part A of figure is 
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contribution of neogenesis would most likely be small and would be restricted to or more 
prevalent in regenerating tissue, this study did not conclusively show that β cell 
neogenesis fails to occur after PPx or under normal conditions in the adult. 
To address some of the above concerns, these studies were repeated with some 
modifications, seeking to determine whether β cell neogenesis occurred following 60% 
PPx, and, if so, to determine whether FoxM1 participated in this process.   
Pdx1PB-CreERTM mice were used rather than RIP-CreERTM mice, as the Pdx1PB promoter 
is also endocrine cell- (primarily β cell-) specific but is less leaky than the RIP (Jeanelle 
Kantz and Dr. Al Powers, Vanderbilt University; personal communication).  60% PPx 
was used as the method of pancreatic injury to induce regeneration, and the regenerating 
portion of the pancreas was separated from the remaining portion for analysis, as this 
portion is most likely to undergo neogenesis (see Chapter III).  Five week old mice were 
injected subcutaneously with 3 injections of 8 mg tamoxifen each, and 60% PPx was 
performed 2 weeks after the final injections (Figure 57B), as it was hypothesized that 
tamoxifen would be cleared from the system within this time period. 
 
Results 
The original experimental design included Foxm1floc/-;Pdx1PB-CreERTM;R26R and 
Foxm1flox/+;Pdx1PB-CreERTM;R26R mice, in order to address both aims of this study with 
one set of experiments.  However, despite multiple breeding schemes, there was no 
success in obtaining mice with a Foxm1fl allele on the R26R background, suggesting that 
the Foxm1 and Rosa26 loci were linked.  In fact, both loci are located 13.3 centimorgans 
(cM) apart on mouse chromosome 6 (Figure 58A).  Although this distance confers an 
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Rosa26 locus
Chrom 6; 48.7cM; 113,012,092-113,026,574bp
Foxm1 locus
Chrom 6; 62.0cM; 128,328,595-128,341,500bp
Figure 58.  The Foxm1 and Rosa26 loci are closely located on mouse chromosome 
6.  (A) Chromosomal locations of Rosa26 (Thumpd3) and Foxm1 loci, provided by the 
University of California Santa Cruz (UCSC) Genome Browser.  (B) Recombination 
efficiency of Cre recombinase diminishes with distance between loxP sites.  The 
approximate distance and recombination efficiency between Rosa26 and Foxm1 are 




approximate 13% chance of recombination between the loci, no appropriate mice were 
generated after 6 litters and 47 pups.  Even if these mice were generated, though, the 
presence of loxP sites within both the Foxm1 and Rosa26 loci presents the potential 
problem of Cre-mediated excision of the intervening sequence between the two loci, 
which includes multiple genes as well as the LacZ knock-in and could confound the 
results.  Although rare, Cre-mediated recombination can occur between distant loxP sites 
(Zheng et al., 2000) (Figure 58B). 
To avert these concerns, R26R mice were replaced with Z/EG mice, which were 
generated by random transgenic insertion of a floxed LacZ coding sequence upstream of 
an EGFP coding sequence, driven by a ubiquitous CMV enhancer/chicken β-actin 
promoter (Novak et al., 2000) (Figure 19).  Unfortunately, Z/EG mice on the C57Bl/6 
strain background, which was the background of the Foxm1flox/- and Pdx1PB-CreERTM 
mice used in these studies, often displayed delayed growth and failure to thrive, which 
has also been observed by Jackson Laboratories, from which the mice were procured.  
This phenotype would have confounded assessment of physiological parameters and β 
cell mass, rendering these mice unusable for these experiments as well. 
Finally, it was determined that Pdx1PB-CreERTM;R26R mice would be used for 
lineage tracing analysis to assess whether β cell neogenesis occurs following 60% PPx, 
while Foxm1flox/-;Pdx1PB-CreERTM and Foxm1flox/+;Pdx1PB-CreERTM mice would be used 





Efficiency of Pdx1PB-CreERTM-Mediated Recombination of R26R 
 The protocol of 3 subcutaneous injections of 8 mg tamoxifen into 5 week old 
Pdx1PB-CreERTM;R26R female mice resulted in ~90% recombination of R26R in β cells 
by 9 weeks of age, assessed by double-labeling with anti-insulin and anti-β-galactosidase 
antibodies.  At 8 weeks old, mice were subjected to either 60% PPx or Sham, and one 
week later the percentage of total β cells that were β-galactosidase+ was compared.  
Preliminary analyses of the percentage of β-galactosidase+ β cells in the splenic 
pancreatic lobe of mice that underwent 60% PPx versus a Sham operation revealed no 
obvious difference in β cell labeling (Figure 59A-C).  These results may indicate that 
non-β cells (unlabeled) did not give rise to new β cells after 60% PPx, although further 
analysis is necessary. 
 
Longevity of Cre Nuclear Localization Following Tamoxifen Injection 
 Although tamoxifen injection is often used to perform “pulse-chase” experiments, 
the particular nature of this lineage labeling study requires that the “pulse” time frame be 
very well defined to ensure that any β cells that may differentiate from unlabeled 
precursors during the “chase” period do not undergo CreER-mediated recombination and 
express the lineage label.  Because CreER nuclear localization correlates with 
recombination activity and is dependent on tamoxifen presence, anti-Cre antibody 
labeling was performed in order to assess Cre protein sub-cellular localization after 
tamoxifen injection, as an indirect assessment of tamoxifen presence.  The PPx 
experiments were designed to account for slow clearing of tamoxifen, with  
Pdx1PB-CreERTM;R26R mice subjected to PPx or Sham two weeks after tamoxifen 
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Figure 59.  Pdx1PB-CreERTM mediated high levels of recombination of R26R in β
cells.  Pdx1PB-CreERTM;R26R mice were injected 3 times with 8 mg tamoxifen and 
underwent a Sham operation or 60% PPx.  (A) Cryosections of the splenic lobe of 
Sham and (B) PPx-operated mice were labeled for Insulin (green), β-galactosidase
(red), and DAPI (blue).  Inset shows an additional islet.  (C) Approximately 90% of β
cells were β-galactosidase+ at 7 days after either a Sham operation or 60% PPx. All 












































injection and then sacrificed one week after the operation.  Surprisingly, even after this 
three week “chase” period, Cre protein was localized primarily to the nuclei of the 
majority of β cells (Figure 60A,A’).  In contrast, Pdx1PB-CreERTM;R26R mice injected 
with vehicle (corn oil) alone did not display any significant amount of nuclear-localized 
Cre (Figure 60B,B’).  These findings suggested that tamoxifen was still present in 
injected animals for much longer than anticipated.  Thus, lineage labeling experiments 
were postponed until the time frames of tamoxifen and Cre activity were better 
characterized. 
 To determine whether there was a time point by which Cre was no longer 
localized to the nucleus, time course experiments were performed in which  
Pdx1PB-CreERTM;R26R mice were administered 3 injections of 8 mg tamoxifen each, and 
the mice were sacrificed at various time points thereafter for Cre labeling of pancreatic 
sections.  This analysis revealed that the intensity of Cre labeling in individual nuclei, 
tended to decline over time, although a significant number of β cell nuclei were labeled 
strongly for Cre even 8 weeks after tamoxifen injection (Figure 61A,A’,B,B’). 
 To determine whether the relatively high dose of tamoxifen was responsible for 
the persistent Cre nuclear localization, the number of tamoxifen injections was reduced to 
either two injections of 8 mg tamoxifen each or a single injection of 8 mg tamoxifen.  At 
five weeks after two injections, Pdx1PB-CreERTM;R26R mice displayed similar results as 
observed at three or five weeks after three injections, with the majority of β cells 
exhibiting strong nuclear Cre labeling (Figure 62A,A’).   However, five weeks after a 
single tamoxifen injection, there were very few β cell nuclei labeled with Cre (Figure 
62B,B’), implying that the dose of tamoxifen administered correlated with nuclear 
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Figure 60.  Cre was primarily localized to islet nuclei 3 weeks after Pdx1PB-
CreERTM;R26R mice were injected 3 times with 8 mg tamoxifen.  (A) Cryosections
of the splenic lobe from Sham-operated mice previously injected with tamoxifen were 
labeled for Insulin (green), Cre (red), and DAPI (blue).  The majority of β cells 
exhibited strong Cre labeling within the nucleus.  (B) Pancreas cryosections from 
Pdx1PB-CreERTM;R26R mice injected three times with vehicle (corn oil) alone showed 
















































































Figure 61.  Nuclear localization of Cre persisted until at least 8 weeks after 
tamoxifen injection.  Pdx1PB-CreERTM;R26R mice were injected 3 times with 8 mg 
tamoxifen, and pancreatic tissue was harvested either 5 weeks (A) or 8 weeks (B)
following tamoxifen injection.  Pancreatic cryosections were labeled for Insulin 
(green), Cre (red), and DAPI (blue).  Inset shows an additional islet.  The intensity of 
Cre labeling appeared to decrease with time, although the majority of β cells 
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Figure 62.  Tamoxifen dose correlated with nuclear localization of Cre protein in 
Pdx1PB-CreERTM;R26R mice.  Pdx1PB-CreERTM;R26R mice were administered either 
(A) 2 injections of 8 mg tamoxifen each or (B) a single injection of 8 mg tamoxifen.  
Five weeks later, pancreatic cryosections were labeled for Insulin (green), Cre (red), 
and DAPI (blue).  Inset  shows an additional islet.  Five weeks after 2 injections, the 
majority of β cells exhibited strong Cre labeling within the nucleus.  However, after 
only a single injection, the majority of β cells showed strong cytoplasmic, but not 
nuclear, Cre labeling, although there was substantial variation among islets.  All 




localization of Cre.  Similarly, tamoxifen dose directly correlated with R26R 
recombination, assessed by β-galactosidase expression.  Pdx1PB-CreERTM;R26R mice 
after only one or two tamoxifen injections displayed a reduced percentage of β-
galactosidase+ β cells compared to that observed after three injections (Figure 
63A,A’,B,B’). 
 The persistence of Cre nuclear localization suggested that perhaps tamoxifen is 
not readily metabolized and cleared from the body.  To directly address this issue, our 
laboratory in collaboration with Rachel Reinert and Dr. Al Powers (Vanderbilt 
University) are planning experiments to determine the pharmacokinetic profile of 
tamoxifen in mice and to determine whether Pdx1PB-CreERTM;R26R islets will undergo 
recombination when transplanted into mice previously injected with tamoxifen. 
 
FoxM1∆islet Mice Subjected to 60% PPx 
 Although lineage tracing experiments were inconclusive and were postponed due 
to possible confounding effects of tamoxifen longevity, data from studies performed on 
Foxm1flox/flox;Pdx15.5kb-Cre (FoxM1∆panc) and Foxm1flox/flox mice indicated that β cell 
neogenesis occurred following 60% PPx and was not impaired in the absence of FoxM1 
(see Chapter III).  Supporting experiments were designed to determine whether FoxM1 is 
required in non-endocrine cells for the generation of new β cells after 60% PPx, using 
Foxm1flox/-;Pdx1PB-CreERTM (FoxM1∆islet) and Foxm1flox/+;Pdx1PB-CreERTM female 
littermates.  These mice were subjected to 60% PPx or a Sham operation, and 
regeneration of β cell mass was evaluated.  Additionally, the extent of β cell mass 
regeneration in these mice was compared to that of FoxM1∆panc mice to determine 
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Figure 63.  Tamoxifen dose directly correlated with β-galactosidase expression in 
Pdx1PB-CreERTM;R26R mice.  Pdx1PB-CreERTM;R26R mice were administered either 
(A) 2 injections of 8 mg tamoxifen each or (B) a single injection of 8 mg tamoxifen.  
Five weeks later, pancreatic cryosections were labeled for Insulin (green), β-
galactosidase (red), and DAPI (blue).  In both cases, the percentage of β-
galactosidase+ β cells was less than 90%.  Inset  shows an additional islet.  All images 
were captured at 400X magnification.
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whether loss of FoxM1 in all pancreatic cells was more detrimental than islet-specific 
loss of FoxM1.  If at 7 days after PPx, β cell mass in FoxM1∆islet mice was reduced 
compared to Control littermates, and if this reduction was proportionate to the reduced β 
cell mass observed in FoxM1∆panc mice compared to their Control littermates (Chapter 
III), then these results would suggest that FoxM1 was only required islet cells for β cell 
mass regeneration.  In contrast, if at 7 days after PPx, β cell mass in FoxM1∆islet versus 
Control littermates was reduced to a lesser extent than observed in FoxM1∆panc versus 
Control littermates, then these results would suggest that both islet and non-islet cells 
required FoxM1 for regeneration of β cell mass.  Both interpretations are dependent on 
high CreER-mediated recombination efficiency of the Foxm1flox/flox locus. 
 Fourteen mice have thus far been included in the experiment, of which only six 
have been evaluated for β cell mass.  Regardless of genotype or tamoxifen injection, all 
mice exhibited similar body weight (Figure 64A) and glucose tolerance 7 days after PPx 
(Figure 64B).  Of the pancreata that have been analyzed to date, the weight of the splenic 
lobe 7 days after PPx was slightly reduced in FoxM1∆islet mice compared to Controls, 
whereas duodenal lobe weight was increased (Figure 65A).  Furthermore, there appeared 
to be reduced regeneration of β cell mass in the splenic lobe of FoxM1∆islet mice 
compared to Controls (Figure 65C), which correlated with reduced percent insulin+ area 
on pancreatic sections (Figure 65B).  In comparison to FoxM1∆panc female mice, 
however, FoxM1∆islet mice exhibited similar reductions in β cell mass regeneration 
compared to their respective Control littermates.  One week after 60% PPx, β cell mass in 
FoxM1∆panc mice was ~50% that of Control littermates (0.057 mg versus 1.02 mg; Figure 
27C), and FoxM1∆islet mice similar exhibited only ~50% the β cell mass of Control 
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Figure 64.  Foxm1∆islet and Control mice exhibited similar body weights and 
glucose tolerance.  Mice were injected with either vehicle (corn oil) or tamoxifen and 
then subjected to 60% PPx.  7 days after PPx, (A) body weight was measured, and (B)
IPGTT was performed.  Error bars represent SEM.  Two-way ANOVA with 
Bonferroni’s post-tests was used to measure significance.  n=2-3 per group for Corn 
Oil-injected, 4-5 per group for Tamoxifen-injected.
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Figure 65.  After 60% PPx, β cell mass in the regenerating splenic lobe of 
Foxm1∆islet mice was reduced compared to Control mice.  Mice were injected with 
tamoxifen and then subjected to 60% PPx.  (A) 7 days after PPx, splenic lobe weight 
was slightly reduced, while duodenal lobe weight was increased, in Foxm1∆islet mice 
versus Controls.  (B) Percent insulin+ pancreatic area on sections was also reduced in 
the splenic, but not duodenal, lobe of Foxm1∆islet mice versus Controls.  (C) Taking 
into account tissue weight and % insulin+ area, β cell mass in the splenic lobe was 
reduced, while that in the duodenal lobe was increased, in Foxm1∆islet mice versus 
Controls. Error bars represent SEM.  Two-way ANOVA with Bonferroni’s post-tests 
was used to measure significance.  n=1-3 per group.
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littermates at the same time point (0.035 mg versus 0.077 mg; Figure 65C).  The different 
mixed strain backgrounds of the two Cre-expressing mouse lines likely accounted for the 
different β cell mass results in the respective Control mice.  Of course, additional 
analyses need to be performed on the remaining tissue samples before any conclusions 
can be drawn from these experiments. 
 
Discussion 
 The field of β cell regeneration has been debated for quite some time regarding 
not only the source(s) and mechanism(s) of such regeneration, but also whether β cell 
neogenesis in fact occurs.  There is also debate over whether neogenesis refers solely to 
progression from an undifferentiated cell to a differentiated one, or whether it can 
encompass such processes as de-differentiation and re-differentiation, and 
transdifferentiation.  Regardless, it is clear that the type of pancreatic injury induced is 
paramount to the interpretations of the results, as is the precision with which analyses are 
performed.  It is also clear that neogenesis is not the primary mechanism by which the β 
cell population regenerates or grows.  However, the there is great potential for β cell 
neogenesis to influence future therapy for diabetic patients. 
 This study was begun before Xu et al. (2008) and Bonner-Weir et al. (2008) 
reported direct mechanistic and lineage tracing evidence for β cell neogenesis, 
respectively.  These reports and the data presented in Chapter III substantiate the 
histological findings that have been reported by many groups in support of the occurrence 
of neogenesis.  However, additional lineage tracing studies, particularly using other 
injury models, are vital to the field.  Thus, these studies still merit completion. 
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 Although the lineage tracing study has not yet been completed, it raised the 
possibility of an important caveat to time-sensitive CreERTM-mediated lineage labeling 
systems, as nuclear-localized CreER protein was evident for many weeks after tamoxifen 
injection.  Prior studies utilizing CreER lineage labeling suggested a 48 hour window of 
tamoxifen-induced CreER activity (Gu et al., 2002).  However, these studies utilized 
intraperitoneal injections of pregnant moms and analyzed embryonic recombination, 
which may have produced different results than observed in this study using 
subcutaneous injections and adult analyses.  In general, substances injected 
intraperitoneally are more readily introduced into the bloodstream than if injected 
subcutaneously. 
Of course, maintenance of Cre nuclear localization does not necessarily correlate 
with tamoxifen presence.  Although CreER is translocated to the nucleus by binding to 
tamoxifen, it is unclear whether CreER is shuttled out of the nucleus in the absence of 
tamoxifen, and if so, how quickly this occurs.  The slow reduction in nuclear-localized 
Cre protein after tamoxifen injection observed in this study could be due to slow 
clearance of tamoxifen and/or to high perdurance of Cre protein in combination with 
slow nuclear exclusion.  However, it would not be surprising if tamoxifen is cleared 
slowly from the body, as tamoxifen and its metabolites are extremely hydrophobic 
(Figure 66) and consequently are stored at relatively high concentrations in adipose tissue 
(Kisanga et al., 2003; Kisanga et al., 2005).  Furthermore, tamoxifen metabolites in 
general exhibit greater activity than tamoxifen itself (Lim et al., 2005), meaning that 
extensive metabolism is required to clear tamoxifen activity.  Therefore, pharmacokinetic 
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Figure 66.  Tamoxifen metabolism pathways. Tamoxifen is extensively 
metabolized by the Cytochrome P450 (CYP) family in the liver.  The metabolites 4-
hydroxy-tamoxifen and N-desmethyltamoxifen have particularly high activity.  Figure 
is from Kisanga et al. (2005).
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profiling of tamoxifen, administered in the same manner (location and dose) used for 
lineage tracing studies is necessary for proper interpretation of results of such studies. 
The study described in Chapter III suggested that FoxM1 is not required for β cell 
neogenesis following 60% PPx, utilizing FoxM1∆panc mice.  The studies described here 
were designed to complement the original study, utilizing FoxM1∆islet mice and lineage 
labeling of β cells.  Preliminary results suggested that regeneration of β cell mass was not 
improved in FoxM1∆islet versus FoxM1∆panc mice, indicating that FoxM1 was not required 
in non-endocrine cells for generation of new β cells.  It is possible, however, that Foxm1 
was not actually deleted in FoxM1∆islet mice, as Foxm1 transcript levels have not yet been 
measured in these mice by our laboratory.  Interestingly, despite ~90% recombination of 
the R26R reporter in β cells using the same method of CreER induction (Figure 59C), 
Foxm1 transcript levels were only reduced by 27% in FoxM1∆islet islets compared to 
Foxm1+/+;Pdx1PB-CreERTM Control islets sent to a collaborating lab (Jeremy Lavine and 
Dr. Alan Attie, University of Wisconsin – Madison, personal communication).  These 
conflicting results could be due to differing efficiencies of CreER-mediated 
recombination at the Rosa26 and Foxm1 loci.  To avoid the possibility of inefficient 
recombination, future experiments could use Rip-Cre mice to delete Foxm1 in β cells.  
These mice may in fact provide a better comparison against FoxM1∆panc mice, as they 
would also undergo deletion of Foxm1 during development.  FoxM1∆islet mice were 
initially used in these experiments with the plan that they could be used for lineage 
tracing studies as well.  However, combining these studies has been impossible, and the 
inherent difficulties and possible low efficiency of CreER-mediated recombination makes 
a constitutive Cre line preferable. 
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Another possible explanation for the lack of a difference in β cell mass 
regeneration between FoxM1∆islet and FoxM1∆panc mice is that, as Chapter III describes, 
the contribution of neogenesis to β cell mass recovery following 60% PPx is small in 
comparison to that of proliferation.  Therefore, it may simply be difficult to detect a 
difference in neogenesis between FoxM1∆islet and FoxM1∆panc mice using the methods 
described here.  However, direct lineage tracing using the recently-published duct-
selective CAII-CreERTM (Bonner-Weir et al., 2008) or Cytokeratin (CK) 19-CreERTM 
(Means et al., 2008) mouse lines, in combination with Foxm1 deletion, could potentially 








 FoxM1 was first identified in 1994 as an antigen for the MPM2 antibody, which 
recognizes a specific serine/threonine phosphorylation epitope in proteins phosphorylated 
during mitosis (Westendorf et al., 1994).  However, this antibody recognizes many other 
M-phase phosphorylated proteins (MPPs), meaning it is not selective for FoxM1.  Since 
then, many anti-FoxM1 antibodies have been generated by various companies and 
laboratory groups.  However, many of these antibodies specifically react with human 
FOXM1, but not mouse FoxM1.  Furthermore, several of these antibodies were generated 
against a peptide and have not been verified.  In order to perform analyses of FoxM1 
expression, cellular and sub-cellular localization, and post-translational modification, it is 
necessary to have a specific antibody that can be used for these specific applications. 
 Our laboratory first utilized a polyclonal anti-FoxM1 antibody generated against 
the N-terminus by Dr. Robert H. Costa’s laboratory (University of Illinois at Chicago) 
(Ye et al., 1997) to detect FoxM1 protein in embryonic, perinatal, and adult pancreatic 
sections (Zhang H et al., 2006).  However, this antibody was only available for a short 
period of time, and results could not be replicated with other antibody preparations.  
Commercially-available antibodies from Santa Cruz Biotechnology that were generated 
against various fragments of the FoxM1 protein and have been used for 
immunocytochemistry on human cell lines (Ma et al., 2005) have not been shown to 
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work on mouse tissue, and our laboratory was unable to detect a specific signal using 
these antibodies for immunohistochemistry on mouse tissue sections.  Furthermore, 
commercially-available antibodies from AbCam that were generated against a FoxM1-
specific peptide have not been verified by other groups, and indeed, our laboratory did 
not obtain positive results using such antibodies for immunohistochemistry. 
 Generally, it is difficult to detect protein on tissue sections due to the fixation 
process involved and the quarternary structure of the protein of interest, which can mask 
the epitope recognized by the antibody.  Although many antigen retrieval methods exist 
to aid in exposing the epitope of interest, they are not always sufficient.  Despite using 
protease digestion and heat-denaturing in both acidic and basic solutions with the anti-
FoxM1 antibodies mentioned above, our laboratory has been unable to detect FoxM1 
protein on mouse tissue. 
 Western immunoblotting avoids the concerns mentioned above with regard to 
immunohistochemistry because the proteins are denatured prior to incubation with the 
antibody and are separated based on mass.  Thus, all epitopes should be exposed, and 
specificity is not a primary concern because the protein of interest can be identified by its 
size.  A polyclonal anti-FoxM1 antibody generated against the C-terminus by Dr. Robert 
H. Costa’s laboratory (University of Illinois at Chicago) (Wang et al., 2005) was used for 
western immunoblotting of mouse protein.  However, our laboratory found that the signal 
produced by this antibody was not specific for FoxM1, despite appearing at an 
appropriate mass, because signals were observed in lanes containing both WT and 
Foxm1-/- protein (Figure 67A).  Similar results were observed using a commercially-
available polyclonal anti-C-terminal-FoxM1 antibody from Santa Cruz Biotechnology 
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Figure 67.  Available anti-FoxM1 antibodies are not specific. Western 
immunoblots were performed using protein extracted from embryonic liver from WT 
and Foxm1-/- littermates.  (A) A polyclonal anti-C-terminal-FoxM1 antibody provided 
by Dr. Robert H. Costa’s laboratory bound to a protein at slightly higher than 83 kDa
(arrow), but bands at this size were also observed in Foxm1-/- protein extracts, and 
consistent results were not observed between different WT protein samples.  (B) A 
polyclonal anti-C-terminal-FoxM1 antibody from Santa Cruz Biotechnology also 
bound to a protein at slightly higher than 83 kDa (arrow) in WT protein extracts, but 

































































































(Figure 67B), and no published studies using either of these antibodies had included 
protein from Foxm1-/- tissue.  To determine whether Foxm1 was actually deleted in 
Foxm1-/- mice, PCR was performed for the Foxm1WT and Foxm1null alleles (Figure 68A-
D), and qRT-PCR was used to compare Foxm1 transcript levels in embryonic liver 
samples between WT and Foxm1-/- littermates (Figure 68E).  These results confirmed that 
Foxm1-/- mice indeed contained the truncated Foxm1 gene but not the full-length gene, 
and that Foxm1 transcripts were nearly undetectable.  Thus, we are confident that 
Foxm1-/- extract and tissue can be used to identify specific anti-FoxM1 antibodies, and 
that the antibodies tested to date do not specifically recognize FoxM1.  
 As described in Chapters III and IV, qRT-PCR specifically detects mouse Foxm1 
or human FOXM1 transcripts.  However, as with western immunoblotting, expression 
cannot be assessed on a cellular basis.  In an attempt to identify Foxm1 transcript on 
tissue sections, in situ hybridization was performed.  Radioactive in situ hybridization 
had previously shown widespread Foxm1 expression on whole-embryo sections, 
including within the pancreas (Ye et al., 1997).  This finding was confirmed using non-
radioactive in situ hybridization, which revealed that Foxm1 was found to be expressed at 
relatively high levels in the embryonic cords, along the ductal epithelium, at e15.5 
(Figure 69A) and in embryonic liver (Figure 69B).  These results were similar to those 
observed in the pancreas using an anti-N-terminus FoxM1 antibody on embryonic mouse 
sections (Zhang H et al., 2006) (Figure 14) and in the liver using radioactive in situ 
hybridization (Ye et al., 1997).  However, because of the high levels of RNase proteins 
within the pancreas after birth, in situ hybridization failed to detect Foxm1 in adult 
tissues. 
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Figure 68.  Confirmation of Foxm1-/- tissue. Embryos from Foxm1+/- inter-crosses 
were genotyped for Foxm1 (A) null and (B) WT alleles using DNA from tail tissue.  
Foxm1-/- embryos (#2, 6, and 8, asterisks) and Foxm1+/+ embryos (#1, 5, and 9, 
circles) were confirmed using DNA from pancreatic tissue sections by the presence of 
the (C) Foxm1 null allele and the absence of the (D) Foxm1 WT allele.  Genotyping 
for IL-2 was used as a control.  ns=non-specific.  (E) Real-time qRT-PCR was used to 
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Figure 69.  In situ hybridization for Foxm1. (A) Foxm1 mRNA was detected in 







 Currently, no antibody exists that can specifically detect mouse FoxM1 using 
immunohistochemistry or western immunoblotting.  Such analyses would enhance the 
studies presented in Chapters III-V and could be used in future studies by our laboratory 
and others.  To this end, our laboratory decided to generate an anti-FoxM1 antibody.  
This chapter describes the processes of generating and screening a monoclonal anti-
FoxM1 antibody, which was done in collaboration with the Vanderbilt Monoclonal 
Antibody Core.  However, some of the methods used and reagents generated in this 
project could be used for future production of other antibodies, such as phospho-specific 
or peptide antibodies. 
 The choice to generate a monoclonal versus polyclonal antibody was made based 
on the need for a highly-specific antibody for use primarily in immunohistochemistry.  
Because monoclonal antibodies recognize an individual epitope, they are more specific 
than are polyclonal antibodies, which can recognize multiple epitopes.  Although in many 
cases, the multiple epitopes recognized by polyclonal antibodies are still specific to the 
protein of interest, there is a greater risk of cross-reaction with epitopes on other proteins.  
Because FoxM1 is part of a large family of proteins that all share homology in the DNA 
binding domain, cross-reactivity is concerning.  Additionally, monoclonal antibodies can 
be produced in unlimited quantity, and all lots have similar characteristics because they 
are produced from a clonal population of hybridoma cells.  Polyclonal antibodies are 
collected from animal sera, which can vary greatly.  Therefore, a monoclonal antibody 




Progress to Date and Future Directions 
Because FoxM1 is a rather large protein with multiple domains, and its three-
dimensional structure is not known, it was decided that a protein antigen would be 
preferable to a peptide antigen for generation of a monoclonal antibody.  However, 
because of FoxM1’s size and because of the concern regarding cross-reactivity with other 
Fox proteins mentioned above, it was decided that three fragments of the FoxM1 protein 
would be generated for immunization, none containing the DNA binding domain.  These 
three fragments were generated from mouse Foxm1 cDNA (NM_008021) using PCR, 
with Fragment 1 consisting of bp 172-870 (amino acids 1-233), Fragment 2 consisting of 
bp 1108-1938 (amino acids 313-589), and Fragment 3 consisting of bp 1939-2445 (amino 
acids 590-757) (Figure 70A).  These fragments were designed to specifically exclude the 
forkhead DNA binding domain because BLAST search indicated that FoxM1 shares little 
sequence homology with other proteins outside of this domain (Figure 70B). 
The coding sequence for each FoxM1 fragment was sub-cloned into the pAT107b 
vector that contains an N-terminal high-molecular weight (43.2 kDa) MBP tag, which can 
be cleaved by 3C protease, and a C-terminal small 8x polyhistidine tag, which cannot be 
cleaved.  These tags not only allow for identification of fusion proteins, but the MBP tag 
confers enhanced  solubility and immunogenicity to each fusion protein (Dr. Robert 
Carnahan, Vanderbilt University, personal communication) (Bannantine et al., 2004).  
Additionally, this vector is a derivative of the pET vector, so expression of the fusion 
protein is driven by the T7 promoter, which is induced by IPTG but repressed in the 
absence of T7 RNA polymerase (Figure 71A). 
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Figure 70.  Generation of FoxM1 fragments.  (A) Three fragments of mouse 
FoxM1 were generated, corresponding to the N-terminal, middle, and C-terminal 
regions (Fragment 1, 2, and 3, respectively).  The forkhead (FH) DNA binding 
domain was excluded from these fragments because (B) FoxM1 shares high sequence 
homology with other Fox proteins within this domain.  B was obtained from NCBI 
BLAST search of mouse FoxM1 protein sequence (NP_032047) against mouse 
reference proteins (refseq_protein).  Search was performed on August 12, 2008.
A
B
Fragment 1 Fragment 2 Fragment 3
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Figure 71.  T7 expression system. (A) The pET vector and its derivatives, such as 
pAT107b, consist of a T7 RNA polymerase-responsive promoter (PT7) upstream of a 
lac operon (lacO), a polylinker site (pLink) into which a sequence of interest can be 
inserted, and a lac repressor gene (lacI).  In the absence of T7 polymerase and lactose 
(or IPTG), expression of the gene of interest is repressed.  (B) The host chromosome 
of BL(DE3) E. coli contains the coding sequence for T7 RNA polymerase under 
control of the lac operator system.  Presence of lactose or IPTG de-represses 
expression of T7 RNA polymerase, and the combined presence of these factors 
promotes expression of the gene of interest.
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Each FoxM1 fragment-MBP fusion protein was expressed in BL21-CodonPlus 
(DE3)-RIPL E. coli (Stratagene), which contain the coding sequence for T7 RNA 
polymerase, driven by an IPTG-inducible promoter (Figure 71B).  These bacteria also 
contain plasmids that carry genes encoding the argU, ileY, leuW, and proL tRNAs, which 
are normally rarely expressed in E. coli and can limit translation of heterologous proteins. 
Small-scale inductions were used to assess and optimize culture, induction, and 
purification conditions.  Cultures were induced with IPTG for 2, 4, or 6 hours at 37oC, 
32oC, 29oC, or 25oC.  Initial analyses of bacterial lysates indicated that the Fragment 1-
MBP fusion protein was efficiently induced at 37oC after 2 hours, while Fragments 2- 
and 3-MBP were recovered at much lower levels (bands at 68, 73, and 61, respectively; 
Figure 72).  These results suggested that the Fragment 2-MBP and Fragment 3-MBP 
fusion proteins were relatively insoluble.  Induction for longer periods of time at lower 
temperatures, which can improve solubility, did not produce dramatically different results 
for Fragment 2-MBP compared to induction at 37oC (Figure 73).  However, a slight 
improvement in recovery was observed for Fragment 3-MBP after induction at 32oC for 2 
hours.  Comparison of insoluble (pelleted) and soluble (supernatant) fractions of the 
lysate confirmed that the majority of the Fragment 2- and 3-MBP fusion proteins were 
insoluble, and that Fragment 2-MBP was less soluble than Fragment 3-MBP (Figure 74). 
Large-scale cultures were then induced with IPTG for 2 hours at 32oC, and lysate 
was purified under denaturing conditions using amylose resin, which bound to the MBP 
tag on each FoxM1 fragment and was then competed away by maltose.  All three 
fragment-MBP fusion proteins were efficiently induced (crude lysate, Figure 75).  
However, only Fragment 1-MBP was efficiently purified, while the majority of Fragment 
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Figure 72.  IPTG induced expression of FoxM1 Fragment 1-, 2-, and 3-MBP 
fusion proteins. Crude cell lysates were collected from transformed BL21-
CodonPlus (DE3)-RIPL E. coli prior to or 2, 4, or 6 hours after induction with IPTG.  
Band at 43 kDa represents MBP (vector, 4), band at 68 kDa represents FoxM1 
Fragment 1-MBP (1), band at 73 kDa represents FoxM1 Fragment 2-MBP (2), and 
band at 61 kDa represents FoxM1 Fragment 3-MBP (3).  Bands at 26 and 38 kDa
represent chloramphenicol acetyl transferase (5) and the streptomycin resistance gene 

















Figure 73.  Lower induction temperatures modestly improved FoxM1 Fragment 
3-MBP solubility. Crude cell lysates from BL21-CodonPlus (DE3)-RIPL E. coli
were collected either prior to or 2, 4, or 6 hours after induction at 32, 29, or 25oC. 
Band at 43 kDa represents MBP (vector, 4), band at 73 kDa represents FoxM1 
Fragment 2-MBP (2), and band at 61 kDa represents FoxM1 Fragment 3-MBP (3).  
Band at 38 kDa represents the streptomycin resistance gene product (6), which is 















Figure 74.  FoxM1 Fragment 2- and 3-MBP fusion proteins were highly 
insoluble. Crude cell lysates from BL21-CodonPlus (DE3)-RIPL E. coli were 
collected either prior to or 2 hours after induction with IPTG at 32oC, and then 
centrifuged to separate soluble (supernatant; sup.) and insoluble (pellet) fractions.  
Band at 43 kDa represents MBP (vector, 4), band at 73 kDa represents FoxM1 
Fragment 2-MBP (2), and band at 61 kDa represents FoxM1 Fragment 3-MBP (3). 
Band at 38 kDa represents the streptomycin resistance gene product (6), which is 
















Figure 75.  Final purification of FoxM1 Fragment 1-, 2-, and 3-MBP fusion 
proteins. Small samples of crude cell lysates were collected from BL21-CodonPlus 
(DE3)-RIPL E. coli transformed with either FoxM1 Fragment 1-MBP, Fragment 2-
MBP, or Fragment 3-MBP prior to induction (uninduced) or 2 hours after induction 
with IPTG at 32oC (induced).  The remainder of the large-scale culture was then 
collected, and the lysate supernatant (soluble extract) was incubated with amylose
resin.  After pelleting of the resin and bound proteins, the supernatant (unbound) was 
collected.  Bound proteins were then eluted from the resin (purified). Band at 68 kDa
represents FoxM1 Fragment 1-MBP (1), band at 73 kDa represents FoxM1 Fragment 
2-MBP (2), and band at 61 kDa represents FoxM1 Fragment 3-MBP (3).  Band at 38 
kDa represents the streptomycin resistance gene product (6), which is inherent to 











































2- and 3-MBP were not bound or purified by the amylose resin.  Additionally, none of the 
fragments were completely purified, as a number of contaminating proteins remained in 
each preparation after eluting from the amylose resin.  Despite these difficulties, a 
sufficient amount of Fragment 1-MBP and Fragment 3-MBP were recovered for injection 
into recipient mice in the Vanderbilt Monoclonal Antibody Core. 
Mice were injected with both Fragment 1- and Fragment 3-MBP fusion proteins 
simultaneously.  Pre-immune and post-immune sera were collected from mice and 
screened for reactivity against mouse FoxM1 protein on embryonic mouse liver sections 
and protein extracted from mouse embryos.  Specificity was analyzed by comparing 
tissue or protein from WT and Foxm1-/- embryos.  Sera collected after three total 
injections of Fragment 1-MBP and Fragment 3-MBP showed no specific reactions 
against FoxM1 using either screening method.  However, after a fourth injection, sera 
from two mice reacted with protein at ~83 kDa, the predicted molecular weight of mouse 
FoxM1 (Figure 76).  These bands were only observed in extracts from WT, but not 
Foxm1-/-, embryos, suggesting that these mice are producing antibodies specific to 
FoxM1.  To confirm that this band likely represented FoxM1, HeLa cells were 
transfected with full-length mouse Foxm1 cDNA, and protein extracts were subjected to 
western immunoblotting with sera from mice injected with Fragment 1-MBP and 
Fragment 3-MBP.  This screen showed that all injected mice were producing antibodies 
that reacted against a protein at ~83 kDa in transfected cells (Figure 77).  This band was 
very weak in extracts from HeLa cells transfected with a negative control, likely 
representing relatively low levels of endogenous human FOXM1 expression.  The fact 
that all serum samples reacted with FoxM1 in transfected HeLa cell extracts but only two 
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Figure 76.  Endogenous mouse FoxM1 was detected by sera from two antigen-
injected mice.  Total protein extracts were collected from WT and Foxm1-/- embryos 
and used for western immunoblotting with sera from antigen-injected A/J and Balb/c
mice.  Sera from two mice produced bands at ~83 kDa (arrows) specifically in WT, 
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Figure 77.  Recombinant FoxM1 was detected by sera from all antigen-injected 
mice. HeLa cells were transfected with no DNA (lane 1) or mouse Foxm1 cDNA in 
pcDNA3.1 (lanes 2 and 3).  Nuclear proteins were then extracted and used for western 
immunoblotting with sera from seven different antigen-injected A/J or Balb/c mice 
(#1-7).  All sera samples produced bands at ~83 kDa that were predominant in the 
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serum samples reacted with endogenous FoxM1 in mouse embryo extracts was likely due 
to the relatively higher amount of FoxM1 being produced by the transfected HeLa cells in 
comparison to embryonic tissue,  along with differences in antibody affinity.  Based on 
these results, it is highly probable that the endogenous mouse protein bound by the sera 
from the two mice was indeed FoxM1.  No specific reactions were observed using these 
sera for immunohistochemistry on mouse embryonic liver paraffin sections.  Instead, 
several of the serum samples reacted with both WT and Foxm1-/- tissue.  However, there 
was not enough sera available to test using various antigen retrieval methods, on 
cryosections, or to otherwise optimize these experiments. 
Because mice were injected with N-terminal (Fragment 1) and C-terminal 
(Fragment 3) regions of the FoxM1 protein, it is possible that some antibodies produced 
by these mice bind to the N-terminal portion of FoxM1, for which the coding sequence is 
not deleted by recombination of Foxm1flox/flox alleles.  qRT-PCR primers used to detect 
Foxm1 transcripts bind to sequences in exons 4-7, which are not present in the Foxm1null 
allele.  Therefore, it is currently unknown whether truncated FoxM1 mRNA or protein is 
produced after Cre-mediated recombination.  The presence of an N-terminal truncated 
FoxM1 protein could yield false-positive results upon screening of Foxm1-/- tissue.  Thus, 
it is possible that some of the serum samples contain FoxM1-specific antibodies even 
though they react with Foxm1-/- tissue, which may be why no specific reactivity was 
observed on tissue sections but was observed on western immunoblots. 
Based on the positive western immunoblot results, the next step in generating a 
monoclonal antibody will involve isolating the antibody-producing B cells from a chosen 
mouse and fusing these cells with an immortal myeloma cell line to form hybridomas.  
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Hybridoma clones will then be identified and screened for anti-FoxM1 antibody 
production.  Because conditioned media from these cells will be readily available, several 
screening techniques will likely be employed to detect one or more antibodies that can be 
used for western immunoblotting and/or immunohistochemistry, as these will be the 
primary uses for such an antibody in our laboratory.  It is expected that an antibody will 
be identified that yields a positive result upon western immunoblotting, because crude 
sera produced such a result.  However, it cannot be predicted whether or not any antibody 
generated will be able to be used for immunohistochemistry.  Thorough screening using 
multiple antigen retrieval and signal amplification methods will likely be necessary.  If 
after such screening a useful antibody has still not been identified, then efforts should be 
diverted to generating a polyclonal antibody against either a FoxM1 fragment or peptide.  





SUMMARY AND FUTURE DIRECTIONS 
 
 Previous to this work, FoxM1 was known to activate transcription of multiple cell 
cycle regulators in several cell types outside of the pancreas.  Its importance in cell cycle 
control was evident from global deletion studies, which resulted in late embryonic 
lethality (Krupczak-Hollis et al., 2004).  Additionally, FoxM1 had been shown to play an 
important role in liver regeneration, using both deletion and over-expression experiments 
(Ye et al., 1999; Wang et al., 2002a; Wang et al., 2002b).  Pancreas-selective deletion 
studies performed in our laboratory revealed that absence of FoxM1 resulted in reduced 
postnatal β cell mass and proliferation, associated with progressive diabetes (Zhang H et 
al., 2006).  It was just becoming clear at this time that β cells exhibited several unique 
cell cycle characteristics: requirements for particular cell cycle regulators (Rane et al., 
1999; Georgia and Bhushan, 2004; Kushner et al., 2005b), different requirements during 
embryogenesis versus neonatal versus adult timepoints (Krishnamurthy et al., 2006; 
Georgia and Bhushan, 2006; Rachdi et al., 2006; Zhang W et al., 2006), and altered 
expression of different cell cycle regulators in response to different proliferative stimuli 
(Uchida et al., 2005; Cozar-Castellano et al., 2006c; Friedrichsen et al., 2006).  Thus, it 
was of great interest to determine whether FoxM1 is required for proper β cell 
proliferation at different ages and under different circumstances (Figure 78A).  
Additionally, we wanted to determine whether FoxM1 is involved in any of the other 
processes that regulate β cell mass (Figure 78B). 
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Figure 78.  Summary of FoxM1’s role in β cell mass regeneration and expansion.
(A) β cells are known to proliferate in response to pancreatic injury, growth factors, 
hormones, and metabolic stimuli.  Our laboratory seeks to define FoxM1’s role in 
such stimulation of β cell proliferation.  This dissertation revealed a role for FoxM1 
down-stream of 60% PPx.  (B) Proliferation of pre-existing β cells was impaired in 
the absence of FoxM1, whereas proliferation of newly-differentiated (neogenic) β
cells did not require FoxM1.  β cell neogenesis and apoptosis were not affected by 
loss of FoxM1, but β cell hypertrophy was observed in FoxM1∆panc mice.  Check-








































 Mice with a pancreas-wide deletion of Foxm1 (FoxM1∆panc) previously were 
shown to exhibit normal β cell mass at birth and relatively normal growth of β cell mass 
during the neonatal period (Zhang H et al., 2006).  However, at 4 weeks of age and older, 
further growth of β cell mass was inhibited, and β cell proliferation was reduced in 
FoxM1∆panc mice compared to Control littermates.  Findings presented in this dissertation 
revealed that β cell proliferation was not reduced in late-stage FoxM1∆panc embryos 
(Chapter III), indicating that FoxM1 is differentially required for β cell proliferation at 
different ages.  An interesting follow-up experiment would be to analyze β cell 
proliferation during the neonatal period to determine whether, despite normal growth of β 
cell mass, there is defective β cell proliferation that is compensated for by enhanced β 
cell neogenesis, as neogenesis is known to normally occur during this period (Scaglia et 
al., 1997). 
 In an effort to determine whether FoxM1 is required for enhanced β cell 
proliferation in response to pancreatic injury or insulin resistance, euglycemic 
FoxM1∆panc female mice were subjected to 60% PPx or diet-induced obesity, 
respectively.  Other members of our laboratory are investigating FoxM1’s role in β cell 
proliferation stimulated during pregnancy and in response to various growth factors.  
Unfortunately, experimental obstacles beyond our control precluded analysis of high-fat 
diet-induced β cell proliferation in FoxM1∆panc mice at this time, although these 
experiments are ready to be repeated in the future.  With regard to injury-induced β cell 
proliferation, however, it was determined that FoxM1 did indeed play an important role. 
60% PPx stimulated Foxm1 up-regulation within islets and β cell proliferation in 
Control mice.  Proliferation was enhanced in both the splenic (regenerating) and 
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duodenal (expanding) lobes of the pancreas, indicating that β cells were responding to 
general cues, such as growth factors, initiated by injury of only the splenic portion of the 
pancreas.  However, in FoxM1∆panc mice β cell proliferation was only significantly 
stimulated within the splenic/regenerating lobe, although to a lesser extent than in 
Control mice.  Furthermore, β cell proliferation in the splenic lobe was significantly 
blunted by loss of FoxM1 specifically within definitive islets of 9 or more β cells, but not 
within small clusters of 8 or fewer β cells.  As small endocrine cell clusters likely formed 
via neogenesis, while larger islets were likely pre-existing, these results once again 
suggested that β cells have different requirements for FoxM1 at different developmental 
stages (Figure 79). 
Other studies from our laboratory indicated that Foxm1 transcripts were up-
regulated in islets during pregnancy and that FoxM1∆panc female mice exhibited a failure 
of β cell mass expansion and β cell hyperplasia during pregnancy that ultimately resulted 
in gestational diabetes (Hongie Zhang and Jia Zhang et al., manuscript in preparation).  
In contrast to the results observed following 60% PPx, no increase in β cell proliferation 
was observed in FoxM1∆panc female mice in response to pregnancy, further supporting the 
conclusion that FoxM1 is absolutely required for proliferation of pre-existing β cells in 
the adult. 
Because of the interest in stimulating β cell proliferation as a therapeutic method 
for diabetic patients, understanding the proliferative cues to which β cells respond and the 
pathways activated by such cues could greatly improve this endeavor.  Currently, the 
growth factors HGF and IGF-1 and the pregnancy hormone PL are being investigated in 
our laboratory to determine whether they act upstream of FoxM1.  Additionally, it could 
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Figure 79.  Working model of FoxM1’s role in β cell proliferation. β cells 
differentiate from Ngn3+ precursor cells in the ductal epithelium, both during 
development and during regeneration after 60% PPx.  Initially, these newly-formed β
cells can replicate in a FoxM1-independent manner.  However, after a certain point, 
which has not yet been clearly determined, β cells become dependent on FoxM1 for 
continued proliferation.
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prove useful to determine which growth factors are up-regulated and/or released in 
response to 60% PPx, as these are likely to act through FoxM1 to stimulate β cell 
proliferation. 
These and other signaling pathways may act through FoxM1 by enhancing its 
transcription or its activity, both of which should be evaluated in future studies.  As 
discussed in Chapter I, little is known regarding which factors and which regions of the 
Foxm1 promoter are responsible for controlling FoxM1 expression.  Furthermore, based 
on the over-expression studies presented in Chapter III, in which Rosa26-FOXM1c Tg 
mice did not exhibit any effects of ubiquitous FoxM1 over-expression on β cells or 
glucose homeostasis after 60% PPx, it is possible that expression of FoxM1 does not 
always correlate with activity.  Thus, there is also need for further study of FoxM1’s 
post-translational modifications and their influence on FoxM1 activity.  It is known that 
FoxM1 is phosphorylated on multiple residues, some of which are necessary for FoxM1’s 
sub-cellular localization and/or transcriptional activity (Major et al., 2004; Ma et al., 
2005), and it will be important to evaluate FoxM1 phosphorylation status as well as its 
expression in future studies.  Additionally, with regard to manipulating β cell 
proliferation, it may be necessary to specifically activate FoxM1 or over-express a 
constitutively active form of FoxM1 in order to achieve the desired effect(s).  This could 
be accomplished by activation of specific signaling pathways or kinases, or by phospho-
mimetic mutation of specific FoxM1 amino acids. 
Our laboratory is currently developing a monoclonal antibody for analysis of 
FoxM1 expression levels and sub-cellular localization (Chapter VI).  However, phospho-
specific antibodies may also be useful to better evaluate FoxM1 activity.  Anti-FoxM1 
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antibodies could also be used in chromatin immunoprecipitation (ChIP) experiments to 
examine down-stream targets of FoxM1, both to verify putative targets in β cells, 
including those up-regulated after PPx along with FoxM1, and to identify new targets.  
Other laboratories have shown that FoxM1 directly activates transcription of genes, such 
as Lama4, ERα, and Jnk1, which have functions not exclusive to proliferation (Kim et al., 
2005; Madureira et al., 2006; Wang et al., 2008a).  Because we have identified a 
potential role for FoxM1 in β cell insulin secretory function, it is likely that other targets 
remain to be discovered in the β cell.  ChIP on chip and ChIP-Seq techniques, in addition 
to microarray data comparing FoxM1∆panc and Control islets, could be used to elucidate 
such targets. 
Although insulin secretion may be impaired in FoxM1∆panc mice, β cell 
differentiation does not seem to be impaired, as neither insulin expression per β cell nor β 
cell neogenesis, during either development or regeneration, are affected by loss of 
FoxM1.  Thus, FoxM1 may regulate targets that are involved in the mechanics of insulin 
exocytosis, as observed in Foxa2flox/flox;Pdx1-CreERT2 mice, which displayed insulin 
secretory defects associated with changes in expression of genes involved in insulin 
granule synthesis, vesicular trafficking, and exocytosis (Gao et al., 2007).  Because 
impaired insulin secretion was only observed in FoxM1∆panc mice fed a high-fat diet, 
FoxM1 may regulate genes that are involved in β cell compensation.  It is known that 
enhanced insulin secretory function and β cell hypertrophy occur in response to diet-
induced obesity and insulin resistance (Lingohr et al., 2002; Kahn et al., 2006), and it is 
hypothesized that these two responses are related.  It is clear from the studies presented in 
Chapters III and IV that FoxM1∆panc mice exhibit β cell hypertrophy under normal 
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conditions, and this basal state may impede adaptation to cellular stressors.  Thus, further 
investigation of FoxM1’s role in β cell function may lend some insight into how β cells 
compensate for increased insulin demand. 
Because Type II diabetes results from a relative insufficiency of β cell mass and 
function, it is possible that altered FoxM1 expression or activity may be related to 
susceptibility to this disease.  Thus far, no direct link between diabetes and FoxM1 has 
been described in human studies.  However, genome-wide association studies are in their 
infancy, and the fact that polymorphisms in only a handful of genes have thus far been 
linked to Type II diabetes, which is an admittedly complex and multigenic disease, 
suggests that more susceptibility loci remain to be identified.  Additionally, FoxM1 may 
be indirectly implicated by its association with pathways that regulate its expression 
and/or activity.  Again, further characterization of FoxM1’s transcriptional regulation and 
post-translational modification may lend insight into potential defects associated with 
diabetes.  
This dissertation described the effects of loss of FoxM1 on β cell mass 
regeneration and expansion, which are summarized in Figure 78A,B.  These experiments 
demonstrated that FoxM1 played an important role in proliferation of pre-existing β cells 
but not newly-differentiated β cells, and that β cell hypertrophy occurred in the absence 
of FoxM1.  However, neither β cell neogenesis nor apoptosis were affected by loss of 
FoxM1.  Therefore, FoxM1 does play a role in β cell mass regeneration following 60% 
PPx, but its role in β cell mass expansion in response to diet-induced obesity or other 
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